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ABSTRACT
Retinal degenerations, both hereditary and acquired, are major causes of visual 
morbidity world-wide. Two of the principal disease categories are age-related macular 
degeneration (AMD) and retinitis pigmentosa (RP). AMD is the major cause of blind 
registrations in the over 65 age group in the western world and retinitis pigmentosa 
has an incidence of 1:3500 but, significantly, affects much younger patients. As yet 
there are no treatments available for these diseases that are either definitively 
preventative or curative.
Retinal cell transplantation is one treatment strategy that has been proposed for such 
patients: retinal pigment epithelium (RPE) grafts for AMD and neural retina for 
retinal dystrophies. The genetic heterogeneity of retinitis pigmentosa and the lack of 
understanding of the key pathobiological mechanisms in AMD make treating the final 
common pathway with retinal cell transplantation an attractive option. To date results 
in humans have not been encouraging, highlighting the need for further studies in 
animal models in terms of visual function, the basic cellular and molecular 
mechanisms involved and exploration of other potential cell types for transplantation. 
This thesis examines the potential of several different donor cell types, both 
immortalised allogeneic (LD7.4) and xenogeneic (human: hlRPE7 & ARPE19) RPE 
cell lines for treating retinal degeneration in the dystrophic Royal College of Surgeons 
(RCS) rat. The dystrophic RCS rat has a primary RPE defect resulting in failure of rod 
outer segment ingestion and subsequent secondary photoreceptor degeneration. 
Additionally, syngeneic neonatal Schwann cells were transplanted into the subretinal 
space of the rhodopsin knockout (Rho -/-) mouse, a knockout model that never 
elaborates outer segments.
Dystrophic RCS rats (21 days old) received subretinal grafts of immortalised 
allogeneic (LD7.4) RPE cell lines in non-immunosuppressed rats or immortalised 
xenogeneic (hlRPE-7 or ARPE19) cell lines in immunosuppressed rats. Appropriate 
sham control injections were delivered to age-matched groups of rats. The animals' 
visual function was assessed longitudinally using a head-tracking system at 16, 20, 
and 26 weeks of age. Retinal sensitivity maps were produced for selected animals 
from each group at 20 weeks (LD 7.4 only) and 26 weeks (hlRPE7 and LD7.4 cell). 
Further groups of animals received grafts of ARPE19 or LD7.4 cells pre-labelled with 
bromodeoxyuridine (BrdU) in order to identify donor cells in vivo. Another labelling 
technique, transfecting LD7.4 cells with Human Foamy Virus (HFV) expressing 
green fluorescent protein (GFP), was also tested.
Syngeneic neonatal Schwann cells were grafted to the Rho -/- mouse at 5 weeks of 
age, prior to total photoreceptor loss and analysed for functional (electroretinogram, 
ERG) and histological rescue at 10 weeks.
Each cell type demonstrated behavioural, functional and morphological rescue in the 
RCS rat model. In the human cell-BrdU labelled group (i.e. with immunosuppression), 
grafted cells were seen integrated between host RPE cells on Bruch's membrane in 
association with areas of photoreceptor rescue up to five months post-grafting. In 
contrast, animals that received allografted cells prelabelled with BrdU (without 
immunopuppression) were not detectable on the host Bruch's membrane 
immunohistochemically by 4 weeks post-transplantation. Even though no donor cells 
were detectable, host visual function and photoreceptors were preserved. This result 
was repeated in the LD7.4/GFP labelled cell group.
The Schwann cell grafted Rho -/- mice showed significant photoreceptor preservation 
over sham-injected animals at 10 weeks of age.
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These results demonstrate a number of key points regarding cell transplantation 
strategies for retinal degeneration. In some circumstances it is possible to achieve 
integration of grafted RPE cells on host Bruch's membrane with preservation of 
photoreceptors and visual function in the RCS rat. Allografts of immortalised RPE 
cells do not appear to survive in the subretinal space of the RCS rat beyond 4 weeks. 
Schwann cell transplantation to two different rodent models (RCS rat and Rho -/- 
mouse) preserved visual function in the former and morphology in both groups.
Cell transplantation for retinal degeneration is an exciting prospect for treating these 
diseases, RPE transplantation for AMD or primary RPE disease and Schwann cell 
transplantation for hereditary retinal disease (RP). Before these strategies become 
clinically useful a number of issues need to be addressed including integration of the 
grafted material with the host, appropriate functioning of the grafted tissue in the 
subretinal space (SRS) and long-term survival of the transplants.
Chapter 1
i
INTRODUCTION
Blinding disorders that stem from the degeneration of photoreceptor cells in the retina 
affect at least 50 million individuals worldwide. There is currently no effective 
treatment for most of these conditions, including age-related macular degeneration 
(AMD) or retinitis pigmentosa (RP). One approach that has been explored is to 
transplant cells to replace defective ones. The excitement that accompanied the first 
studies showing the potential of retinal cell transplantation to alleviate the progress of 
blindness in such diseases as AMD and RP has diminished as attempts to apply 
research to the clinic have failed, so far, to maintain or restore vision. What these 
studies have shown, however, is not that the approach is flawed, but rather that the 
steps that need to be taken to achieve a viable clinical treatment are many. This thesis 
details a number of experiments conducted to address some of the deficiencies and to 
introduce alternative cell transplants as potential therapies for hereditary 
degenerations.
The first section of the introduction describes retinal anatomy; the second outlines 
some of the principal retinal degenerative diseases and the third discusses some of the 
animal models of retinal degeneration. Section four describes established and 
experimental therapies for AMD and for some of the inherited degenerative diseases 
such as RP. Lastly, the immune status of the subretinal space is discussed.
The ultimate goal of the work is to improve graft survival and function and to develop 
transplant protocols that are effective in the clinical setting.
1.1 Retinal Anatomy
1.1.1 Retinal Pigment Epithelium
The retinal pigment epithelium (RPE) is a monolayer of post-mitotic cells (Fig 1.1 A) 
that play an important role in vision and in the maintenance of ocular immune
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Figure 1.1: Retinal Pigment Epithelium
A) Schematically illustrates the retinal pigment epithelium. The RPE cells lie between 
the neural retina and Bruch’s membrane. These cells have apical microvilli (7-10 pm) 
that engulf shed photoreceptor outer segments. As the RPE cells form a crucial part of 
the outer blood retinal barrier there are numerous junctions including tight junctions 
(shown: apical zonula occludens), adherens junctions (zonula adherentes) and gap 
junctions (on the baso-lateral lateral membrane). The short (1pm) basal infoldings are 
responsible for attachments to Bruch’s membrane through integrin expression. B) 
Intracellular reactions of retinoid metabolism in the RPE cells. The RPE cell recycles 
rhodopsin. The initial conversion (following photon stimulation) from 11 -cis to all- 
trans retinal triggers this recycling process. The molecules are transported from the 
photoreceptor outer segment to the RPE cell as all-trans retinol via the inter­
photoreceptor matrix binding protein (IRBP). Through a series of enzymatic 
processes within the RPE cell, 11 -cis retinal is shuttled back to the outer segment to 
be combined with an opsin protein to reform rhodopsin.
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1.1.2 Neural Retina
The neural retina, shown schematically in Fig 1.2B and in transverse section in Fig
1.2 C, D, is an extension of the central nervous system. It converts photic energy into 
neural activity (phototransduction) as the initial step in image formation. This process 
occurs in the outer retina in photoreceptors (cones and rods) with recycling of the 
photopigment by retinal pigment epithelium (Bok, 1993). The inner retina is 
responsible for initial visual processing involving bipolar cells, amacrine cells, 
horizontal cells and ganglion cells prior to transmission through the optic nerve to 
visual centres in the brain.
The gross retinal structure (Fig 1.2C) consists of three nuclear layers: outer nuclear 
layer (ONL), inner nuclear layer (INL) and ganglion cell layer (GCL). Synapses are 
made between and within these layers in the plexiform layers (inner, IPL and outer, 
OPL) allowing vertical and horizontal transmission of signals in the retina (Fig 1.2B) 
Photoreceptors are composed of two cell types, rods (highly sensitive, low resolution) 
and cones (low sensitivity, high resolution, variable photopigment, and greater 
wavelength range). Both cell types have an outer and inner segment and their nuclei 
are located in the outer nuclear layer (Fig 1.2C,D). The outer segment is the site of 
phototransduction and photoreactive proteins (opsins) are embedded in lipid 
membranes (discs), which are separate in rods and invaginated in cones. There is one 
rod photopigment (rhodopsin) made up of retinal (a vitamin A derivative) and an 
opsin. Cone photopigments are one of three distinct types depending on the attached 
opsin protein (blue, green or yellow) with maximal sensitivity respectively for those 
three wavelengths. These discs are renewed following diurnal shedding into the 
subretinal space (Hogan et al., 1972); maximal rod disc shedding occurs 
approximately one hour after waking.
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Late histological changes in CNV include sub-RPE fibrosis, RPE hyperplasia and 
basal laminar deposits. The scar is located in the SRS and intra-Bruch's region (e.g. 
see 1.5D). The scars may be vascularised from the choroid and occasionally from 
retinal vessels (Green and Enger, 1993). These scars lead to clinical problems as a 
result of exudative leakage with serous retinal detachment and/or haemorrhage with 
subsequent destruction of the photoreceptors.
1.2.2 Hereditary Dystrophies and Related Diseases
Retinitis pigmentosa (Fig 1.10A) describes a group of heterogenous inherited 
diseases; the majority of mutations target various molecular entities with 
photoreceptors, of which the following list represents common examples.
• Rhodopsin
• Peripherin/rds
• ROM-1
• a-Phosphodiesterase
• p- Phosphodiesterase
• a-subunit of rod outer segment gated channel
• Myosin VIIA (Usher IB)
• GTP-ase regulator (RP3)
• a-toco-pherol-transfer protein (secondary vitamin E deficiency leading to 
photoreceptor degeneration)
Although some affect RPE cells directly (Fig 1.1 OB and Gu et al., 1997; Marlhens et 
al., 1997; Maw et al., 1997; Petrukhin et al., 1998). Mutations in over 140 genes have 
been identified which cause photoreceptor loss and many have already been cloned 
(Daiger, RETNET, 1996-2004; Fig 1.11). Their effects are widely distributed
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Figure 1.10: Hereditary Retinal Disease
This panel shows some examples of diseases that are inherited. A) is a retinal 
photograph of a patient with retinitis pigmentosa. It shows the classic features of this 
condition, with “bone spicule” pigmentation, retinal vessel attenuation and optic disc 
pallor. B) Shows a patient with early features of Stargardt’s disease. There is an 
abnormal reflex from the fovea. This disease is due to mutations in the ABCA4 gene, 
expressed in the RPE. Other Stargardt’s phenotypes exist with numerous pale sub­
retinal flecks (fundus flavimaculatus). C) This retinal photograph demonstrates the 
classic features of a patient with Best’s disease (an RPE dystrophy). There is a classic 
pale, yellowish lesion at the macula. This lesion goes through a series of changes 
(Stage 1-5: stage 3 shown). See 1.2.2
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Figure 1.10
Hereditary Retinal Dystrophies
involving such processes as movement of materials in cells, movement of molecules 
between photoreceptors and RPE cells (by targeting transport proteins) and 
phototransduction (van Soest et al., 1999).
Clinically, patients are typically affected by night blindness in their second to third 
decade with a gradual reduction in peripheral visual field. Typically they lose central 
vision later in life, in the fifth to seventh decades. The mechanism of photoreceptor 
cell death is by apoptosis (Milam et al., 1998) as is also seen in animal models of RP 
(Portera-Cailliau C 1994).
Much work has been done on the histological changes in the retinae of RP patients. A 
summary of these changes has been published in an excellent review by Milam et al., 
1998.
Rod loss begins in the mid-peripheral retina and gradually spreads to involve central 
and peripheral rods. This pattern varies between the genotypes of RP. Animal studies 
suggest that incident light plays a role in this degenerative condition because dark- 
reared animals have less severe degeneration than light-reared animals. Outer 
segments are shortened early in the disease and in rhodopsin mutations, for example, 
the mutant protein production may add to problems with normal cellular processing 
and accumulation of abnormal opsins. In turn this can lead to inner segment 
inclusions and/or failure to make outer segment discs, causing phototransduction 
abnormalities. The connecting cilium in RP may occasionally be abnormal leading to 
transport defects. Cilium defects are a feature of Ushers syndrome (Type 2, Hunter et 
a l , 1986). As with other retinal diseases and following retinal detachment there is 
evidence of abnormal rod neurite sprouting (Li et al., 1995). In RP this phenomenon 
is limited to the mid-peripheral and peripheral retina and cone neurites do not 
demonstrate this feature. The abnormal rod neurites bypass the horizontal cells and
22
Figure 1.11: Graph of Mapped and Cloned Retinal Dystrophy Genes 1980-2004
This graph highlights the vast number of genes involved in retinal disease and the rate 
of discovery, especially over the past 10 years.
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Figure 1.11
Mapped and Cloned Retinal Disease Genes 1980-2004
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rod bipolar cells and are closely associated with hypertrophied Muller cell processes. 
This feature has been reproduced in vitro with bFGF suggesting a crucial interplay 
between Muller cells and rod neurites. They do not appear, however, to form true 
synapses (Li et al., 1995). Electroretinogram (ERG) recordings from patients show 
there is abnormal transmission from outer to inner retina (Hood and Birch, 1996). 
Such changes are important when considering photoreceptor transplantation 
techniques (Gouras et al., 1994; Kwan et al., 1999, Jones et al., 2003). If the inner 
retina is incapable of receiving an input signal because of retinal remodelling or glial 
scar formation, no transplant would work. Therefore transplantation would have to be 
performed early or with a co-therapy aimed at preventing or treating these secondary 
changes.
Rod loss is accompanied by secondary cone changes and loss. Changes include outer 
segment shortening, cytoplasmic inclusions, axonal elongation and death (Milam et 
al., 1998). The reason for this secondary loss is presently unclear and numerous 
hypotheses exist, including: a build up of toxic products, loss of structure (e.g. the 
IPM), abnormal supporting cells, altered connectivity or a loss of trophic factors from 
the rods. The latter explanation is increasingly likely now given the recent work by 
Sahel's group in Strasbourg (Mohand-Said et al., 1997; Mohand-Said et al., 1998 
Mohand-Said et al., 2000; Leveillard et al., 2004). They have identified a factor (Rod 
Dependent Cone Viability Factor I, RdCVF-I: Fig 1.16) that may play a role in 
maintaining cones in rod-based degeneration. Cone loss is the key event in RP leading 
to marked visual morbidity. When all rods are lost the macula maintains a monolayer 
of cones with shortened outer segments (Bunt-Milam et al., 1983). Interestingly 
however, Sieving's group have described the histology from a patient with autosomal 
dominant RP (P23H) with a flat ERG and a monolayer of cones who maintained 6/12
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vision until her death (Sieving 1999). This has key implications for treatment, since 
researchers may initially aim to preserve just two to three layers of photoreceptors to 
maintain functional vision before attempting heroic treatments such as photoreceptor 
transplantation.
The subretinal space in RP is depleted in volume and characterised by the loss of IPM 
(LaVail et al., 1985) with total loss of photoreceptors. The collapse of the SRS and 
alterations in the constituents of the SRS, such as depleted inter-photoreceptor retinal 
binding protein (IRBP) may compromise any attempted therapy (Milam et al., 1996). 
Reduced IRBP may effectively lead to a local vitamin A deficiency and explain the 
efficacy of vitamin A therapy in some patients with RP (Berson et al., 1993).
Retinal pigment epithelial cells in RP detach from Bruch's membrane and migrate to 
blood vessels giving the classical bone-spicule pigmentation seen in these patients. It 
is not known why the cells detach and migrate but it is thought to reflect the RPE 
affinity for basal lamina (Li et al., 1995). The choriocapillaris underlying regions of 
degeneration also tends to atrophy (Li et al., 1995).
Muller cells undergo considerable change in RP, including cellular hypertrophy, 
migration to the outer retina and increased glial fibrillary acidic protein (GFAP) 
content in reactive cells. Muller cell reactivity and the invariable glial scar formation 
have marked implications for photoreceptor transplantation and integration. As 
previously mentioned grafted photoreceptors may only form neurites rather than true 
synapses, and these neurites may not be able to extend through the glial scar. 
Intraretinal microglia play an important role in removing apoptotic neurons and there 
is evidence of increased numbers of activated microglia in animal models of 
degeneration such as the RCS rat (Thanos and Richter 1993).
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Inner retinal neurons have been felt to remain largely unaffected in hereditary retinal 
degeneration (Milam et al., 1998). However, recent studies on animal models by 
Villegas-Perez et al., (1998) and Jones et al., (2003) have demonstrated marked inner 
retinal remodelling with amacrine, bipolar and ganglion cell loss, Muller cell 
hyperplasia and ganglion cell axon looping all centred on glial cell columns.
Ganglion cell loss is a feature of RP and generally parallels photoreceptor loss (Stone 
et al., 1992). Vascular changes also occur, for instance, vessels with RPE attached 
acquire an extracellular matrix between the vessel wall and RPE cell (Li et al., 1995) 
and eventually this matrix may occlude the vessels, seen clinically as attenuated 
vessels (Fig 1.10A). Ultrastructural studies have identified fenestrations between the 
endothelial cells (Li et al., 1995) explaining the leakage of dye seen during 
fluorescein angiography (Krill et al., 1970).
It is clear that retinitis pigmentosa does not just affect the outer retina, and future 
therapies must take these secondary changes into consideration. Transplantation 
strategies may need to be applied early in the disease or a preventative/maintenance 
therapy, such as growth factor or gene delivery, may have to be used.
In contrast to AMD, retinal dystrophy research has been aided by the availability of a 
range of animal models (either naturally occurring or engineered) that compare 
variably with human disorders. This is particularly true for RP, where there are a 
range of homologous disorders in mice, dogs and cats. More recently, the range of 
models has been augmented by transgenic animals, including rats and pigs, expressing 
human gene defects for particular forms of RP.
1.3 Animal Models of Retinal Degeneration
1.3.1 The Royal College of Surgeons Rat
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The dystrophic Royal College of Surgeons rat has a defect of the retinal pigment 
epithelium characterised by an inability to phagocytose rod outer segments. The 
defect has been localised to a gene encoding the receptor tyrosine kinase Mertk 
(D’Cruz et al., 2000). As a result there is a gradual degeneration of photoreceptors 
commencing at 3 weeks of age with near complete loss by 12 weeks (Fig 1.12B) 
compared with the congenic retina (Fig 1.12A; Dowling and Sidman, 1962; Sauve et 
al., 2001). The initial changes are seen in the rod outer segments (Davidorf et al., 
1991). The model shares homology with a few rare phenotypes of human retinitis 
pigmentosa (Gal et al., 2000) but may also be relevant to AMD. The exact aetiology 
of AMD is presently unclear but the RCS rat, although not directly homologous with 
any known human form of AMD, does compare in having an RPE dysfunction 
leading to photoreceptor loss. It thus provides a useful bioassay for examining the 
potential for RPE replacement in alleviating retinal disease secondary to RPE 
dysfunction.
In addition to photoreceptor degeneration there are secondary inner retinal vascular 
changes which result in the loss of ganglion cells (Villegas-Perez et al., 1996, 1998; 
Jones et al., 2003). Similar changes are observed in human retinitis pigmentosa (see 
1.2.2). Thus the features of the RCS rat lend it to studies on both AMD and RP. 
Treatment strategies will be presented in this thesis.
Numerous transplant studies in the RCS rat have demonstrated a protective effect of 
allogeneic and xenogeneic retinal pigment epithelial transplants in preserving 
photoreceptors (Li and Turner, 1988; Lopez et al., 1989; Yamamoto et al., 1993; 
Litchfield et al., 1997; Castillo et al., 1997) and their function (Jiang et al., 1994, 
Sauve et al, 1998). Other donor cell types shown to be of benefit include Schwann 
cells (Lawrence et al., 2000) and iris pigment epithelial cells (Rezai et al., 1997).
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Figure 1.12: Retinal Histology of Royal College of Surgeons (RCS) Rat
A) Light micrograph is from a 6 month old congenic RCS rat. It illustrates the normal 
retinal architecture in these animals. There is a full complement of nuclei in the outer 
nuclear layer (ONL). The inner (IS) and outer (OS) segments are regularly arrayed 
adjacent to the retinal pigment epithelium (RPE). Inner nuclear layer (INL); Outer 
plexiform layer (OPL). Scale bar: 40pm. B) Light micrograph of a retina from a 6 
month old dystrophic RCS rat. There is total loss of photoreceptors (the ONL is 
absent) and a disorganised inner nuclear layer (INL). There is also an increase in 
Muller cell fibrils (arrowed). Scale bar: 30pm.
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Figure 1.12
Retinal Histology of the Royal College of Surgeons Rat
1.3.2 The Rhodopsin Knockout Mouse
The rhodopsin knockout (rho-/-) mouse has a targeted disruption of the rhodopsin 
gene such that rod outer segments are not generated (Humphries et al., 1997). 
Photoreceptors are lost from four weeks to 12 weeks of age by apoptosis (Fig 1.13 
C,D). A normal mouse retina is shown in Fig 1.13 A and B. Animals as young as 
eight weeks of age have lost photopic ERG responses. There is never a scotopic 
response as would be expected in an animal model that fails to elaborate rod outer 
segments (Humphries et al., 2001).
Since many of the human forms of retinitis pigmentosa are caused by disruptions in 
the rhodopsin gene, studies on this animal model are important and relevant. In 
contrast to the RCS rat, the pathology and progression of disease is more analogous to 
human disease states. As in human retinitis pigmentosa rods are lost first and there is 
a secondary degeneration of cones.
Further studies on the knockout mouse developed by Humphries and co-workers have 
looked at differential degeneration in two strains of rhodopsin knock-out mice on 
different genetic backgrounds: C57BL/6J and Svl29 (Fig 1.13E). Photoreceptor 
degeneration commences at 1 month with near total loss by 4 months. The rate of loss 
in the Rho-/- Svl29 is more rapid than in the Rho-/- C57BL suggesting a differential 
apoptotic process in cones between the two species (Humphries et al., 2001). Thus 
differences in genetic background may play a role in modifying apoptosis, although 
specific genetic differences are yet to be identified.
Studies on another rhodopsin knockout mouse (Lem et al., 1999), using the C57BL/J 
background, have demonstrated the potential protective benefit of a gene therapy 
approach delivering secretable CNTF (sCNTF) to the retina (Liang et al., 2001).
The studies presented in this thesis (Chapter 6) use the Rho-/- Svl29 strain.
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Figure 1.13: Retinal Histology of Rhodopsin Knockout (Rho-/-) Mouse
A) Low power view of a normal Svl29 mouse at 10 weeks of age illustrating a full 
complement of nuclei in the outer nuclear layer (ONL) and a regular arrangement of 
inner (IS) and outer (OS) segments. Scale bar: 40pm. B) Shows a higher power view 
of the same retina. Scale bar: 20pm. C) Low power light micrograph of a 10-week-old 
dystrophic Svl29 mouse with the rhodopsin gene deleted (Rho-/-). There is a marked 
reduction in nuclei in the outer nuclear layer. There are no outer segments. Scale bar: 
40pm. D) Higher power view illustrates this point more clearly, the nuclei are only 
separated from the RPE by a layer of Muller cell processes. Scale bar: 20pm. E) 
Graph demonstrating the reduction in nuclei in the outer nuclear layer of two strains 
on rhodopsin knockout mice (on an Svl29 or a C57 background). Retinae at 1, 2, 3, 
and 4 months postnatal. The tabulated numbers of ONL nuclei represent the mean of 
at least 10 eyes. The rate of decline is clearly seen and is more pronounced in the 
Svl29 strain. From Humphries et al., (2001).
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Figure 1.13
Retinal Histology of Rhodopsin Knockout (Rho -/-) Mouse
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1.3.3 Large Animal Models
As mentioned above, there are no good animal models of AMD available for pre- 
clinical study. By comparison there are a number of well-characterised models for 
hereditary retinal degeneration research with more analogous human correlates 
(Hafezi et al., 2000; Li 2001) including cat (Barnett and Curtis, 1985), dog (0- 
phosphodiesterase defect: Aquirre et al., 1978; RPE65: Narfstrom et al., 1989; rdy: 
Kommonen et al., 1994) and pig (rhodopsin: Petters et al., 1997). See 1.3.3.2 for more 
details.
1.3.3.1 Age-Related Macular Disease
Large animal models of age-related macular degeneration have been limited to 
debridement models and laser induction of choroidal neovascular membranes. Until 
the exact pathogenesis of AMD is discovered this will probably remain the case. 
Debridement models do, however, allow investigation of the effects of RPE cell loss 
on the neural retina and underlying choriocapillaris. Del Priore et al., (1996) have 
examined these effects in vivo in a porcine model, using mitomycin C and edetic acid. 
Choriocapillaris atrophy and retinal atrophy was observed at four weeks post­
operative. While such a preparation is useful for the study of replacement strategies, 
such as transplantation, it does not mirror the clinical situation following removal of 
CNV in patients where Bruch's membrane is invariably damaged. As mentioned 
earlier in vivo and in vitro studies have shown that damaged Bruch's membrane (with 
inner layers removed) does not adequately support seeded RPE cells whether they be 
fresh or cultured, adult or foetal (Tezel et al., 1999a and b; Tsukahara et al., 2002). 
Interestingly, a study comparing two methods of debridement, abrasive and hyraulic 
removal of RPE in the cat (Leonard et al., 1997) has shown that abrasive removal is 
more deleterious. Secondary changes are more marked and there is no RPE regrowth;
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this more closely resembles the human situation following CNV removal. The 
hydraulic removal method does, however, provide a good model for treating 
geographic atrophy.
Laser induction of CNV is another technique used to create animal models of AMD. 
Eyes are exposed to a long duration intense argon laser bum (Ohnishi et al., 1987). 
These models have been used to assess treatments for CNV, such as argon laser and 
photodynamic therapy (Obana et al., 2000) and anti-angiogenic dmgs (Hikichi et al., 
2001). While these models have some validity they do not allow researchers to 
develop preventative therapies.
There is a naturally occurring model expressing the early changes seen in AMD. A 
colony of semi-ffee-ranging rhesus monkeys has been located in the Caribbean and 
they have been intermittently monitored for 16 years. These monkeys are considered a 
model for AMD, since they show dmsen, pigmentary changes and, in late stage 
disease, hyperfluorescent patches (related to atrophy and not CNV). 
Electrophysiology showed loss of central visual function. All of these changes were 
age-related and the incidence was higher in specific maternal lineages (Dawson et al., 
1989; Hope et al., 1992). To date, these animals have not been used in therapeutic 
studies and have been reserved for the analysis of the natural history of the disease.
1.3.3.2 Hereditary Retinal Disease
There are many rodent models of hereditary retinal disease (reviewed in Li 2001). In 
recent years large animal models have been developed and/or discovered. Large 
models allow investigation of aspects of potential treatments that cannot be assessed 
in smaller models such as surgical technique, reliability and secondary retinal effects. 
The Abyssinian cat (Bamett and Curtis, 1985) is a model of retinitis pigmentosa with 
a defect in the rdy gene characterised by degeneration commencing at 22 months and
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complete by 27 months. The degeneration appears to specifically affect the outer 
retina with relative sparing of the inner retina (Narfstrom et al., 2001).
The Briard dog (Narfstrom et al., 1989) has a defect in RPE65 gene, an essential 
component of the functioning RPE cell (Bok, 1993), and is responsible for 
approximately 20% of human congenital stationary night blindness (CSNB).
Fulton Wong's group has developed a transgenic pig (Petters et al., 1997) with an 
autosomal dominant rhodopsin mutation (Pro347Leu substitution) characterised by a 
bimodal retinal degeneration. Rod degeneration commences by week 2 with complete 
loss by 9 months. Cone loss follows rod loss, commencing at 4 weeks of age with 
early immunohistochemical changes, and structural degeneration is seen from 9 to 20 
months (Tso et al., 1997; Li et al., 1998).
1.4 Established Therapies and Potential Treatments for AMD
1.4.1 Introduction
Presently no effective treatments are available for this disease but there are a number 
of lines of investigation, which suggest potential approaches.
Treatments for AMD fall into three categories: i) controlling the secondary changes in 
late AMD, notably the development of choroidal neovascular membranes (CNVM), 
ii) preventing RPE degeneration and iii) replacing damaged or lost RPE cells by 
translocation or transplantation. The ideal treatment would prevent RPE cell loss, but 
until the exact pathogenesis of AMD is known such an approach is not feasible. The 
next best approach is to control the early events in the disease process such as drusen 
deposition and RPE cell loss. This could be achieved by transplanting healthy RPE 
cells.
I.4.I.I. Established Therapies for AMD
1.4.1.1.1 Controlling secondary degenerative events
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In humans, most attention has concentrated on controlling the secondary 
histopathological events in AMD, particularly by treating choroidal vessels that have 
broken through the weakened Bruch’s membrane.
Current proven treatments aimed at limiting the progression of disease and 
minimising trauma to the neural retina include argon laser photocoagulation (Macular 
Photocoagulation Study Guidelines: MPS, 1991a,b,c; 1993a,b; 1994) and
photodynamic therapy (PDT, Schmidt-Erfurth et al., 1999). These treatments are 
destructive and are only appropriate for a sub-group of patients with AMD i.e. those 
with predominantly classic type membranes. The MPS guidelines recommend the 
treatment for those with classic extra- and subfoveal membranes. Subfoveal 
membrane treatment results in total loss of central vision and the relative benefit 
(greater in the marked visual loss group: visual acuity (VA) < 6/36) is only seen two 
years following treatment (MPS, 1994). Extrafoveal treatments delay central visual 
loss but there is a 10% per year recurrence risk and ultimately central vision tends to 
be lost.
Photodynamic therapy is a relatively new treatment that has been proposed for 
treatment of choroidal neovascular membranes, specifically subfoveal neovascular 
membranes. The technique, a two-step outpatient procedure, involves an injection of a 
photosensitive dye, verteporfrin (Visudyne™), followed by delivery of a “cold” light 
spot to the membrane (Miller et al., 1999). This results in the local production of 
oxygen free radicals with focal tissue damage and destruction of the neovascular 
membrane complex. Optimum performance of the drug is determined by selectivity, 
absorption spectrum, photosensitising potency and pharmacokinetic properties. The 
ability of verteporfin to clear rapidly from the outer retina (within 2 hours) and from 
the body (plasma half life of 2-5 hours) and responsivity to long wavelengths (689nm)
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means that it lends itself to ocular use. Once injected, verteporfrin binds to plasma 
LDL (low density lipoprotein) and enters the cells via LDL receptors which are 
preferentially found on endothelial cells. Pre-clinical studies and early phase I/II 
trials determined the effective and safe dose of veteporfin to be used. Systemically the 
dose used was safe; however, leakage of fluorescein recurred at 12 weeks post­
treatment. A laser energy of 50J/cm2 was used because it was associated with the 
greatest degree of absence of leakage at 4 weeks, and least progression at 12 weeks. 
With these details decided, a phase III trial was designed. The main outcomes of this 
study were a) the proportion of eyes with moderate (> 3 lines) and severe (>6 lines) 
vision loss was greater in the placebo group; b) verteporfin-treated eyes tended to 
have better vision at 12 months (better than 20/200) and c) there was overall better 
preservation of contrast sensitivity in the verteporfin group. Further analysis showed 
that the group with wholly classic or predominately classic (>50%) CNV did 
particularly well with PDT treatment. Occult and minimally (<50%) classic CNV 
lesions did not do statistically better with PDT treatment.
While photodynamic therapy produces improved results by comparison with argon 
laser photocoagulation treatment, it does not address the causes of the neovascular 
process or the events leading to RPE failure.
1.4.1.2. Non-surgical Experimental Treatments for AMD
1.4.1.2.1. Non-Surgical and drug treatments
There are many potential treatments under investigation including i) radiotherapy 
(Marcus et al., 2001), although several studies have shown no benefit for preserving 
visual function in patients with choroidal neovascular membranes secondary to age- 
related macular degeneration; ii) transpupillary thermotherapy (TTT) has shown some 
benefit in preliminary studies for the treatment of CNV (Newsom et al., 2001) and a
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randomised trial is underway (TTT4CNV study); iii) anti-angiogenic strategies have 
also been applied to this disease including interferon 2-a but many studies (e.g. 
Pharmacological Therapy for Macular Degeneration Study Group, 1997) have 
determined that not only is interferon not beneficial in this disease it is also potentially 
detrimental to the general health of the retina. Lastly, Thalidomide treatment has been 
shown to have some potential benefits (e.g. Ciulla et al., 1998).
Recent exciting agents that have undergone early clinical trials include Macugen (an 
anti-VEGF165 aptamer) and RhuFab (an anti-VEGF antibody). These agents have 
managed to suppress CNV growth in patients with both classic and occult 
membranes.
1.4.1.2.2. Dietary supplements
In AMD, there is contradictory evidence for the beneficial effects of antioxidants in 
the diet. Seddon et al., (1994) suggested that increasing the consumption of foods rich 
in certain carotenoids, in particular dark green, leafy vegetables, might decrease the 
risk of developing advanced or exudative AMD, but both Mares-Perlman et al., 
(1996) and Smith (1999) found no beneficial effect of dietary anti oxidants on AMD. 
Recently the results of a large multi-centred, randomised controlled clinical trial were 
published, examining the benefits of high-dose supplementation with vitamins C and 
E, P-carotene and zinc in AMD (AREDS Report, 2001). This study demonstrated the 
benefit of dietary supplementation with zinc and antioxidants for patients with 
intermediate changes (drusen size >64jim: category 3) or fellow eye, late stage AMD 
(category 4). The risk of developing marked visual loss and development of CNV or 
geographic atrophy was significantly reduced in the group that took antioxidant and 
zinc supplementation. This is a significant result since it is the first clear
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demonstration of a protective effect using dietary supplements for the treatment of 
AMD.
1.4.1.3 Experimental Surgical Techniques for AMD
1.4.1.3.1 Surgical removal of choroidal neovascular membranes
Surgical strategies have been explored for treating age-related macular degeneration. 
These include removal of subretinal neovascular membranes (Submacular Surgery 
Trial I& II, 2000a and b). This trial indicated no benefit of submacular surgery and 
removal of CNVM compared with argon laser photocoagulation. Over 80% of treated 
eyes had a final vision <6/36 following surgery (Thomas et al., 1994). Most of these 
failures related to the histopathological observation, already discussed, that most 
membranes in AMD are sub-RPE and their removal will also remove the RPE and 
photoreceptors. Other complications include CNV regrowth (46%), entry site breaks, 
retinal detachment and cataract. For this technique to work there must be regrowth of 
RPE across the defect or donor cells must be grafted in their place. Numerous animal 
studies have demonstrated that RPE cells do not grow well on damaged Bruch's 
membrane (e.g. Leonard et al., 1997) which is invariably the position following 
membrane removal.
1.4.1.3.2 Macular translocation
Another approach that has been advocated is moving the macula away from the 
subfoveal scar to a new location with relatively healthy underlying retinal pigment 
epithelium. Macular translocation has been performed using two different methods: i) 
a 360 degree retinotomy followed by a total retinal detachment and relocation of the 
retina either superior or inferior to the neovascular membrane (Eckardt et al., 1999) or 
ii) limited translocation, termed redistribution of the neural retina (NRN, DeJuan and 
Vander 1999; Wong et al., 2000) with subsequent argon laser treatment for the
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CNVM. These techniques have been uniformly classified recently (Au Eong et al., 
2001). There has been a limited success using this treatment with up to 40 per cent of 
patients describing some improvement in vision (Eckardt et al., 1999). The first 
technique (total retinal detachment with 360° translocation) has, however, been 
complicated by a number of sequelae, notably proliferative vitreoretinopathy (PVR), 
retinal detachment and strabismus. These complications have also been described in 
limited macular translocation (Fujii et al., 2000). With all these considerations the 
American Academy has decided to withhold ratification of translocation as a 
mainstream practice pending a controlled trial (AAO Committee on Ophthalmic 
Procedures Assessment Retina Panel, 2000). While the overall results have not been 
very encouraging, there has been no randomised clinical trial and the few successes 
described may give hope that early intervention could be beneficial. Transplantation 
could play an important role in replacing scarred, diseased RPE with fresh cells, 
although survival and integration of donor tissue remains a concern.
1.4.1.3.3 RPE translocation
In an approach that is similar in concept to macular translocation, some groups have 
proposed RPE translocation, either as a patch including Bruch's membrane (Stanga et 
al., 2002; van Meurs et al 2004) or by harvesting autologous RPE cells 
(autotransplantation, Binder et al., 2002). The latter technique involved removing 
cells from underneath the nasal retina, centrifuging them to a pellet and resuspending 
them in a small volume of fluid. This generated approximately 5,000-50,000 cells/ml 
for transplantation. Cells were then injected into the subretinal space following 
removal of subfoveal neovascular membranes. A number of patients (57.1%) also had 
cataract surgery at the same time. Results showed an improvement of visual acuity of 
up to 6 Snellen lines (1 patient) but scotometry and fixation tests failed to identify
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foveal fixation (none at all in 50% and extrafoveal in 50%). Although some of the 
visual results are encouraging, the lack of surgical controls and performance of 
cataract surgery at the same time in a significant proportion of this group limits the 
conclusions that can be drawn from the results. While this technique might overcome 
difficulties of immune rejection, it fails to address the other crucial issues necessary 
for successful transplantation, namely cell viability and cell integration. The donor 
cells are subjected to a high degree of stress and they are then required to settle onto 
damaged Bruch's membrane. Zarbin and co-workers (Tsukahara et al., 2002) have 
identified key features for in vitro cell integration on Bruch's membrane. Foetal cells 
integrate more reliably than adult cells, yet cultured cells integrated best of all. All 
groups integrated more completely when Bruch's membrane was intact, preservation 
of the RPE basement membrane or at least the inner collagenous layer of Bruch's 
being necessary. This work confirms previous in vitro studies conducted by Del 
Priore and co-workers (Tezel et al., 1999a and b). Zarbin et al., (2002) suggest that 
cultured foetal cells may integrate more efficiently because they express more key 
adhesion or integrin proteins. Thus, there are many reasons why these autografts may 
not succeed. There may be insufficient donor cells to patch the damage, they may not 
express key integrins and Bruch’s membrane may be damaged by the surgery.
1.4.2 Transplantation of RPE cells
1.4.2.1 Cell transplantation to the RCS rat retina
RPE transplantation has the potential to replace the defective cell type in age-related 
macular disease, unlike the treatments previously described.
Introduction of RPE cells into the subretinal space, before substantial photoreceptor 
loss has occurred, can limit the disease process and functional deterioration in the 
RCS rat. Donor cells used to date include fresh (Li and Turner, 1988; Li et al., 1991;
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Figure 1.14: Transplantation of Foetal RPE Cells to Patient with Exudative 
AMD.
A) Fundus photograph from patient one day after RPE transplantation. The graft is 
seen as a pigmented patch at the fovea. B) and C) show the same patient at 1 and 3 
months respectively: there is increasing macular oedema (see E) and subretinal 
fibrosis (whitening above the graft in C). The fluorescein angiogram at one month is 
shown: early (D) and late (E) views of oedema in the region of the graft. (From 
Algvere et al., 1994).
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Figure 1.14
Foetal RPE Transplant to a Patient with Exudative AMD
From Aigvere P, Berglin L, et al. (1994)
Lopez et al., 1989, Whiteley et al., 1996), cryopreserved (Durlu and Tamai, 1997), 
cultured primary (Lopez et al., 1987; Sheedlo et al., 1989), or immortalised RPE cells 
of animal or human origin (Keegan et al., 2000; Coffey et al., 2000a and b) and iris 
pigment epithelial cells (Rezai et al., 1997; Schraermeyer et al., 1999, 2000). Early 
studies concentrated on the RCS rat (as it has a primary RPE defect: see 1.3.1). 
Neonatal RPE cells, freshly harvested from pigmented rats, and grafted into the 
subretinal space of albino RCS rats preserve photoreceptors (Turner and Blair, 1986; 
Gouras et al., 1989). Both groups identified pigmented cells in the subretinal space 
and these were believed to be the donor cells. Since no specific cell label was used in 
these studies, the cell origin and type cannot be definitively proved. Zhang and Bok
(1998) extended these studies in the RCS rat to include an immunological analysis 
(see 1.4.1.3.5: Immunology section). While again no specific cell label was used, they 
were able to detect donor cell specific major histocompatibility Type II (MHCII) 
antigens at 5 months post-grafting. In reality however, until recently a direct 
relationship between donor cell survival and host photoreceptor rescue had not been 
described (see Lund et al., 2001a or b; Coffey et al., 2002; and Chapter 3). Also, as 
will be discussed later and detailed in Chapter 5, almost any treatment preserves 
photoreceptors in the dystrophic RCS rat retina, including sham surgery alone 
(Silverman and Hughes, 1989), growth factor injections (eg. Faktorovich et al., 1990) 
and cell grafts of various types. Thus, it would seem that the presence of donor cells 
may not always be necessary to preserve photoreceptors. Indeed, iris pigment 
epithelial cells transplanted to the choroid of RCS rats also preserve photoreceptors 
(Schraermeyer et al., 2000) suggesting that a trophic effect is the primary mechanism 
by which grafts preserve photoreceptors in this model. The relationship between graft 
cell survival and function is not known and may be a more important index to be
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assessed c.f. photoreceptor preservation. Recently, RPE cells have been transplanted 
to the retina of the RPE65 (-/-) knockout mouse (Gouras et al, 2002). The results 
suggested a morphological and a functional (electroretinogram) benefit. However, 
again the cells were not labelled and the ERG findings may be equivocal.
In animal studies, photoreceptor loss has secondary consequences, involving both cell 
loss in the inner retina and vascular pathology (Villegas-Perez et al., 1998, Jones et al
2003). These issues have received much less attention in experimental interventions 
although it has been suggested that RPE transplants can reduce some secondary 
vascular events (Seaton and Turner, 1992; Seaton et al., 1994).
1.4.2.2 RPE cell transplantation to other animal models
Other transplant studies have transplanted RPE cells from a range of sources (fresh, 
cultured and with/without membrane support) to other animal models such as rabbits 
(Shiragami et al, 1998), and pigs (Kiilgaard et al 2002: Del Priore et al 2003 a and b;
2004). Xenografts into rabbits survive using immunosuppression (Craaford et al., 
2000). Interestingly this group could not repeat these results using allografts with or 
without immunosuppression (Crafoord et al., 1999, 2000). Recently, autologous RPE 
cells transplanted into rabbits have attenuated choriocapillaris atrophy and reduced 
photoreceptor loss (Phillips et al., 2003). Although morphological rescue of 
photoreceptors was demonstrated in these studies, there was no functional assay. 
Nevertheless, each study adds to the knowledge base and eventually a clear direction 
for clinical therapies will emerge.
1.4.2.3 RPE transplantation to patients with AMD
A number of studies have been published describing the results of RPE 
transplantation in patients with AMD (Algvere et al., 1994, 1997, 1999; Kaplan et al., 
1998; Weisz et al., 1999; Del Priore et al., 2001). In the first group of experiments
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(Algvere et al., 1994) patients with neovascular AMD (n=5) received transplants of 
patches of RPE cells freshly harvested from aborted foetuses. These patients had a 
reduction in visual acuity initially at 2 weeks but it recovered to pre-operative levels 
within one month. However, the three patients with foveal transplants experienced 
further reduction in vision to below pre-operative levels (Algvere et al, 1994, 1997). 
The foveal transplants were associated with macular oedema, which was interpreted 
as evidence of graft rejection and failure (Fig 1.14). This conclusion may not be 
entirely correct since one might expect that graft loss would mean there was no 
obstruction to fluid outflow and the retina would be atrophic rather than oedematous. 
Similar results were seen in a second group of patients, with geographic atrophy, who 
also received grafts (Algvere et al., 1997, 1999). To date, clinico-histopathological 
correlates (Del Priore et al., 2001) are only available for one patient who was on triple 
immunosuppression (prednisolone, cyclosporine and azathiaprine) following RPE 
patch transplantation. A multilayered patch of pigmented cells was assumed to be the 
donor cells. Some cells appeared to be integrated on host Bruch's membrane and the 
retina overlying these patches was better preserved. Areas with mounds of cells were 
not so well preserved and there was invasion of the inner retinal layers by these 
pigmented cells. Macrophage-like cells were seen in the subretinal space and 
occasional lymphocytes were seen in the choroid, in spite of immunosuppression. The 
visual function in this patient, and 12 others treated similarly, was unaffected by the 
treatment. There were, however, no ophthalmic signs of graft rejection. The 
multilayered pigmented cells are a feature seen in some animal studies of RPE 
transplantation (see chapter 3 and 4; Del Priore et al., 2003a and b). Further analysis 
of these cell groups showed that many macrophages were present in the subretinal 
space and even on Bruch's membrane. Multilayering may also be due to folding of the
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graft or the failure of the cells to attach to Bruch's membrane. Care should be taken in 
the interpretation of clinical and histological results since cells identified as grafted 
RPE cells could, in reality, be host macrophages loaded with donor cell debris. Some 
100 patients have received RPE cell grafts and as such, transplantation is the only 
interventional experimental technique to have been applied clinically. Results so far 
have not been encouraging but since most recipients were at an advanced stage of 
functional loss, little improvement could be expected. Benson et al., (1998) noted 
some limitation of further deterioration, using a series of psychophysical tests: 
otherwise objective functional assessment after transplantation has not been 
employed. It must also be added that the human studies so far have included only 
some of the pre- and post-operative assessments that would be necessary for drawing 
reasonable and substantive conclusions, see Chapter 7, section 7.10 (Algvere et al., 
1997; Binder et al., 2002). With the technology that is now available the work-up 
should be as thorough as the patients can tolerate, including high-resolution confocal 
scanning laser ophthalmoscopy (cSLO) (microperimetry), focal ERGs and 
autofluorescence. The SLO is especially important in the current cohort of patients 
being recruited to trials since they have poor central vision pre-operatively and good 
vision is unlikely to be restored by a supportive,RPE graft. The SLO would be able to 
pick up visual improvements as a result of grafting at the edges of the lesion, as 
opposed to the fovea. Trials could then proceed to less severely affected patients 
whose central vision is only moderately affected and where it might be expected that 
transplantation strategies could maintain or even improve vision. Careful selection of 
a distinct patient phenotype for testing will also increase the success rate.
In spite of the fact that clinical experiments are in progress, basic research remains 
essential and to some extent, these have been prompted by the clinical results obtained
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so far. New treatments need to be tested, effective screening ‘bioassays ’ must be 
developed, immune problems must be overcome, alternatives to fresh cell 
transplantation sought, and a comprehensive assessment of the degree of functional 
recovery must be made. The poor results achieved so far do not necessarily mean that 
the transplant approach is without merit.
1.4.2.4 Problems to be resolved in transplantation studies: Immunology 
Apart from all the issues raised in the above section, it is obvious that for successful 
transplantation, potential immune or inflammatory reactions should be avoided or 
controlled. Allogenicity of donor and recipient and mismatch of major 
histocompatibility complex (MHC) haplotypes (especially class I, Zhang and Bok, 
1998) can compromise the graft, as does the up-regulation of MHC class II expression 
in donor cells (Kohen et al., 1997). There have been reports of RPE cell rejection 
(Jiang et al., 1994, 1995; Algvere et al., 1994, 1997; Zhang and Bok. 1998; 
Gabrielian et al., 1999), even though the undisturbed subretinal space has been 
regarded as an immune-privileged site. While the subretinal space may be considered 
a partially immunologically privileged site, foreign tissue is not necessarily protected 
from immune attack. Its immune status is atypical (Jiang et al, 1995; Grisanti et al.,
1997) and like the anterior chamber, exhibits a phenomenon now referred to as 
Anterior Chamber Associated Immune Deviation (ACAID, Streilein et al., 1980; 
Streilein and Niederkom, 1985; Ksander and Streilein, 1989). This response to 
antigen placement in the subretinal space is an active systemic process leading to 
down-regulation of the normal delayed-type hypersensitivity (DTH) response seen
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Figure 1.15: Immunological Properties of RPE Cells
A) Illustrates the pro-immunogenic factors of RPE cells. These properties may 
predispose RPE cells to graft rejection (see section 1.4.2.4). B) Demonstrates the anti- 
immunogenic properties of RPE cells that may aid graft tolerance following 
transplantation (see 1.4.2.4).
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Figure 1.15
Immunological Properties of RPE
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after transplantation of tissue to non-immune privileged sites (Hall, 1991; Piccotti et 
al., 1997). The mediators of this predictable response are thought to be locally 
produced cytokines (e.g. TGF-p and IL-10; D'Orazio and Niederkom, 1998; Takeuchi 
et al., 1998) and the spleen which diverts the immune response from the Th-1 type T- 
cell population seen in DTH to the Th-2 type (Streilein 1990, 1995, 1999). 
Lymphocytes from the spleens of these animals were capable of suppressing DTH 
when adoptively transferred to naive individuals (Wenkel and Streilein, 1998). 
Studies have shown that this process requires an intact blood-retinal barrier (BRB, 
Wenkel and Streilein, 1998).
Diseased retinae often display leakage and abrogation of the BRB as do those of 
dystrophic RCS rats (Villegas-Perez et al., 1998) and rd mice (Wang et al., 2000). 
Furthermore, a possible consequence of transplantation to the retina will be the 
breaching of the BRB thus exposing the graft to immune surveillance by lymphocytes 
that normally circulate in the blood (Wekerle et al., 1987). Once in place the grafted 
cells not only have to survive immediate immunological attack but must reform a 
crucial aspect of the outer blood retinal barrier and will be exposed to circulating 
choroidal macrophages. In both instances the exact mechanisms occurring in these 
situations have yet to be elucidated. The type, pattern and timing of inflammatory and 
immuno-modulatory factors (both molecular and cellular) produced in response to 
surgical injury and placement of the grafted cells must be determined in dystrophic as 
well as non-dystrophic strains (Abe et al., 1999). To date no detailed analysis of the 
inflammatory response to retinal degeneration or to retinal cell transplantation in the 
immediate post-operative phase has been made in a dystrophic model.
Allogeneic grafts placed in the subretinal space can still be lost despite 
immunosuppressive therapy (Cyclosporine-A, Craaford et al., 2000), again indicating
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possible non-T-cell dependant graft destruction. Fas (CD-95)/Fas-ligand (CD-95 L) 
interactions are important in immune modulation as this interaction leads to the 
apoptosis of Fas-expressing activated T-cells (Griffith et al, 1995; Jorgensen et al., 
1998). It has been shown that the RPE cells express Fas-L (Weller et al., 1996; 
Jorgensen et al., 1998; Winton et al., 1999), and this feature of host RPE cells may be 
important in down-regulating activation of T-cells in the region (Jorgenssen et al.,
1998). Moreover, it has been shown that RPE cells constitutively express Fas but are 
resistant to Fas / Fas-L dependent apoptosis under normal conditions. However, in 
inflammatory conditions such as proliferative vitreo-retinopathy (PVR) this protection 
is lost (possibly by inhibition of RNA or protein synthesis) and these cells can be 
apoptosed via the Fas/Fas-L pathway (Weller et al., 1996). This may one mechanism 
of graft cell loss post-transplantation. It is obvious that the RPE cell possesses both 
pro- and anti-immunogenic properties and as such it is difficult to predict the exact 
processes that will dominate in the subretinal space following transplantation (Fig 
1.15).
Additionally, it has been shown that RPE cells must attach to undamaged Bruch’s 
membrane. Any impediment to grafted RPE cells accessing Bruch’s membrane 
would prejudice against survival and lead to apoptosis. In contemplating such 
transplantation in humans the graft bed will have to be carefully prepared so that 
Bruch’s membrane is stripped of host cells but remain undamaged.
Another factor to affect the stability of any immune privilege is the loss of vascular 
integrity since disruption of the blood-retinal barrier will expose the retina to immune 
surveillance (Wenkel and Streilein, 1998). This may complicate the use of the RCS 
rat in transplantation studies unless the grafts are syngeneic because its retinal vessels 
become fenestrated and ‘leaky’ as they near the choroid (due to the loss of
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photoreceptors and RPE migration into the retina). Since vascular integrity is lost in 
some human retinal diseases, notably RP and neovascular AMD, the potential 
problems of transplantation into the subretinal space with a persistently compromised 
BRB cannot be ignored. The duration of the disease process could also affect immune 
privilege since it is lost in older rd mice (Welge-Lussen et al., 1999). It is clear from 
the above evidence and earlier studies in the brain that the question of immune 
privilege and transplant rejection is a particularly important one for clinical use. To 
date, results from the RCS rat have been difficult to interpret in the context of graft 
rejection because donor cells have generally not been labelled and studies to assess 
the number of RPE cells that may have been lost because of failure to adhere to 
Bruch’s membrane have also not been carried out.
In summary, it is clear that mismatched cells introduced into the subretinal space are 
potentially vulnerable to immune surveillance and rejection. Since diseased retinae 
often have a compromised BRB, the risk of rejection is increased. However, an 
understanding the basic mechanisms underlying the concept of ‘immune privilege’ in 
the retina is essential for the management of mismatched grafts.
1.5 Potential Treatments for Hereditary Retinal Dystrophies
1.5.1 Introduction
A number of potential treatments are being considered. They include the 
administration of growth factors, gene therapy, dietary and drug treatments and 
transplantation of retinal tissue or microelectrode prostheses.
1.5.2 Preventative Treatments
1.5.2.1 Administration of growth factors
A number of growth factors (including basic fibroblast growth factor, bFGF; ciliary 
neurotrophic factor, CNTF; glial-derived growth factor, GDNF) and, to a lesser
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extent, their receptors have been identified in the retina or in retinal cultures (e.g. 
Rakoczy et al., 1993; Gao and Hollyfield, 1995; Jing et al., 1996; Hallbook et al., 
1996; Bugra and Hicks, 1997; Carwile et al., 1998; Jomary et al., 1999). Although 
there is some variability in the results from these studies, this is almost certainly due 
in part to the use of different developmental stages, use of different animals and use of 
techniques with different sensitivities when studying factor and receptor localisation. 
All the above growth factors have been shown to slow photoreceptor loss in a range 
of rodent models, including light damage (Faktorovich et al., 1992; LaVail et al., 
1992; Masuda et al., 1995), the RCS rat (Faktorovich et al., 1990; Perry et al., 1995), 
the retinal degenerate, rd (LaVail et al., 1998; Frasson et al., 1999a) and the retinal 
degenerate slow (rds) mouse (LaVail et al., 1998) as well as in transgenic rats (LaVail 
et al., 1998). Similar studies are being conducted in larger animals (e.g. CNTF in the 
Abyssinian cat, Chong et al., 1999). A simplified mechanism of action is shown in 
Fig 1.16.
To achieve rescue, these factors have been injected into the vitreous cavity with a 
single or multiple injection regimen. Since it is apparent that some factors at least 
(e.g. PEDF, Cayouette et al., 1999) remain in the vitreous for as little as 24 hours, 
other methods of factor delivery need to be devised for the long-term maintenance of 
photoreceptors. One such approach is the development of encapsulated cell 
technology (REFS) to deliver a sustained amount of growth factor (CNTF) to treat 
retinal degenerations in rodent and large animal models. Another approach has been 
to introduce message for growth factors using gene transfection (see 1.5.1.2.3), and 
the results obtained validate the principle of growth factor delivery as a treatment of 
potential importance. Functional assessment in growth factor delivery experiments 
has so far been restricted to electroretinogram (ERG) recordings, which indicate
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Figure 1.16: Possible Growth Factor Mechanisms in the Retina
This figure illustrates a simplified scheme of growth factor production within the 
pigmented and neural retina with the sites of action shown (receptors). Note that 
Muller cells appear to play a key orchestrating role, mediating growth factor activity 
in the retina. Brain-derived neurotrophic factor (BDNF), Ciliary neurotrophic factor 
(CNTF), Glia-derived neurotrophic factor (GDNF), Rod-derived cone viability factor 
(RdCVFl), FGF2 (Fibroblast growth factor-2, also known as bFGF, basic fibroblast 
growth factor), Growth factor receptor-1 (GFR-1), Tyrosine receptor kinase receptor 
(TrkB). See 1.2.2 and 1.5.2.1.
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Figure 1.16
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functional responses in some models (CNTF in rds, Cayouette et al., 1998) but not in 
others (bFGF in mi/vitiligo mouse, Smith et al., 1996). This variability suggests, not 
surprisingly, that individual growth factors may be differentially effective in different 
forms of RP and that a single factor may not be a cure for all forms of the disease. 
Indeed, Ogilvie et al., (2000) have shown that a combination of growth factors 
rescued rd mouse photoreceptors in organ culture but each factor presented singly did 
not. As yet there is no indication of how much form and pattern vision remains after 
growth factor treatment. Appropriate dosage protocols (amount and frequency) need 
to be established for each growth factor, and any side effects assessed.
1.5.2.2 Schwann cells as sources of growth factors
Schwann cells are the myelinating cells of the peripheral nervous system. They extend 
multiple processes, forming intemodal myelinations of several axons. They are 
surrounded by their own basement membrane. There is also a subpopulation of non­
myelinating Schwann cells (Mirsky and Jessen, 1983).
Previous studies have shown that grafts of peripheral nerve segments support neuron 
survival and axon regrowth in a number of central nervous system locations including 
the spinal cord (e.g. Richardson et al., 1980), and thalamus (Morrow et al., 1993). In 
the retina, (e.g. Villegas-Perez et al., 1988) they have been shown to promote 
regeneration of severed optic axons from the back of the eye to the CNS where they 
form synapses and can mediate visual responses to light. Greater retinal ganglion cell 
rescue is achieved if peripheral nerve segments are placed in the vitreous of eyes with 
axotomised optic nerves (Lau et al., 1994). These properties are dependent on the 
presence of viable Schwann cells in the graft (Berry et al., 1988; Smith and 
Stevenson, 1988). Purified populations of Schwann cells transplanted on artificial 
substrates (Xu et al., 1997) or grafted as cell suspensions (e.g. Brook et al., 1993;
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Raisman et al., 1993; Brook et al., 1994; Stichel et al., 1996,) have also been shown 
to support cell survival and axon regrowth in the brain and spinal cord. Schwann cells 
injected into the vitreous of the eye promote RGC survival after optic nerve section 
(Maffei et al., 1990). When grafted into the visual cortex of dark-reared rats, Schwann 
cells contributed to the normal development of visual response properties (Fagiolini et 
al., 1997). Schwann cells play a very important supportive role to neurons, producing 
neurotrophins such as nerve growth factor (NGF), brain-derived neurotrophic factor 
(BDNF, Meyer et al., 1990), neurotrophin-3 (NT-3) and neurotrophins-4/5 (NT-4/5) 
(von Bartheld, 1998). Other trophic factors produced are CNTF (Sendtner et al., 
1992), bFGF (Fujimoto et al., 1997; Neuberger and de Vries, 1993) and GDNF 
(Hammarberg et al., 1996). Many of these factors have been shown to have retinal 
activity (e.g. LaVail et al., 1992, 1998) and receptors for them are present on 
photoreceptors and RPE cells (See section 1.5.2.1 and Fig 1.16).
All this evidence raises the possibility that Schwann cells, which can be delivered as 
an autologous graft, might be effective not only in supporting ganglion cell survival 
but also of protecting photoreceptors from death. Recent studies by Lawrence et al., 
(2000 and 2004) show this to be the case and a Schwann cell line engineered to 
overexpress GDNF or BDNF maintains visual function as well as photoreceptor 
morphology.
1.5.2.3 Gene therapy
Several studies have indicated that a) cells in the retina can be transfected using an 
adenovirus vector (e.g. Li et al., 1994) and b) photoreceptor loss may be slowed with 
appropriate wild type transfects (Bennett, 1996; Ali et al., 1996,1997, 2000; Jomary et 
al., 1997). Growth factor transfects can survive in the retina and reduce photoreceptor 
loss. Thus, rd mice had more rows of surviving photoreceptors 18 days after Ad-
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CNTF injection (Cayouette and Gravel, 1997) and improved survival was also seen in 
the rds mouse for as long as 52 days (Cayouette et al., 1998). Injecting adenovirus- 
carrying bFGF has improved photoreceptor survival in the RCS rat for 56d compared 
with untreated rats (Akimoto et al., 1999). A recent study has demonstrated 
significant photoreceptor preservation by transfecting the Rho -/- mouse retina with 
an attenuated adenovirus (AAV) vector containing a CNTF construct (Liang et al., 
2001).
Very exciting results are arising from the work of Bennett and co-workers on gene 
therapy and the Briard dog (an animal model of Leber’s Amaurosis characterised by a 
gene defect affecting RPE65 protein). They have successfully treated a dog and have 
evidence of restored visual function (Acland et al., 2001) Other workers, also using a 
RPE65 mutant dog, have demonstrated morphological evidence of rescue (Narfstrom 
et al., 2003).
In terms of safety, several studies reported no detection of virus in the blood or in any 
other organs, suggesting that infectivity had not spread. However, Dudus et al.,
(1999) found evidence of a persistent transgene product in the CNS after introduction 
into the eye, raising the possibility that virus might spread beyond the site of injection. 
Recent fatalities in human gene therapy experiments (Lehrman, 1999; Marshall, 1999; 
Sibbald 2001) and the development of leukaemia in two gene therapy subjects (for x- 
SCID, Williams and Baum 2003) argue for caution in the use of the current vector 
approaches and for the development of new vectors. It is important, however, to 
emphasise that the latter two patients received systemic therapy (of adenovirus and a 
retrovirus respectively), and once investigated there may be no causal link between 
the treatment and the deaths. Locally delivered genes may not affect patients in the 
same way.
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As with the growth factor studies, most of the replication defective adenovirus 
transfer studies in animals reported a loss of label and loss of photoreceptors after 
relatively short periods of time. The reasons for this are not known: possibly the 
transgene is unstable, exposure to the virus is eventually toxic, or alternatively, the 
transgenes may persist but become ineffective because other regulatory elements are 
lost. A further explanation is that the cells themselves are eventually removed by 
immunological mechanisms (Reichel et al., 1998).
However, until safe vectors, producing stable, long-term expression of factors can be 
identified this is unlikely to be a suitable treatment, especially since for maximum 
effectiveness the treatment has to be given early in life. In addition, the complex 
genetics of RP makes it difficult to establish commercially viable treatments when 
homologous genes are introduced, especially since each patient group will often be 
quite small (the most common subtype in the USA and Europe, P23H, represents 
about 11% of autosomal dominant RP (Sohocki et al., 2001). For the larger AMD 
group, since the genetic correlates are presently undefined, a gene therapy treatment 
would be difficult to develop at this point other than one involving a relatively non­
specific approach such as growth factor delivery or anti-angiogenic factors as 
described above.
1.5.2.4 Dietary and drug treatments
Modification of diet may be useful in some specific forms of retinal dystrophy. 
Examples include Refsum disease (a phytanic acid deficiency); vitamin A 
supplementation for a-beta-lipoproteinaemia (Gouras et al., 1971) and vitamin B6 for 
gyrate atrophy (Kennaway, et al., 1989) but not all patients benefit from the 
treatment, suggesting disease heterogeneity. Such heterogeneity may also have been a 
factor in a randomised, controlled, double-blind clinical trial on the use of vitamin A
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and vitamin E in the treatment of RP (Berson et al., 1993), where only a subset of 
patients appeared to benefit from vitamin A supplementation. Moreover the beneficial 
effect was only demonstrated in electroretinograms; there was no treatment effect on 
visual acuity. Recently D-cis-diltiazem, a calcium-channel blocker that also acts on 
light-sensitive cGMP-gated channels, has been shown to rescue photoreceptors and 
preserve visual function in the rd mouse (Frasson et al., 1999b). Controversially, this 
finding was not replicated by a separate group of investigators (Pawlyk et al., 2001) 
and further studies will be required to assess whether this drug will have a real 
application in retinal disease therapy.
1.5.3 Treatments Directed at Replacing Lost Photoreceptors
1.5.3.1 Introduction
Once the photoreceptors are lost, the only option available is to reconstruct the outer 
retina. This is not an insignificant task, requiring reconstruction of information flow 
circuitry. Presently two approaches are being explored i)transplantation of new 
photoreceptors either as cell dissociates or as a retinal sheet and ii) the implantation of 
a microchip that can take over the phototransduction role of the photoreceptors and 
relay information to the CNS sufficient for sensory discrimination.
1.5.3.2 Cell transplantation
Early experiments transplanting photoreceptors used embryonic or perinatal tissue 
grafted into adult rat eyes (Turner and Blair, 1986). Graft success appeared to be age- 
dependent, with a marked drop in viability after embryonic day 21 (Aramant et al., 
1988). Instead of showing normal tissue orientation, the grafts formed rosettes. 
Silverman et al., (1989) harvested and transplanted photoreceptors as a sheet, a 
procedure that improved cell orientation. There was also evidence from these pioneer
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studies that photoreceptors might integrate with host neural structures (del Cerro et 
al., 1989; Silverman et al., 1992; Gouras et al., 1994; Adolph et al., 1994).
More recently, sheets of embryonic retina have been introduced into the subretinal 
space using a carrier device that allows them to unfold flat (Bergstrom 1994; Sharma 
et al., 1997; Aramant et al., 1999; Ghosh and Ehinger, 2000). These sheets 
subsequently survived and maintained orientation in the subretinal space. In another 
approach, Kwan et al., (1999) transplanted partially dissociated post-natal mouse 
retina into the subretinal space of rd mice. These grafts reformed into a well-organised 
photoreceptor layer, which developed a synaptic interface with host retina. They also 
showed improved visual function in photophobia tests.
Clinical retinal transplantation experiments, apart from showing that such grafts 
appear not to cause additional damage, have produced either no, or ambiguous, 
evidence of functional improvement (Kaplan et al., 1997; Das et al., 1999; Berger et 
al 2003). For systematic application to humans, not only is it necessary to identify a 
source of easily available, tissue-matched, disease-free cells of appropriate age, but 
also neuronal pathways must be reconstructed with sufficient precision to provide an 
effective substrate for vision. In a pilot attempt to transplant retinal sheets, two blind 
patients with RP reported some visual sensation (Radtke et ah, 1999). Whether such 
responses were mediated through the transplant or were due to effects on the 
remaining retina is not presently clear.
Like RPE grafts, some neural retinal grafts have been shown to survive for prolonged 
periods following transplantation to the subretinal space (Gouras et al., 1994) and 
Larsson et al., (1999) showed that allografts, albeit of foetal tissue, had comparable 
survival times to syngeneic grafts. Neural retinal grafts placed in immune-privileged 
sites (eg. the anterior chamber) display features of ACAID, with a down-regulation of
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normal delayed-type hypersensitivity (Jiang et al., 1993), but they eventually 
succumb to atypical graft rejection (Jiang et al., 1995).
To provoke a more typical form of graft rejection, antigen must be presented to host 
T-cells in association with MHC II molecules on antigen-presenting cells (Van 
Buskirk et al., 1997, and see Fig 7.1) and some up-regulation of MHC II expression in 
subretinal grafts has been described (Ghosh et al., 2000; Larsson et al., 1999). Unlike 
RPE cell grafts, neural retinal grafts contain a heterogeneous cell population and, 
although the identity of the antigen-presenting cells in the neural retina is not entirely 
clear, donor microglia (termed passenger leukocytes by Ma and Streilein, 1998) are 
likely candidates. The observed increase in MHC II expression may be on these 
microglia. Thus, while the neural retina itself may not be immuno-provocative, other 
associated donor cells could be. Their management might provide a focus for the 
control of graft rejection in the future.
1.5.3.3 Microelectrode prostheses
An alternative approach to replacing photoreceptors with cells is to use implanted 
microphotodiodes to carry a visual signal to the cells of the inner retina (Humayun 
and de Juan 1996; Zrenner et al., 1997; Chow and Peachey, 1998, 1999; e.g. see Majji 
et al., 1999; Normann et al., 1999; Rizzo et al., 2001). Using various animal models, 
photodiode arrays have been placed either subretinally (Peyman et al., 1998) where 
they would be expected to stimulate bipolar cells or adjacent to the vitreal surface to 
stimulate cells of the ganglion cell layer. These artificial implants appear to remain 
stable and are biocompatible (Peyman et al., 1998; Zrenner et al., 1997; Majji et al., 
1999).
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In humans, direct pattern stimulation of the surface of the retina can elicit simple 
percepts (Humayun et al., 1996), but long-term implantation of functioning 
photodiode/electrode arrays has yet to be reported.
Much still has to be done to ensure that a significant signal can be presented to cells 
of the inner retina and that the progressive deterioration of the inner retina (which 
normally follows outer retinal cell degeneration) does not compromise efficacy. It has 
yet to be seen how far the CNS can interpret signals delivered through such prostheses 
to elaborate visual images. Presently the best that might be expected from such 
endeavours would likely be a fairly crude image, but this may be sufficient to permit 
navigation around obstacles.
Nevertheless, this type of therapy is potentially very exciting and advances are being 
made in chip technology. The first human chip implantation was recently performed 
in the USA (Margalit et al 2003). They implanted a chip on the patient's macula, 
securing it with retinal tacks. The chip was linked to an external camera, which 
received, encoded and then transmitted to the chip. The implant decoded the signal 
and generated another signal to stimulate the array to facilitate neuronal transmission. 
Zrenner and colleagues have concentrated on developing a biocompatible system 
(Zrenner 2002) that the retina tolerates, and which allows neuron growth but the chip 
erodes by 6 months. This may be a future therapy, although many technical problems 
need to be overcome, but one of the greatest difficulties would be the secondary inner 
retinal remodelling that occurs in retinal disease (Jones et al., 2003). The retinal 
ganglion cell pathway could be so compromised that no interpretable image could be 
sent to the visual centres of the brain.
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1.6 Summary
Some of these therapies have great potential but so far no treatment is problem free. 
The approaches to AMD and RP will essentially be different. Therapy for AMD will 
rely on preventative dietary supplementation and vascular containment initially. Until 
the pathogenesis of AMD understood, it will be necessary to concentrate on treating 
the final effects of the disease i.e. RPE failure with CNV and GA development. To 
this end replacement of the diseased RPE is an attractive option but the treatment 
would have to be performed prior to extensive photoreceptor loss.
I believe that initial trials in inherited retinal disease should concentrate on 
maintenance strategies, such as the use of growth factors or cells that release growth 
factors. Since genetic research has given us the opportunity to identify specific groups 
of patients pre-clinically it will be possible to identify suitable cohorts of patients who 
would benefit most from any given treatment. While the ultimate goal of this 
research would be the restoration of as near-normal a retina as possible, simply 
maintaining some degree of functional vision in patients (who would otherwise be 
blind) would be highly desirable, both for the patient and the economy. It is through 
carefully designed animal studies that such clinical goals can be achieved.
1.7 Specific Aims of the Thesis
Development of Alternative Cell Transplantation Paradigms for Retinal Disorders
A) Investigate the potential of immortalised RPE cell lines (both human and rat) 
for preventing photoreceptor loss in the dystrophic RCS rat.
B) Determine the behavioural and functional outcomes of these procedures, as 
well as morphology.
C) Examine the relationship between function and morphology following RPE 
transplantation to the retina of the RCS rat.
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D) Reliably locate the grafted cells following transplantation.
E) Investigate the potential of syngeneic Schwann cells to rescue photoreceptor 
morphology in the rhodopsin knockout mouse.
Chapter 2 will describe the materials and methods common to all the experiments. 
Chapters 3-6 describe the experimental design and the results with a specific 
discussion relevant to the aims of the experiments. Chapter 7 discusses general 
themes important for the application of cellular transplantation as a clinical 
therapy.
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Chapter 2
62
MATERIALS AND METHODS 
2.1 Introduction
The following chapter describes 1) the generation and characterisation of all the donor 
cell types used in the experiments; 2) the techniques common to most of the projects 
such as transplantation surgery and visual function tests and 3) the experiments 
themselves.
Tissue culture, transplantation surgery, behavioural studies, immunohistochemistry 
and histological analysis have all been carried out by myself. The electrophysiology 
and the development of the complex mathematical formulae have been carried out by 
my collaborators. Details of these have been included in the thesis because they are 
important and integral to the work. I am, however, familiar with these procedures.
2.2 Generation and Characterisation of Potential Donor Cells
2.2.1 Immortalised Retinal Pigment Epithelial Cells
2.2.1.1 LD7.4. an immortalised rat pigment epithelial cell line
A retinal pigment epithelial cell line (named LD7.4) was used for allogeneic 
transplant studies. It was derived from the PVG rat (Greenwood et al., 1996) at the 
Institute of Ophthalmology, London. Briefly, primary cultures of RPE cells were 
derived from 6-8 day old PVG rats (Fig 2.1 A). A replication deficient SV40 retrovirus 
(encoding a temperature sensitive large T-antigen (tsa58) and a neomycin resistant 
gene) was used to infect cultures. Cells were subsequently selected with 800pg/ml 
G418 (Life Technologies, Paisley, UK) and appropriate clones were grown in 
selective media. A single clone with stable RPE phenotype and morphology was 
selected (LD7.4) and expanded for use in transplantation studies (Fig 2.IB). Cells 
were grown in Ham's F-10 (Gibco/ Life Technologies, Paisley, UK) supplemented
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Figure 2.1: Primary and Immortalised Rat RPE Cells
A) Phase contrast light micrograph of primary rat retinal pigment epithelial (RPE) 
cells in culture (passage 3). B) Phase contrast light micrograph illustrating an 
immortalised RPE cell line following infection with a replication deficient retrovirus 
encoding a temperature sensitive large T-antigen (tsa58). Illustration shows cells at 
passage 22. Note the preserved morphology. Scale bar = 20pm.
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Figure 2.1
Primary and Immortalised Rat RPE Cells
with 20% foetal calf serum (FCS, Life Technologies, Paisley, UK), 20mM HEPES, 
7.5% sodium bicarbonate, 2 mM glutamine, lOOU/ml penicillin and lOOpg/ml 
streptomycin (Sigma, Poole, Dorset).
2.2.1.2 LD7.4 Cells Labelled with Green Fluorescent Protein
2.2.1.2.1 Generation of Human Foamy Virus:
The replication defective Human Foamy Virus (HFV) was generated as described in 
Bieniasz et al., (1997). In brief, a plasmid pRFF62 was constructed containing HFV 
LTRs, gag, pol and env genes with bel-1 and bel-2 reading frames destroyed. The 
green fluorescence protein (GFP) gene was inserted into the bel genomic region under 
the transcriptional control of an SV40 promotor.
2.2.1.2.2 Transfection of LD7.4 Cells:
RPE cells were seeded at 5x103 cells/well in a 24 well plate. Twenty-four hours later 
the cells were transfected with 5xl04 virus particles. After six hours, the medium was 
changed and fresh medium containing 5xl04 virus particles added to the cells. The 
medium was changed on the following day. When the cells were 90% confluent (2 
days later) the cells were detached from the 24 well plate using trypsin and grown in 2 
Falcon flasks (Nunc, Gibco, UK) for another 3 days. After trypsinisation the cells 
underwent flow cytometry, which showed a transfection rate of more than 60%. The 
GFP-transfected rat RPE cells were separated from the non-transfected cells by cell 
sorting (B & D cell sorting, BD Biosciences, UK). Once 10,000 positive cells had 
been collected, they were grown again in a Falcon flask. Even after 4 weeks, flow 
cytometry showed that more than 90% of cells were positive.
2.2.1.3 hlRPE-7. an Immortalised Human Retinal Pigment Epithelial Cell Line 
A human RPE cell line, hlRPE-7, also derived at the Institute of Ophthalmology, was 
used for xenogeneic transplant studies. Briefly, RPE cells were cultured from an eye
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obtained with informed consent from a 50 year-old female Caucasian donor under 
local ethics committee approval. The RPE was isolated, the cells extracted and seeded 
onto tissue culture flasks and culture medium added. The culture medium consisted of 
Ham’s F-10, 20% heat-inactivated foetal calf serum, 2mM L-glutamine, lOOU/ml 
penicillin, lOOpg/ml streptomycin (Gibco / Life Technologies, Paisley, UK) and 
1 pg/ml amphotericin B (Boehringer Mannheim, Germany). Medium was changed 
every 2-3 days and all cells were cultured at 37°C in 5% CO2 . Primary cultures were 
genetically modified to extend their in vitro life span by transfection with RSV puro 
(Neurotech S.A., Evry, France; which encodes a puromycin-selectable marker) and a 
construct encoding SV40 large T-antigen that was deleted for the small T-antigen 
(pVim TAt). The construct was generously provided by Denise Paulin, University of 
Paris, Paris, France. Lines were established by selection in lpg/ml puromycin. A 
number of genetically modified human RPE cell lines were screened for the 
expression of SV40 large T-antigen, cytokeratins (5, 8 and 18) and for the junctional 
protein zonula occludens-1 (ZO-1). Cell monolayers were fixed with either 3.7% 
paraformaldehyde (for detection of ZO-1 and SV40 large T-antigen) or cold acetone: 
methanol (1:1 for cytokeratins). Cells were permeabilised with 0.25% Triton X-100 
(BDH/Merck, Poole, Dorset) and phosphate-buffered saline (PBS) and blocked for 15 
mins with 10% goat serum and PBS. Primary antibodies were diluted in blocking 
solution and placed on the cells for lh at room temperature and detected using 
appropriate FITC- or TRITC-conjugated secondary antibodies (1: 50) for lh in the 
dark. Omission of the primary or secondary antibody provided negative controls. 
Primary antibodies for immunohistochemistry were hamster SV40 large T-antigen 
(ascites; a gift from Dr M. Viguier, Institut Cochin de Genetique Moleculaire, Paris);
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Figure 2.2: Primary RPE Cells and Characterisation of Immortalised Human 
hlRPE7 Cells
A) Phase contrast micrograph of contact-inhibited monolayer of primary cultured 
human donor RPE cells 10 days after seeding and B) of immortalised human clone 
hlRPE-7 cells derived from the culture depicted in A (scale bar: 100pm). Both 
cultures exhibit the cobblestone morphology characteristic of RPE cells. C) 
Immunocytochemical detection by epifluorescence microscopy of SV40 large T 
antigen showing correct nuclear expression (scale bar: 20pm). D)
Immunocytochemical detection by confocal scanning laser microscopy (projected 
images) of junctional protein ZO-1 showing an almost continuous pattern of 
peripheral staining (scale bar: 20pm). E) Immunocytochemical detection of the RPE 
cytokeratins 5 & 8. F) Overlay of images depicted in immunomicrographs D) and E) 
plus bisbenzimide (Hoechst) DNA stain (blue) to highlight the cell nuclei (scale bar: 
20pm).
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Figure 2.2
Primary Human RPE Cells and Characterisation of 
Immortalised Human RPE (hlRPE7) Cells
rabbit polyclonal ZO-1 (Zymed, Cambridge Bioscience, Cambridge); monoclonal 
antibodies RGE-53, specific for cytokeratin 18, RCK-102 specific for cytokeratins 5 
and 8 (Eurodiagnostica, Arnhem, The Netherlands) and NCL-5D3, specific for 
cytokeratins 8 and 18 (Novocastra Laboratories, Newcastle-upon-Tyne). The goat 
anti-mouse and goat anti-rabbit secondary antibodies were supplied by Jackson 
ImmunoResearch Laboratories (Westgrove, PA). Cells were viewed on a Zeiss 
epifluorescence or confocal laser-scanning microscope. From this 
immunocytochemical assay, a cell line, designated hlRPE7, was selected (Fig 2.2) 
(see Winton et al., 2000), which was positive for SV40 large T-antigen, ZO-1 and 
cytokeratins 5, 8 and 18.
ARPE 19, a spontaneously derived RPE cell line obtained from the American Type 
Culture Collection (ATCC; CRL-2302; Rockville, MD) and exhibiting an extended in 
vitro life span was also examined. These cells were cultured in medium that consisted 
of Dulbecco's modified Eagle's medium (DMEM): Nutrient Mixture F I2, 1:1 mixture, 
with Hepes buffer (Gibco, UK) containing 10% fetal bovine serum , 56 mM final 
bicarbonate concentration, 1% (by volume) 200 mm L-glutamine, 0.1 mg ml"1 
streptomycin and 100 U ml"1 penicillin (all Gibco / Life Technologies, Paisley, UK). 
The medium was replaced weekly, as previously described, (Dunn et al., 1996). Cells 
were also positive for ZO-1 and the cytokeratins.
2.2.1.3.1. Mixed lymphocyte reaction to evaluate the potential of hlRPE7 and 
ARPE 19 cell lines to induce T-cell proliferation.
Ideally donor cells should not provoke a host lymphocyte response. The two human 
RPE cell lines were tested to assess their capacity to induce T-cell proliferation in 
vitro as follows:
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Human peripheral blood mononuclear cells (PBMCs) were harvested from a healthy 
human donor by density-gradient centrifugation on Ficoll-Paque™ (Pharmacia 
Biotech AB, Uppsala, Sweden). The PBMCs were then plated onto plastic Petri 
dishes for 45 min at 37°C/5% CO2 to allow monocytes to adhere. Non-adherent cells 
were removed and the enriched population of T-lymphocytes was co-cultured (2 x 105 
cells/well) with either stimulated (IFN-y, R&D Systems, Abingdon, UK, lOOU/ml for 
48 h) or unstimulated human RPE cell lines that had previously been irradiated 
(240Gy). The RPE cell lines, hlRPE7 and ARPE19, were plated out at various 
concentrations: 2 x 104, 1 x 104, 0.5 x 104 and 0.25 x 104 cells/well in triplicate in 96 
well plates in 200pl of RPMI 1640 (Life Technologies, Paisley, UK) supplemented 
with 10% FCS, penicillin 100 U/ml and streptomycin 100 pg/ml. Two irradiated 
(120Gy), allogeneic human B-cell lines (MOU, 9,050; SA, 9,001; from the Xth 
International Histocompatibility Workshop, New York, 1987) were used as positive 
controls at the same concentrations as the RPE cells. The allogeneic T-cells were 
harvested and proliferation was assessed on day 6 following an eighteen-hour pulse
3 3with [ H]-thymidine (0.5pCi/well) by measuring incorporated [ H]-thymidine by 
liquid scintillation spectroscopy. Background uptake of [3H]-thymidine into the 
irradiated cells alone was subtracted from the harvested T-cell data.
2.2.2 Generation of Neonatal Mouse Schwann Cells
Mouse Schwann cells were generated from SI29 mice using sciatic nerves dissected 
from postnatal day 5-7 pups (n=17) and transferred to Leibowitz’s L15 medium (Life 
Technologies, Paisley, UK). After removal of contaminating tissues, the nerves were 
chopped into 100pm pieces using a Mcllwain Tissue Chopper and digested in a 
collagenase/trypsin mixture (Dong et al., 1997) in Dulbecco’s Modified Eagles 
Medium (DMEM, Life technologies, Paisley, UK) plus HEPES and FCS for 75 mins
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at 37°C. The digestion was stopped using DMEM plus 10% foetal calf serum (Harlan 
Seralab, Crawley Down, UK). After spinning at lOOOrpm for 5mins the cells were 
resuspended in medium and triturated through a glass capillary and a 25-gauge 
needle. Cells were plated onto poly-l-lysine (Sigma-Aldrich Co., Irvine, UK) coated 
dishes in DMEMF, plus glutamine, pyruvate and penicillin/streptomycin (Brook et 
al., 1993) and incubated at 37°C / 5% CO2 . After 24h the medium was changed to 
remove unattached cells and debris. One week later, cells were removed from the dish 
with trypsin/EDTA and suspended in DMEM. Contaminating fibroblasts were 
removed using a panning method (Dong et al., 1997). Briefly, cells were incubated at 
37°C in a 100mm plastic dish (not tissue culture plastic) previously coated with rabbit 
anti-rat IgG (Dako, Ely, UK) and Thy 1.2 IgM (the latter being a supernatant from a 
mouse 129 hybridoma cell line, generous gift of Dr. Roger Morris, Kings College, 
London). Most fibroblasts had attached to the dish after lOmins, and floating cells 
were removed, centrifuged and resuspended in DMEMF prior to replating onto poly-l- 
lysine coated dishes (Fig 2.3). Cells were ready for transplantation within 24-48h. 
After assessing for the percentage of contaminating fibroblasts (less than 10%), cells 
were removed from the dish and centrifuged as before. Cells were counted and 
transplanted in suspension to Rho-/- mice in DMEM plus DNase (DNase 1, 5pl/ml, 
Sigma UK). DNase reduced cell aggregation in suspension by digesting the ‘sticky’ 
DNA released by dead cells.
2.2.2.1 Growth factor production by mouse Schwann cells in vitro 
To examine growth factor production by mouse Schwann cells, a batch of cells was 
prepared as for transplantation but left in culture for a further 7 days after purification. 
Cells were trypsinised from the dish, and the enzyme activity quenched with 
DMEMF. The cells were centrifuged at 1000 rpm for 5 minutes, the pellet was
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Figure 2.3: Neonatal Mouse (S129) Schwann Cells invitro.
The spindle-shaped appearance of the mouse (129) Schwann cells is shown. The 
isolation technique involves purifying the culture to remove the majority of 
contaminating fibroblasts. Primary cultures do not divide rapidly hence the relatively 
sparse numbers.
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Figure 2.3
Neonatal Mouse (S I29) Schwann Cells In Vitro
resuspended in a large volume of DMEM and the cells were spun again. The 
supernatant was removed and the cells were suspended in a small volume of DMEM 
and transferred to an eppendorf tube. The cells were centrifuged once more and as 
much DMEM as possible was removed. They were frozen rapidly prior to analysis by 
reverse transcriptase PCR (RT-PCR) following the manufacturer's protocol (Life 
Technologies, Paisley, UK). Messenger RNA was extracted using the RNeasy kit 
(Qiagen, Crawley, UK). The growth factors assayed were BDNF, CNTF, GDNF, 
NGF (nerve growth factor) and bFGF. See Table 1.
Table 1: Primers used for the target growth factor genes with the product sizes of the 
corresponding PCR product, annealing temperatures and number of cycles.
Gene Sequence Product 
Size (bp)
Number 
of cycles
Annealing 
Temp (°C)
1. NGF 5 ’-ATGTGGTTCCTGATCCTG-3 ’ 
5 ’ -T GT GAT ACT C AGGGG-3 ’
796 35 48.2
2. bFGF 5 ’-GCCACTTCAAGGATCCC-3 ’
5 ’-GGAAGA AACAGTATGGCCTTC-3 ’
378 35 57
3. CNTF 5 ’ -GT AGCCGTT CT ATCTGG-3 ’
5 ’-G AAGGTC ATGGATAGACC-3 ’
479 35 48.2
4. GDNF 5 ’-AAGC ACAGCTACGGGATG-3 ’ 
5 ’-GGGAGGAGCAGCCATTG-3 ’
707 35 57
5. BDNF 5 ’-ACGTCC ACGGAC AAGG-3 ’ 
5 ’-CACTTGGTCTCGTAG-3 ’
489 35 48.2
22.2.2 Fibroblasts
Since it was not possible to completely eliminate fibroblasts from the mouse Schwann 
cell cultures and in order to control for any potential rescue effect conferred by them,
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fibroblasts were also transplanted. These donor cells were obtained from the cells left 
attached to the Thy 1.2 coated dishes after panning (2.2.2). They were trypsinised off 
the dish and transferred to flasks containing DMEMF (10% FCS). The fibroblast 
cultures were left to expand almost to confluency. Prior to transplantation cells were 
trypsinised off the flasks, counted and suspended in carrier medium (DMEM) with 
DNase, as for the mouse Schwann cell cultures.
2.3 Subretinal Transplantation Surgery
All animal care was in accordance with Institutional and Home Office (UK) 
regulations and the UK Animals (Scientific Procedures) Act, 1986.
For the transplantation procedure (Fig 2.4), rats and mice were anaesthetised with 
intraperitoneal injections of ketamine (80 mg/kg)/xylazine (20 mg/kg), and the pupil 
was dilated using Tropicamide (1% Mydriacyl®, Alcon Labs., Hemel Hempstead, 
UK). Surgery was visualised using a Leitz operating microscope. The eye was 
proptosed with a 6/0 silk suture and stabilised with a fine forceps. The conjunctiva 
and Tenon’s capsule were gently tom open with a bent 27G needle. The sclera was 
breached using a 30G needle, extending to the subretinal space. Cultures of LD7.4, 
hlRPE7, ARPE19 or neonatal mouse Schwann cells and fibroblasts were trypsinised, 
washed and cells in suspension were delivered trans-sclerally to the dorso-temporal 
subretinal space of anaesthetised host dystrophic RCS rats (P21-23) or rho-/- mice 
(P35). Cells were suspended in 2pi of Hams F-10 (Gibco) and injected through a fine 
glass pipette (internal diameter 75- 150pm) attached to a lOpl Hamilton syringe. All 
transplants were to one eye only. Unoperated eyes served as controls. Sham-injected 
rats received the same volume of carrier medium alone (or carrier medium plus 
DNase in the Schwann cell and fibroblast groups). The degree of retinal detachment 
was assessed at the time of surgery (Fig 2.4B), using a scale from 1 to 10 where 10
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Figure 2.4: Transplantation Procedure
A) Schematic diagram of the process of cell culture from cell dissociation to 
transplantation. Cells, in suspension, are drawn up into a microsyringe and injected 
into the subretinal space of the host animal’s eye at a concentration of lxlO5 RPE 
cells/ml (2pi) or lxlO4 Schwann cells (2 pi). The animals are then assessed 
behaviourally and the eyes sectioned for histology.
B) Illustrates the transplant procedure photographically: left panel shows the animal’s 
posterior pole (note the centrally placed optic disc: arrowed), middle panel 
demonstrates the sclerostomy (arrowed) and the right hand panel shows the induced 
peripheral detachment (arrowed).
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Figure 2.4
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represented an excellent detachment. Animals were removed from the experiment if 
grafted cells penetrated through the retina to the vitreous. Animals receiving 
xenografts (ie. cells of human origin) and the sham controls in xenograft experiments 
were placed on ad libitum oral cyclosporine A (concentrate for infusion, Sandimmun, 
Sandoz, Camberley, UK; 210mg/l of drinking water) from 2 days before 
transplantation until sacrifice.
2.4 Assessment of Visual Function
2.4.1 Introduction
Visual function in operated and unoperated rats was assessed using two 
complementary techniques. The first involves testing the animal’s ability to track a 
moving stimulus (head-tracking) and is dependent on an intact retina. Since it is a 
non-invasive technique it enables longitudinal determination of visual performance. 
The second, more discriminatory, test assesses retinal function by determining 
threshold sensitivity to a variable light stimulus, recording responses in the superior 
colliculus (SC).
2.4.2 Head-tracking
This procedure is based on an optokinetic test devised by Cowey and Franzini, (1979) 
(Fig 2.5A). At regular intervals (usually 4 weeks) animals were placed individually 
into a stationary enclosed perspex container surrounded by a motorised drum (Fig 
2.5B) that revolved at a constant velocity (12°/sec). Interchangeable panels (mean 
luminosity 240 lux) of vertical black and white stripes with spatial frequencies of 
0.125, 0.25 and 0.5 cycles/degree were placed on the wall of the outer drum. Each 
was presented, in a random order, to the animal over three consecutive days. A test 
period consisted of 4 one-minute sessions of rotation interspersed with 30sec rest 
intervals. The direction of rotation was alternated so that at the end of the test period
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Figure 2.5: Head-Tracking to High Contrast Square-Wave Gratings.
A) Diagram of head-tracking apparatus. This figure shows the set-up employed to 
record the head tracking performance. The subject rat is placed in a Perspex holding 
chamber and varying sized gratings are rotated around them. A video-camera 
mounted above the animal records its movement. The investigator, monitor and 
video-recorder are placed in an adjacent room so that there are no extraneous stimuli. 
Time spent tracking the moving stripes is documented by the observer.
B) Photograph of a RCS rat in the holding chamber surrounded by the rotating drum 
lined with square-wave grating.
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Figure 2.5
Head-Tracking to High Contrast Square-Wave Gratings
rats had experienced 2x1 min clockwise rotation and 2x1 min anticlockwise rotation. 
Presentation of the moving vertical stripes stimulated a turning reflex such that a 
seeing animal involuntarily moved its head, tracking the lines. Animals were timed 
only for periods during which head turning corresponded with the speed of rotation of 
the stripes: habitual and other randomised movements were excluded. The perspex 
container was cleaned between animals. At each time point, testing was carried out 
blind by the same observer. A video-camera mounted above the apparatus recorded 
head movements, thus permitting measurements to be checked by an independent 
observer.
All behavioural data at each time point was subjected to a 3-way analysis of variance 
with one repeated measure (ANOVA: Group x Eye x Grating Frequency-repeated). 
Post-hoc Student-Newman-Keuls were performed on any significant factors to 
determine the source of the significance. Statistical analysis was performed using the 
statistical package STATVIEW (SAS Institute Inc.).
2.4.3 Electrophysiology (Threshold Collicular Mapping)
Following the final head-tracking tests electrophysiological assessments of the area of 
visual field rescue and changes in threshold sensitivity were made (Fig 2.6). Under 
urethane anesthesia (1.25g/kg) the test eye was immobilised using 6-0 sutures 
attached to the frame, and the pupil was dilated with topical Tropicamide (Alcon 
Labs., Hemel Hempstead, UK). Corneal clouding was prevented using a non­
corrective contact lens. Animals were dark-adapted for one hour at 0.02cd/m2 (low 
mesopic range) prior to recording from the superficial layers of the superior colliculus 
(SC) contralateral to the experimental eye. Multi-unit activity was recorded across the 
surface of the SC along a rectilinear grid of 200pm periodicity: each step 
corresponded to approximately 10°-15° displacements in the visual field. This
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Figure 2.6: Electrophysiological Collicular Field Mapping
A) Photograph of the apparatus used for electrophysiological collicular mapping. The 
large Ganzfield bowl is set up such that the entire visual field of the animal is 
covered. Light stimuli of varying intensities are presented to the animal while they are 
on the platform (arrowed). B) Illustrates this process diagrammatically. A light 
stimulus is presented and nearly all retinal input is transmitted to the contralateral 
superior colliculus. An electrode within the colliculus detects unfiltered transmission 
from the retina. Threshold responses necessary to ellicit a response are recorded at 76 
points across the colliculus and each is recorded to generate a threshold response map 
of the entire retina, this two dimensional map is shown in the bottom right comer.
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Figure 2.6
Electrophysiological Collicular Field Mapping
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procedure was repeated for 76 independent points. In some animals recordings were 
made at 400pm intervals, in which case intervening points were interpolated by taking 
average visual threshold recordings from all the immediately adjacent points. The 
validity of this approach was confirmed by random recording of such points. Visual 
thresholds were measured as the increase in intensity over background (maintained at 
0.02 candela/m2 to minimise rod saturation) required for activating units in the 
superficial 200pm of the SC with a spot of light 3° in diameter. Data gathered from 
each point was assembled to give a global image of the eye.
After head-tracking or electrophysiological recording eyes were processed for light or 
electron microscopy as described in 2.5 below and retinal sensitivity/histology 
correlation maps were generated. Sample sections are taken at regular intervals 
(700pm) through the retina (the central % of the retina is taken, as the outer regions 
are cut too tangentially to be reliably used). Each photoreceptor nucleus is counted 
across the section in 700pm bins. Thus a numerical gradient across the retina is 
obtained. This process is repeated for sections at 700pm intervals. A two dimensional 
histological map of the retina is achieved. Using a bespoke mathematical programme 
a three-dimensional map is created and compared with the retinal sensitivity map. 
(Fig 2.7: see figure legend and chapter 3.2 for details).
2.5 Morphological and Immunohistochemical Studies
2.5.1 Light microscopy
2.5.1.1 Polyester wax embedded tissue
Tissue embedded in this low melting point wax (circa 40°C, BDH) can be readily 
processed for antibody staining because 100% alcohol and xylene are not used in the 
dehydration/clearing procedures.
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Figure 2.7: Generation of the Retinal Sensitivity/Histology Correlation Maps
This figure details the process involved in generating the correlation maps. 
Electrophysiological recordings are obtained as described (2.4.3 and Fig 2.6). These 
logarithmic scales are converted to a decibel scale (ascending, thus greater sensitivity 
is shown as a peak). Through a bespoke mathematical programme the two- 
dimensional maps obtained are converted into a three dimensional map for 
comparison. On the right hand side of the figure the process for generating the 
histological map is shown. See chapter 3.
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Figure 2.7
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Animals were euthanised using Euthatal (Rhone Merieux, UK) and perfused 
transcardially with PBS followed by periodate-lysine-paraformaldehyde (PLP, 
McLean and Nakane, 1974, see Fixatives, Appendix I). Prior to eye excision a suture 
was placed dorsally in order to maintain tissue orientation. After excision and brief 
post-fixation in the same fixative, eyes were washed in PBS and dehydrated through a 
graded series of alcohols (from 50 to 95%). The cornea and lens were dissected out in 
95% alcohol. Eyes then passed through mixtures of 95% alcohol and molten wax (2:1 
and 1:2) prior to overnight impregnation with pure wax, and embedding the next day 
(See Protocol for polyester wax embedding, Appendix I).
Sections (8pm) were cut using an American Optical bench microtome (maintained in 
a cool room), mounted on charged glass slides (Superfrost Plus, BDH/Merck, Poole, 
UK) and dried under a current of air before storing at 4°C. Prior to use for 
immunohistochemistry, sections were dewaxed by briefly immersing in absolute 
alcohol, followed by lOmins in 95% alcohol. Sections were dried again in a current of 
cool air before staining.
2.5.1.2 Frozen sections
Animals were euthanised using Euthatal (Rhone Merieux, UK) and perfused 
transcardially with PBS followed by periodate-lysine-paraformaldehyde (PLP) or 4% 
paraformaldehyde in PBS (See Fixatives, Appendix I). A suture was placed in the 
dorsal pole to maintain orientation and the eye excised and post-fixed in the same 
fixative for lh. The eyes were rinsed in PBS and ciyoprotected in 10%, 20% and 30% 
sucrose in PBS for lh in each solution or until the tissue had sunk to the bottom of the 
vial. The lens was removed through a cut in the cornea and the eye embedded in 
optimal cutting temperature compound (OCT; Tissue-Tek, Miles, Raymond Lamb, 
London, UK). The tissue was frozen in a freezing mixture of dry ice and acetone and
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stored at -70°C. Sections were cut at 14pm using a Leica CM3050 cryostat and 
mounted on charged glass slides in 5 consecutive series. The first series was stained 
with cresyl violet (0.5%, BDH/Gurr, Poole, UK) or haematoxylin and eosinyellowish 
(BDH/Gurr, Poole, UK: see Histological stains, Appendix I) for examination of 
retinal histology including the degree of photoreceptor survival and any evidence of 
pathological events. The remaining series were stored at -70°C and used for 
immunohistochemical studies. Prior to staining sections were brought to room 
temperature and dried in a current of air for one hour.
2.5.1.3 Immunohistochemistry
Sections were placed in PBS and then blocked with 5% defatted milk in PBS or serum 
appropriate to the animal the secondary antibody was raised in. Milk could not be 
used with secondary antibodies supplied by Jackson Laboratories. After blocking 
sections were placed in the primary antibody, diluted in antibody diluent and blocking 
serum. Sections were usually incubated overnight at 4°C in a humidified chamber. 
After washing in PBS, sections were reacted with diluted biotinylated secondary 
antibody for 30 mins followed by a streptavidin complex tagged with horseradish 
peroxidase (ABC Elite; Vector Laboratories, Peterborough, UK), or by streptavidin 
complexed with alkaline phosphatase (Dako, Ely, UK). Horseradish peroxidase was 
visualized using 1% nickel chloride and 3-3' diaminobenzidine (DAB, Sigma, Poole, 
UK) and alkaline phosphatase (AP) was visualised with Vector blue (Vector 
Laboratories, Peterborough, UK), using levamisole (Dako, Ely, UK) to inhibit 
endogenous alkaline phosphatases. Sections visualised with DAB were dehydrated 
through a graded series of alcohols and xylene and mounted (DePeX; Merck/BDH, 
Poole, UK). AP sections were dehydrated through alcohols to Neo-Clear 
(Merck/BDH, Poole, UK) and mounted in Vector Mount (Vector Laboratories,
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Peterborough, UK). Negative control sections were incubated in defatted milk or 
serum overnight without primary antibodies before proceeding with the secondary 
antibodies as described. For details see Appendix I.
The antibodies used will be listed with each experiment.
2.5.2. Electron microscopy
Animals were overdosed with Euthatal (Rhone Merieux, UK), perfused intracardially 
with PBS and fixed with 2.5% paraformaldehyde (TAAB, Aldermaston, UK), 2% 
glutaraldehyde (TAAB, Aldermaston, UK) and 0.01% picric acid in 0.1M phosphate 
buffer (See Fixatives, Appendix I). A suture was placed opposite the site of 
transplantation before the eye was excised into fresh fixative in order to maintain 
tissue orientation. After overnight immersion, eyes were transferred to 0.1M 
cacodylate buffer (TAAB, Aldermaston, UK) and the lenses removed through an 
incision in the cornea. Eyes were post-fixed in 1% osmium tetroxide in 0.1M 
cacodylate buffer, followed by dehydration through a graded series of alcohols and 
epoxypropane before embedding in Agar resin (Agar Scientific, Stanstead, UK). For 
details see: Processing tissue for electron microscopy, Appendix 1. Semithin sections 
were cut on a Leica ultramicrotome and stained with toluidine blue (Sigma, Poole, 
UK). Ultrathin sections were cut from selected areas, mounted on copper grids (Agar 
Scientific, Stanstead, UK) and stained with alcoholic uranyl acetate and aqueous lead 
citrate (see Appendix I). Sections were viewed using a Jeol 1010 electron microscope.
2.5.3. RPE Donor Cell Identification 
2.5.3.1. Introduction
Accurate identification of grafted donor cells in the host animal is exceptionally 
important in transplantation studies. A considerable amount of time has been devoted 
to developing reliable and reproducible labelling techniques for RPE cell lines.
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2.5.3.2 Identification of bromodeoxvuridine labelled cells
Cells for grafting were pre-labelled in vitro with 20pM bromodeoxyuridine (BrdU, 
Sigma, Poole, UK) 48 hours prior to transplantation.
Frozen or polyester wax sections from the BrdU-labelled eyes were reacted with 
mouse anti-BrdU antibody (1:1000; Sigma, Dorset, UK). The secondary antibody was 
a preadsorbed biotinylated goat anti-mouse (1:200; Jackson ImmunoResearch 
Laboratories, Inc, USA). Streptavidin, complexed with alkaline phosphatase, was 
visualised with Vector Blue (Vector Laboratories, Peterborough, UK). For details see: 
BrdU visualisation protocol in Appendix I.
2.5.3.3 Identification of HFV/GFP labelled LD7.4 cells
Green fluorescent protein-labelled cells were identified in frozen section using anti- 
GFP antibody (Chemicon, Harrow, UK, 1:750) visualised with alkaline phosphatase 
and Vector Blue as in 2.5.3.2.
2.6. Experimental Design
A number of experiments were designed to test the capacity of the various donor cell 
types to maintain photoreceptors and visual function in the dystrophic RCS rat and the 
rhodopsin knockout mouse. These are described in detail in chapters 3-6. A scheme of 
each experiment is illustrated in Figures 3.1, 4.1, 5.1 and 6.1.
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3. TRANSPLANTATION OF IMMORTALISED ALLOGENEIC 
RPE (LD7.4) CELLS TO THE SUBRETINAL SPACE OF 
DYSTROPHIC RCS RATS 
3.1 Introduction
Freshly harvested RPE cells have been shown to delay both functional and anatomical 
retinal degeneration in the RCS rat (1.3.1). However, while effective, they are likely 
to have limited application clinically given the large number of patients that may 
benefit. In particular, it would be difficult to provide sufficient numbers of healthy 
and phenotypically robust cells that are free from potentially harmful pathogens. 
Furthermore, ethical issues regarding the use of foetal tissue must also be considered 
(Gieser, 2001). This has led to the development of the genetically engineered cell 
lines, LD 7.4 (Greenwood et al., 1996) and hlRPE-7, (Kanuga et al., 2002; Lund et 
al., 2001a) to be tested in this thesis. Preliminary work in the laboratory initially 
confirmed the efficacy of the LD 7.4 cell line compared with primary rat RPE 
cultured cells to preserve photoreceptors.
3.2 Experimental design
The purpose of this experiment is to examine the degree to which visual function can 
be preserved by allografted cell lines and the level of functional rescue that can be 
sustained over time without the use of immunosuppression. The experimental design 
is shown schematically in Fig 3.1. A total of 49 rats received unilateral subretinal 
grafts (2xl05 cells per injection) of LD7.4 cells and 30 had sham injections. Nine 
grafted rats were allowed to survive for 5 months and 10 were sacrificed at 6 months 
with the remainder being sacrificed at earlier time points for anatomical assessment of
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Figure 3.1: Flow Diagram of Transplantation Studies using Immortalised LD7.4
Allogeneic RPE Cells
See section 3.2
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Figure 3.1
Flow Diagram of Transplantation Studies Using 
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short-term changes associated with transplantation. Age-matched non-dystrophic RCS 
rats provided an additional control group. Viability of residual RPE cells remained at 
>90% as assessed by trypan blue exclusion at the end of a transplant session. No 
immunosuppression was used in this group. A separate group of animals (n=ll), for 
histological analysis alone, received grafts of LD7.4 cells and were placed on ad 
libitum oral immunosuppression (cyclosporine: 210mg/l of drinking water). Lastly, in 
order to establish whether the fall off in photoreceptor preservation and visual 
function over time was due to the loss of grafted cells, 25 dystrophic RCS rats were 
grafted with LD7.4 cells prelabelled with bromodeoxyuridine.
Rats were head-tracked at 4 months (10 unoperated non-dystrophic animals, 28 
grafted dystrophic animals and 16 sham-operated dystrophies), 5 months (n=8, 22 and 
11, respectively) and 6 months (n=4, 6 and 5 respectively) of age. The times spent 
head-tracking were summed, averaged and the groups compared. Transplanted 
animals were divided into two groups for analysis, those that fell within two standard 
deviations of the sham performance (unsuccessful transplants) and those performing 
above this level (successful transplants): validity was confirmed on histology of "poor 
tracking" transplanted animals versus "good tracking" animals. Behavioural data was 
stored using Excel (Microsoft, USA). Results were analysed using a two-way analysis 
of variance (ANOVA), and post-hoc analysis on factors was performed on factors 
shown to be significant, using the Student-Newman Keuls test.
Electrophysiological recordings were made from 34 animals, (transplanted animals at 
5 months, n=5; and 6 months, n=6; non-dystrophic controls at 5 (n=3) and 6 months 
(n=3); unoperated dystrophic controls at 5 (n=3) and 6 months (n=4) and sham- 
operated dystrophies at 5 (n =5) and 6 months (n=5). Results from individual points of 
up to 6 animals per group were averaged for the respective 76 points in the superior
colliculus and subjected to statistical analysis using both a randomisation test and a t- 
test to compare the thresholds from animals receiving LD7.4 cells compared with 
shams. A group of grafted (n=3) and sham-operated (n=2) animals were compared 
with histological maps (see below: Fig 2.7) to test for any correlation.
At the end of the experiment, at five or six months of age, eyes were retrieved, fixed 
and embedded in polyester wax (transplanted eyes n = 5 at 5 months and 3 at 6 
months; sham-operated eyes n = 3 and 3 respectively) or resin (transplanted eyes n = 
4 and 3 respectively; sham-operated eyes n = 1 and 2 respectively). Three of the 
retinae (from animals at 6 months) and two sham-operated retinae were analysed for 
detailed histological assessment using cresyl violet (CV) or haematoxylin and eosin 
(H&E). Photoreceptor counts were made across representative sections (10-12 per 
eye) to give a detailed histological picture using an image analysis system (Image Pro 
Plus, Media Cybernetics, USA). The wax embedded eyes were cut at 8|um intervals in 
three series. Sections located 700pm apart were selected for analysis. Individual 
sections were divided into 700pm blocks (10-13 per section) and each photoreceptor 
cell counted in the block. The data from multiple sections were grouped into a 
histological map that was comparable to the retinal sensitivity maps generated from 
SC mapping. This histological map was then compared with retinal sensitivity maps 
and any correlation observed (Fig 2.7).
At various survivals, sectioned eyes were reacted for BrdU, macrophage markers 
(ED-1, 1:200 and ED-2, 1:400: Chemicon, Harrow, UK) and examined for apoptosis 
with NeuroTACS™ II in situ apoptosis detection kit, (R&D Systems Europe, 
Abingdon, Oxon, UK), see Appendix I.
3.3 Results
3.3.1 Head-Tracking
Previous studies have described the pattern of head-tracking in dystrophic versus non- 
dystrophic pigmented RCS rats (Lund et al., 2001b; Lawrence et al., 2000) and 
demonstrated that by 2 months of age dystrophic animals had lost the ability to track 
gratings of 0.125, 0.25 and 0.5 cycles/degree (c/deg). The performance of both control 
animals and those that had received subretinal grafts of LD7.4 cells at 3 weeks of age 
was evaluated using the same head-tracking procedure (2.4.2). By 4 months of age, 
two distinct sub-groups had emerged in the transplanted animal group: those that 
tracked well and those that did not (Fig 3.2A). This separation was based on the 
performance of transplanted animals at 4 months. Those animals with a head-tracking 
performance within two standard deviations of the mean sham performance were 
judged to be in the poor transplant group while those with performances better than 
two standard deviations were placed in the good transplant group. The differences in 
head-tracking performance between the good and poor transplanted groups at the 4 
month time point could not be explained by the perceived success of the grafting 
procedure at the time of surgery (section 2.3) but did exhibit a close post-hoc correlate 
with anatomical preservation of the retina as illustrated in Fig 3.2B,C which shows 
the anatomy of a representative good (B) and a representative bad (C) transplant at the 
same time point. Thus, a grafted animal that tracked well at 4 and 5 months (12.82 
and 9.08 seconds respectively) had better preservation of its outer nuclear layer 
compared with a grafted animal that tracked poorly (3.84 and 4.06 seconds 
respectively) at the same time points (Figure 3.2D). Analysis of variance (ANOVA) 
of the head-tracking data at 4 months of age revealed significant differences between 
the different experimental groups (F= 13.408, df=3,49 /?<0.0001). Post-hoc Student- 
Newman-Keuls showed no significant difference between the congenic non- 
dystrophic group (n=10) and the transplanted animals that tracked well (n=8).
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Figure 3.2: Head-tracking responses of rats with grafts of LD 7.4 cells and 
sham-operated rats at 4, 5 and 6 months and comparative histology.
A) Head-tracking performance of transplanted animals (successful and unsuccessful 
transplants) compared with normal (non-dystrophic) and sham-operated (sham) 
animals at 4, 5 and 6 months. Mean head-tracking times (all gratings) for successful 
transplants versus sham and unsuccessful transplants at 4, 5 and 6 months are shown 
as histograms on the right of each graph. Validity of this separation was confirmed on 
sample animals with histology (B,C). Data for dystrophic controls is not shown, as the 
mean was less than one second at all time points. There is some variation in head- 
tracking for normal congenic animals but they perform significantly better than 
unsuccessful transplant and sham groups (p < 0.05), and at 4 months there is no 
significant difference between successful transplant and non-dystrophic (p > 0.05) 
groups. At 4 months successful transplants are significantly better than sham and 
unsuccessful transplants (p < 0.05). B) A representative retina from an animal that 
performed well on head-tracking with a marked preservation of the outer nuclear layer 
(ONL) and outer segment material (OSM). C) Illustrates a representative section of 
retina from a poorly performing animal, analogous to the area shown in B, i.e. within 
200pm of the injection site: there is no ONL survival. Ganglion Cell Layer (GCL), 
Inner Plexiform Layer (IPL), Inner Nuclear Layer (INL), Outer Plexiform Layer 
(OPL), Outer Nuclear Layer (ONL), Outer Segment Material (OSM), Retinal Pigment 
Epithelium (RPE). Scale bar: 20pm. D) Histogram comparing the average 
transplanted and sham-operated animals head-tracking ability with the representative 
"good" and "poor" performers at 5 months, histologically represented in B and C 
respectively. Transplanted group (LD), Sham-operated group (Sh), Successful grafted 
animal (S) and Unsuccessful grafted animal (Un).
91
Tr
ac
ki
ng
 
(s
ec
)
Figure 3.2
Head-tracking Responses of Rats With Grafts of LD7.4 Cells and 
Sham-operated Rats at 4, 5 and 6 Months and Comparative Histology
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However, non-dystrophic animals and animals with good transplants were 
significantly better than poor transplants (n=13) and sham-operated (n=5) animals (p 
<0.05). There was no significant difference between sham and poorly performing 
transplant animals (p >0.05). Furthermore, increasing the spatial frequency of the 
grating resulted in a significant decrease in the amount of tracking in all groups 
(F=9.019, df=2,98 /?<0.001). At 5 months of age non-dystrophic animals still tracked 
all the gratings (F= 13.24, df=3,36 /?<0.0001; post-hoc Student-Newman-Keuls, 
p<0.05) whereas the performance of the good head trackers fell to a level not 
significantly different to those of poor trackers and sham-operated animals (p>0.05). 
At 6 months of age overall performance was reduced and there was no significant 
difference between any of the dystrophic groups. This reduction in visual function 
with time in the transplanted animals, as assessed by head-tracking behaviour, was 
therefore most striking between 4 and 5 months of age. At 6 months, however, 
photoreceptor rescue and head-tracking performance no longer correlated.
3.3.2 Threshold response mapping
Using head-tracking performance to identify good grafts, further studies were then 
carried out on this group of animals. Perimetric evaluation of threshold responses to a 
3° light stimulus in the superior colliculus (SC) was assessed as previously described 
(Sauve et al., 2001) and topographic data from individual animals of each 
experimental group were pooled. Point-to-point comparisons across the visual field of 
pooled groups were made to determine statistical differences between transplanted 
and control animals. Earlier studies using this technique (Sauve et al., 1998) measured 
the response to a spot of light of standard intensity, 4 log units above background but 
in this study a range of light levels was used to determine the relative threshold level 
at each point tested in the visual field (Sauve et al., 2001). Such an approach allowed
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a more careful analysis of sensitivity across the retina. Transplanted animals were 
tested at both 5 (n=5) and 6 (n=6) months of age together with unoperated dystrophic 
(n=4) and sham-operated (n=4) animals. The specific time points of five and six 
months of age were chosen in order to determine whether there was deterioration in 
graft efficacy with time. At earlier time points, the background and sham effects are 
still prominent making it difficult to separate deterioration of the graft-induced effect 
from background events. Furthermore, these ages were ones at which donor cells 
could no longer be detected histologically, allowing the opportunity to see whether 
function persisted beyond graft survival. The relative pooled threshold results at 6 
months of age are shown in Fig 3.3A-D where the threshold scores (log 
c/m2) have been inverted (inverted value: 0 - 4.5) to represent greater sensitivities as a 
peak. In non-dystrophic animals, a threshold level of between 3.8 -  4.2 was typical 
(Fig 3.3A) whereas in dystrophic non-transplanted animals, retinal sensitivity was 
extremely poor at 6 months of age, with levels typically of 0 -  1 (Fig 3.3B). Sham- 
operated animals demonstrated a focal area of improved retinal sensitivity in the 
immediate region of the injection site (Fig 3.3D) with individual points as good as 
2.0. In the transplanted animals, an area covering as much as 30% of the retina had 
sensitivities better than 2.5 (Fig 3.3C) extending well beyond the area of injection. 
Some points, however, had sensitivity thresholds as good as 3.9.
Additionally, a point-to-point comparison was made across the visual map of the 
colliculus in animals at six months. The analysis showed that in grafted animals, there 
was an area with statistically significant higher sensitivity levels which corresponded 
with the dorso-temporal region. This matched the region where the graft was placed 
(Fig 3.4A). Cross-group comparison revealed that the extent of significantly preserved 
threshold sensitivity was far greater in the transplanted retinae compared with both
93
Figure 3.3: Retinal sensitivity mapping of non-dystrophic, dystrophic, grafted 
and sham-operated rats with comparison of grafted and sham data.
This figure maps the collated and averaged threshold sensitivities of animals at 6 
months of age. Threshold (log) scores (A-D) have been inverted (0 -  4.5) to represent 
greater sensitivity as peak values, see 3.3.2. A) Non-dystrophic (n=3) B) Dystrophic 
unoperated (n=4) C) Dystrophic transplanted (n=5) and D) Dystrophic sham-operated 
(n=5). Non-dystrophic animals have uniformly good retinal sensitivity levels (>3.9) 
across the retina. Dystrophic animals have uniformly poor sensitivity levels at this age 
(<0.8). The transplanted animals have preserved sensitivity in the dorso-temporal 
region (injection site). Sham-operated animals demonstrated threshold levels in the 
dorso-temporal retina better than unoperated dystrophic retinae but significantly 
worse than transplanted animals, (D).
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Figure 3.4: Statistical significance maps: comparing grafted, sham and 
unoperated dystrophic rats at 6 months and comparing grafted rats at 5 and 6 
months.
This figure illustrates significance on a direct point-to-point comparison, i.e. 
analagous threshold points on the superior colliculus are summed and compared with 
these points in the other groups, for transplanted retinae compared with A) sham- 
operated animals or B) dystrophic animals at six months. A statistical analysis of 
sham-operated retinae compared with dystrophic retinae is shown in C. Specific 
differences are shown.
A statistical comparison of transplanted animals at 5 (n=5) and 6 (n=6) months 
demonstrates that the area of preserved sensitivity is greater in the younger group (D).
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Figure 3.4
Statistical Significance Maps
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sham-operated retinae (Fig 3.4A) and unoperated dystrophic (Fig 3.4B). Sham- 
operated retinae also demonstrated significantly better threshold levels compared with 
unoperated dystrophies (Fig 3.4C).
The threshold data from individual transplanted animals at five months of age (n=5) 
were grouped and averaged for each point in the plot and compared with similarly 
grouped data from transplanted animals at 6 months of age (n=6). The threshold 
response patterns of transplanted animals at five months were significantly better than 
those at six months of age (Fig 3.4D) suggesting that while the RPE grafts preserved 
retinal function for a considerable period of time, the effect diminished between these 
time points.
3.3.3 Morphological Analysis
Non-dystrophic animals demonstrated normal retinal architecture with an outer 
nuclear layer up to 12 cells thick and regularly arranged inner and outer segments (Fig 
3.5A). Sham-operated animals at both 5 and 6 months of age had a focal area of 
photoreceptor rescue very close to, or extending 300 - 400 pm from, the injection site 
(Fig 3.5D). Beyond this area no photoreceptors could be identified (Fig 3.5E). At 5 
and 6 months those animals that received successful LD 7.4 cell grafts, as previously 
defined by a good head-tracking response, demonstrated a considerable amount of 
photoreceptor rescue, up to 6 cells thick, with marked outer segment preservation (Fig 
3.5B,C).
The area of rescue extended far beyond the injection site (up to 3000pm): this is 
illustrated in Fig 3.6A. Three grafted and two sham-operated animals at 5 months 
were subjected to a more detailed histological examination. The data from multiple 
sections were grouped into a histological (multipoint) map that was comparable to the 
retinal sensitivity maps generated from SC recordings. This analysis demonstrated
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Figure 3.5: Semi-thin histology of grafted compared with sham-operated rats at 6 
months.
A) Non-dystrophic RCS rat retina at 6 months of age. B) Grafted dystrophic retina at 
6 months of age (5 months post-transplant). There is a large amount of photoreceptor 
rescue (up to six cells thick), inner segments (IS) are retained with disorganized outer 
segment material (OSM). There is a small artifactual detachment (asterix) at the site 
of the outer limiting membrane. C) Also shows rescue at 6 months of age in a 
transplanted animal: this is a more typical picture of preservation with ONL 3-4 cells 
thick. D) Shows a sham-operated animal at 6 months of age immediately adjacent to 
the injection site. There are some photoreceptors (ONL) and a persistent debris zone 
(DZ). E) Distant from the injection site there are very few photoreceptors and a sparse 
debris zone, similar in appearance to an unoperated dystrophic RCS rat retina of the 
same age. Scale bar: 20pm.
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Figure 3.5
Semi-thin Histology of Grafted Compared with Control and Sham-
Operated Rats at 6 Months
that the area of photoreceptor rescue varied between 2 and 6 cells thick (90-380 
cells/700pm) and covered between 10% and 30% of the total retinal area. In regions 
distant from the area of graft injection, occasional photoreceptors were encountered in 
a density similar to that found in unoperated or sham-injected rats. The peak cell 
counts correlated to the region of highest retinal sensitivity. Correlation of these maps 
demonstrated the close relation between the amount of photoreceptor rescue and 
retinal sensitivity (Fig 3.6A,B).
3.3.4 Survival of RPE Cell Grafts
Cells labelled with BrdU were seen in the subretinal space of eyes retrieved at 1 and 5 
days and two weeks following transplantation (Fig 3.7A-H). Eyes examined at 4 
weeks following transplantation failed to demonstrate the presence of grafted cells by 
BrdU immunohistochemistry (Fig 3.7J). Despite the apparent loss of grafted cells (Fig 
3.7L,N) the retina adjacent to the injection site showed preservation of photoreceptors 
at 3 and 5 months post-transplantation (Fig 3.7K,M). It was also apparent that the area 
of maximal photoreceptor cell rescue declined with time (Fig 3.7I,K,M). The grafted 
cells did not appear to integrate with host RPE on Bruch’s membrane (Fig 3.7D,F,H). 
To confirm that rapid graft cell loss was occurring, PCR amplification studies were 
performed to identify the presence of SV40 large T-antigen signal at day 5 in 3 
animals studied (Fig 3.8). By day 28 and at 3 months survival, genomic material was 
detected infrequently and by 5 months survival (6 months of age) no signal was 
detectable in any sample (n=7). Single cells (added exogenously) were detected in 
control sections. In conclusion, at 5 months post-graft the absence of signal correlates 
with the absence of grafted cells as determined by immunohistochemistry.
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Figure 3.6: Comparison of retinal sensitivity maps with histological maps of 
individual representative animals at 5 months.
A) Electrophysiological (upper) and histological (lower) maps represented in 3-D. 
Dorsal (D), Ventral (V), Temporal (T) and Nasal (N). In the dorso-temporal region of 
the retina there is greater photoreceptor cell preservation that correlates with the 
maximal area of retinal sensitivity (DGNEM and DGREM). The one transplanted 
animal represented here with poorer retinal sensitivity (DGLEM) also has fewer 
photoreceptors. B) Sham-operated animals generated flatter maps, however the local 
area of photoreceptor rescue is clearly seen and is represented as a spike rising to 90- 
cells/700pm block. These maps were produced by a custom-generated computer 
package in MatLab, version 5.1, using bespoke programmes. The maps confirm the 
relationship between photoreceptor cell preservation and retinal sensitivity. Legends 
under the maps refer to individual animals.
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Figure 3.6
Comparison of Retinal Sensitivity Maps with Histological Maps
at 5 Months
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Figure 3.7: Localisation of grafts
Haematoxylin and Eosin (left column) and Bromodeoxyuridine labelling (right 
column) of retinae taken from animals at 1 (A and B) and 5 (C-F) days, 2 (G and H) 
and 4 (I and J) weeks and 3 (K and L) and 5 (M and N) months post-transplantation.
At day one the grafted cell bolus is clearly seen (A) and confirmed with BrdU 
labelling (B). There is some disorganization in the subretinal space post-graft. In 
addition to the grafted bolus some labelled cells are seen adjacent to Bruch's 
membrane (arrowed). At five days post-transplantation, the grafted cells are seen in an 
organized bolus in the subretinal space (C) and at slightly higher magnification (E). 
The bolus contains grafted RPE cells as illustrated in D and F (arrowed). By two 
weeks there is still some disruption in the subretinal space (G) but only occasional 
donor cells could be identified (H). At four weeks (7-8 weeks of age) there is 
preservation of the outer nuclear layer (I) yet no grafted cells can be identified in this 
section (J) or any others examined (n=6). Photoreceptor preservation in grafted 
animals is seen in retinae at three (K) and five (M) months post-grafting. BrdU- 
labelling at three (L) and five (N) months shows the absence of positive labelling in 
these sections and others examined (n=8 and 7 respectively). This panel of images 
demonstrates a number of key points: the loss of grafted cells over time, the persistent 
preservation of photoreceptors up to five months post-graft and that preservation 
deteriorates with time. The sections illustrated represent maximal rescue in each of 
these retinae.
Outer Nuclear Layer (ONL), Grafted Cells (GC), Subretinal Space (SRS), Artifactual 
Detachment (*). Scale bars: 20pm.
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3.4 Discussion
This study shows that transplantation of a genetically engineered immortalised 
allogeneic RPE cell line, in the absence of immunosuppression, can delay 
photoreceptor degeneration and preserve visual function for up to six months in the 
RCS rat. Preservation of photoreceptors and visual function at 6 months of age, as 
assessed by retinal sensitivity mapping in the SC, was significantly better than in 
sham-operated animals and the two parameters showed a close correlation. However, 
despite significant attenuation in disease progression following cell transplantation, 
there was no evidence of graft cell survival beyond 4 months post-grafting, a time 
point when head-tracking behaviour had reduced to background levels.
Following transplantation of immortalised allogeneic RPE cells, morphological 
examination of good head-tracking animals tested at early survival times revealed 
substantial preservation of photoreceptors at both five and six months of age (4 and 5 
months post-grafting respectively) even though head-tracking no longer discriminated 
cell grafted and sham-injected rats. At 6 months it was not uncommon to find 
retention of two or more rows of photoreceptor nuclei (Fig 3.5C) over as much as 
30% of the retinal area and in some cases the rescue was as much as 7 cells thick (i.e. 
60% of the normal photoreceptor thickness: Fig 3.5B). Associated with this area of 
rescue was clear evidence of outer segment material. This histology was in marked 
contrast to unoperated animals of the same age where only occasional photoreceptors 
could be identified or to sham-injected animals where there was only a small amount 
of rescue (1-2 cells thick) immediately adjacent to the injection site. The level of 
rescue obtained after cell transplantation was similar to previously published results 
with fresh RPE allografts (Li and Turner, 1988; Lopez et al., 1989; Whiteley et al., 
1996).
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In previous studies, a direct correlation between photoreceptor rescue and a functional 
parameter has not been made. This study demonstrates that the region of 
photoreceptor preservation clearly correlates with low threshold response levels 
recorded electrophysiologically in the SC. Thus, the region of preserved retina 
correlates with the region of preserved visual function (Fig 3.6A,B). This observation 
mirrors the situation in some patients with retinal disease such as retinitis pigmentosa, 
where there may be areas of uneven function and retinal preservation (Sieving et al 
1999). Continued function with modest rescue, also noted in a previous study using 
human immortalised RPE cell lines (Coffey et al., 2002), also has a correlate with 
human studies where despite having only a few remaining photoreceptors, patients 
maintain some functional central vision, up to a visual acuity of 20/30 (Sieving et al, 
1999). This has implications for clinical studies since it may be sufficient to preserve 
only a few rows of photoreceptors to permit retention of useful vision. The ability to 
predict retinal sensitivity from anatomical data will have a positive impact on the 
interpretation of other experimental treatment strategies.
The ability of head-tracking to provide a good non-invasive technique for measuring 
transplant efficacy at early survival times makes it a very valuable tool for initial 
screening to discriminate between good and poor transplants (Fig 3.2B-D). The 
deterioration of head-tracking responses with time has been found in previous studies 
(Lawrence et al., 2000) although the reasons for this are presently unclear. Head- 
tracking was originally developed for assessing retinal function in rats without retinal 
pathology (Cowey and Franzini, 1979), but has not been evaluated when used, as 
here, in a situation in which only part of the retina is functional. It is possible that 
good head-tracking performance requires preservation of a sufficiently large area of 
retina, even perhaps a particular region of retina. Thus, even though retinal rescue was
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Figure 3.8: PCR detection of SV40 large T-antigen DNA in retinal sections of 
LD7.4 transplanted RCS rats.
Amplification of SV40 large T-antigen from genomic DNA isolated from five 8 pm 
retinal sections taken from the graft site of animals previously transplanted with 
bromodeoxyuridine labelled LD7.4 cells. SV40 large T-antigen is amplified from 
some animals at 12 weeks post-transplantation but is not present in any of the animals 
tested at 20 weeks post-transplantation. Sensitivity of the PCR reaction has been 
established as a single copy of the SV40 large T-antigen sequence (1 cell). Also 
shown are positive control amplifications from SV40 large T-antigen cDNA and from 
retinal sections spiked with a single and 10 LD7.4 cells. Negative PCR controls have 
the DNA template omitted. The table details the number of animals assayed and 
corresponding positive results at each time point.
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Figure 3.8
PCR Detection of SV40 Large T-Antigen DNA in Sections 
from LD7.4 Transplanted Rats
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demonstrated for several months, the area of preservation may decrease with time to a 
level below the threshold required to initiate a head-tracking response or possibly 
eliminating the crucial region for initiation of the response. This explanation is 
supported by the fact that although preservation of retinal function could be detected 
electrophysiologically, there was a significant reduction in the area of rescue between 
groups of rats allowed to survive for 5 and 6 months. The loss of photoreceptors with 
time after transplantation of RPE cells to RCS rats has a precedent in other studies (Li 
and Turner, 1991; Zhang and Bok, 1998). However, the determining factors 
responsible for the temporal and spatial loss both of photoreceptors and visual 
function have yet to be fully resolved. Various processes may be operating, not 
necessarily exclusively, that result in retinal deterioration. For example, transplanted 
RPE cells may be unable to sustain other necessary functional attributes with time 
such as phototransduction (Bok, 1993). Furthermore, secondary events (Villegas- 
Perez et al., 1998) that result in vascular remodelling in the RCS rat retina adjacent to 
the preserved region may gradually encroach on the preserved retina. A major factor, 
however, is likely to be the host immune response. Although the subretinal space is 
thought to be an immunologically privileged site (Jiang and Hamasaki, 1994) and 
RPE an immunologically privileged tissue (Wenkel and Streilein, 2000), these 
properties are not absolute and may be further compromised by leakage of the blood- 
retinal barrier as a consequence of both the surgery and the disease pathology: inner 
retinal vessels in the RCS rat become fenestrated and leaky as photoreceptors are lost 
and the vessels come to lie adjacent to the choroid (Villegas-Perez et al., 1998) In this 
study, allogeneic cells were grafted and the loss of the blood-retinal barrier may lead 
to some form of immune response and the ultimate destruction of the grafted cells. It 
is clear from preliminary data that a classical immune response is not occurring since
104
there is no leucocyte cuffing of blood vessels or infiltration of lymphocytes but it may 
be driven by a mechanism involving macrophages and activated retinal microglia. 
Immunosuppression with cyclosporine does not alter the kinetics of allograft cell loss 
(unpublished observations) confirming a recent report that cyclosporine does not 
protect against allograft failure in a rabbit model (Craaford et al., 2000). This suggests 
that a non T-cell dependant mechanism is responsible for the loss of grafted cells. 
However, in a complementary xenograft study in which human RPE cell lines were 
grafted into the RCS rat, cyclosporine immunosuppression led to preservation of 
photoreceptors and visual function along with persistence of grafted cells up to 8 
months post-transplantation (see Chapter 5; Lund et al., 2001a; Coffey et al., 2002). 
This study shows preservation of photoreceptors also at 6 months of age, yet, in the 
absence of grafted cells. Similar results have also been reported following human 
RPE cell transplantation in the rabbit (Lai et al., 2000).
LD7.4 cells prelabelled with BrdU were used to establish whether the loss of retinal 
photoreceptors and visual function following transplantation was due to poor graft 
survival in the host retina (see also Ye et al., 1993; Lund et al., 2001a; Coffey et al., 
2002). Although grafted cells were found to survive in the early post-transplant 
period, no cells could be identified at later time points despite the retina in the region 
of the injection site showing significant preservation (Fig 3.7). In order to confirm this 
observation, PCR was used to detect the presence of the SV40 large T-antigen gene in 
sections of grafted retina up to 6 months of age (5 months post-graft: Fig 3.8). Data 
from these studies demonstrated the likely presence of grafted cells in some samples 
up to 4 months of age but no positive detection thereafter. The sampled regions were 
small, so it was not possible to be sure that all the donor cells were lost. Nevertheless, 
these results demonstrate that there is a substantial reduction in graft cell population
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with time. Graft cell loss is unlikely to be a consequence of the stability of the grafted 
cells as the SV40 large T immortalised LD 7.4 RPE cell line is phenotypically stable 
through multiple passages in vitro. Moreover, ongoing studies have shown that these 
cells display normal immunological properties such as MHC and cytokine expression. 
They may fail due to an inability to integrate with the resident host RPE and anchor 
themselves on Bruch’s membrane. One important conclusion from this work is that 
continued presence of large numbers of donor RPE cells is not a necessary 
prerequisite for photoreceptor survival, but rather that survival continues beyond the 
loss of donor cells by two months or more, yet RPE cell loss will ultimately lead to 
functional failure. This novel observation emphasises the need to employ reliable cell 
tracking techniques in experimental transplantation to determine the relationship 
between preserved retina and grafted cells.
To summarise, transplantation of an immortalised allograft RPE cell line delays the 
deterioration of both retinal histology and function. Of particular interest is the 
finding that donor cells do not survive for more than a few months, but that rescue of 
photoreceptors and of visual function continues for a further two or more months. The 
model provides an opportunity to probe the mechanisms that contribute to this rescue 
process, its deterioration over time and the development of strategies to improve the 
efficacy and survival of such grafts.
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Chapter 4
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4. TRANSPLANTATION OF GREEN FLUORESCENT PROTEIN 
LABELLED ALLOGENEIC RPE (LD7.4) CELLS TO THE 
SUBRETIN AL SPACE OF NON-IMMUNOSUPPRESSED
DYSTROPHIC RCS RATS 
4.1 Introduction
In the previous chapter, it was found that photoreceptors and visual function were 
preserved for longer periods than the donor cells themselves.
In other RPE transplant studies various labelling techniques have been utilised such 
as p-galactosidase (Osusky et al., 1995), bromodeoxyuridine (Ye et al., 1993; Lund et 
al., 2001a), Green Fluorescent Protein (GFP, Lai et al., 2000) and in situ hybridisation 
of the Y-chromosome in male to female grafts (Wang et al., 2001). Other studies have 
included Del Priore (2003 a and b, 2004)). To date no group has successfully labelled 
grafted cells for in vivo imaging in the RCS rat model; this would provide an 
important addition to the study of progress of the transplanted cells. The ability to 
compare the location of grafted cells relative to preserved photoreceptors and retinal 
function is essential in determining the relationship of that intervention with outcome. 
The large animal models (e.g. rabbit: Lai et al., 2000) used in previous studies with 
GFP-labelled donor cells were without an inherent degeneration and, aside from 
describing donor cell location, little else could be determined.
In addition to serving as a replacement for defective host RPE cells, the possibility is 
being explored for using the cell as a delivery system for targeted gene therapy e.g. 
antiangiogenics (Otani et al 2002) or growth factors (Tao et al., 2002). That 
possibility prompted this particular experiment.
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In this chapter a novel vector, the Human Foamy Virus (HFV) expressing green 
fluorescent protein, will be used to transfect LD7.4 cells. The Human Foamy Virus is 
a novel retrovirus that does not cause pathology in humans (Ali et al 1996) and has 
been shown to transfect cells in vitro (Bieniasz et al 1997) effectively.
4.2 Experimental Design
The aim of the study is to use GFP labelled LD7.4 cells as donor cells and trace their 
survival through time in vivo using a confocal scanning laser ophthalmoscope. Figure
4.1 illustrates the experimental design schematically.
Twenty four dystrophic RCS rats (PN21) received subretinal grafts of LD7.4 cells 
transfected with HFV expressing GFP (Fig. 4.2). Two microlitres of LD7.4/GFP cells 
in suspension were injected (lx 105 cells/jul) into the dorso-temporal retina. Twelve 
dystrophic RCS rats (PN21) received sham surgery (medium alone).
Sham-operated and animals that received LD7.4/GFP cells underwent serial 
fluorescent imaging using a Zeiss confocal scanning laser ophthalmoscope (cSLO) at 
1 day, 1, 2, and 4 weeks post-transplantation. Rats were anaesthetised with a 
ketamine/xylazine mix (100mg/20mg) and pupils were dilated using Tropicamide 
(Alcon, Hemel Hempstead, UK). An argon laser light (488 nm) was used for 
illumination, and a wide band pass filter with short wavelength cut off (521 nm) was 
inserted in front of the detector to record fundus autofluorescence. The argon laser 
was measured at regular intervals and found to have a constant power output of 250 
pW at the cornea. The automatic gain control was switched off and the instrument 
gain was kept constant for all measurements of both transplanted and sham-opertaed 
animals. A series of images of the eye was recorded at standard video scanning rates 
on VHS video tape. Later, 32 consecutive frames were digitised, aligned, and 
averaged to obtain each image.
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Figure 4.1: Flow Diagram of Transplantation Studies using Immortalised
RPE/GFP Cells
See section 4.2
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Eyes from all treatment groups were harvested at 1, 7, 14, 28, 84 and 120 days post­
surgery and processed for histology to identify donor cells and the host macrophage 
response. The rats were perfused trans-cardially with PBS and 4% paraformaldehyde. 
The eyes were removed, cryoprotected with 10%, 20% and 30% sucrose in PBS 
embedded in optimal cutting temperature compound (OCT; Tissue-Tek, Miles, 
Raymond Lamb, London, UK) and frozen. A number of series of sections were cut at 
12pm and stained with cresyl violet or haematoxylin and eosin. Adjacent serial 
sections were reacted with antibodies for GFP (Chemicon, Harrow, UK 1:750) and 
macrophages (anti-EDl; 1:200 from Chemicon, Harrow, UK and anti-ED2, 1:400, 
from Chemicon, Harrow, UK).
Following transplantation, apoptotic cells were identified in the subretinal space using 
a NeuroTACS™ II in situ apoptosis detection kit (R&D Systems Europe, Abingdon, 
Oxon, UK).
4.3 Results
4.3.1 Cell Labelling
The generation of the vector is detailed in section 2.2.1.2.1. The green fluorescence 
protein (GFP) gene was inserted into the bel genomic region under the transcriptional 
control of an SV40 promotor. RPE cells were seeded at 5xl03 cells/well in a 24 well 
plate. The cells were then transfected with 5xl04 virus particles. Cells transfected with 
the HFV demonstrated GFP expression, by flow cytometry, in 60% of cells (Fig 4.2). 
These were sorted and expanded and when analysed by fluorescence-activated cell 
sorting (FACS) more than 90% of the cells were GFP positive. This was maintained 
through serial passages. This population of high yield GFP positive cells were used 
for transplantation to the dystrophic RCS rat retina.
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Figure 4.2: Retinal Pigment Epithelial Cells (LD7.4) Expressing GFP in vitro
A) Phase contrast and B) fluorescent photomicrographs of cells prior to confluence. 
There is a high expression rate (>90%) of GFP which remains stable through multiple 
passages.
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Figure 4.2
LD7.4 Cells Expressing GFP
B
4.3.2 Confocal Scanning Laser Imaging
Figure 4.3A shows a cSLO image of a suspension of GFP labelled LD7.4 cells prior 
to transplantation. Fourteen rats were imaged at day one. No fluorescent patch was 
evident in the sham-operated animals (Fig 4.3B,C) whereas all grafted animals 
demonstrated a patch of fluorescence in the dorsal retina consistent with the site of the 
transplant (Fig 4.3D,E). As cell suspensions were used the observed area was diffuse 
with an indistinct edge. All retinal detachments had resolved by day one. By week one 
there was an obvious reduction in the strength of fluorescence in the grafted retinae 
(Fig 4.3F,G) and there was further reduction by week 2 (Fig 4.3H,I). By week 4 there 
was no difference in the fluorescence level in the grafted (Fig 4.3J,K) versus sham 
operated animals (Fig 4.3 L,M). The fluorescence seen at this time point is a 
background fluorescence seen in all animals as they age due to RPE/debris zone 
autofluorescence. The GFP signal seen at earlier times is a brighter fluorescence 
which eventually disappears. The time course of disappearance of in vivo 
fluorescence is mirrored in by the histological results using fluorescence microscopy 
and the anti-GFP antibody (Figs 4.4-4.7).
4.3.3 Histology
To determine whether the reduction in fluorescence demonstrated by cSLO imaging 
was due to a loss of donor cells or due to a reduction in GFP expression, graft cell 
survival was examined in sectioned material. Figure 4.4A,B shows the gross 
morphology of the grafted retina at the site of injection. Fluorescent images from 
adjacent sections show numerous fluorescent cells (GFP positive) in the subretinal 
space at one day post-transplantation (Fig 4.4 C,D). However, using macrophage 
antibodies and the Neurotacs™ apoptosis kit, it was found that the cell bolus 
contained a mixed cell population of donor cells, both viable (Fig 4.4E,F) and
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Figure 4.3: Confocal Scanning Laser Ophthalmoscope (cSLO) Images of Cells in 
vitro and in vivo
A) Demonstrates the fluorescent cSLO appearance of a suspension of GFP-expressing 
LD7.4 cells prior to transplantation. Line shows limit of cell suspension. B-M) 
illustrate reflectance (upper) and fluorescent (lower) confocal in vivo imaging of RCS 
rat retinae following sham injection or transplantation. B and C) illustrate images 
from a sham-operated animal one day post-transplantation, there is no fluorescence. D 
and E) are images from a grafted animal at day one. Vessels are arrowed (relate to 
analogous landmark vessels in reflectance and fluorescent images). There is marked 
fluorescence at one day, presumably emanating from grafted cells. F and G) illustrate 
that this fluorescence is reduced at week one and further at week two (H and I). At 4 
weeks transplanted (J,K) retinae are indistinguishable from sham-operated retinae 
(L,M) Imaging at week four demonstrates the inability to distinguish between 
transplanted (J and K) and sham (L and M) due to a) the loss of defined fluorescence 
in the graft and b) background autofluorescence in the RCS rat model.
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Figure 4.3
Confocal Scanning Laser Ophthalmoscope Images of Cells In Vitro
and In Vivo
Figure 4.4: Histology and Immunohistochemistry of Retina One Day after 
Grafting LD7.4/GFP Labelled Cells
A) Light micrograph showing gross morphology of the retina, stained with cresyl 
violet, at the injection site and B) adjacent to it. Numerous subretinal cells can be 
identified. C and D) are fluorescent images from sections adjacent to A and B. E and 
F) are adjacent anti-GFP antibody labelled sections (antibody visualised with alkaline 
phosphatase and Vector blue) confirming that the fluorescence in C) and D) is due to 
GFP. G) and H) show sections labelled with anti-EDl antibody. Only a weakly 
labelled microglial cell can be identified in H. I) shows the presence of many ED2- 
positive cells in the subretinal cell population seen in A. There are no ED-2 positive 
cells identified away from the graft site (J). K) illustrates the presense of apoptotic 
cells (arrowed and labelled with DAB) in the graft cell bolus.
Inner Nuclear Layer (INL), Outer Nuclear Layer (ONL), Subretinal Space (SRS), 
Retinal Pigment Epithelium (RPE), Neural Retina (NR). Scale bars 20pm.
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Figure 4.4
Histology and Immunohistochemistry of Retina One Day After
Grafting LD7.4/GFP Labelled Cells
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apoptotic (Fig 4.4K) and ED-2 positive cells (host macrophages and microglia: Fig 
4.41). Less reactivity was seen with the EDI antibody (Fig 4.4G,H) at one week post­
transplantation the number of labelled cells appeared to have diminished (Fig 4.5A-E) 
and cells positive for EDI and ED2 (Fig 4.4F-H) were present in the vicinity of the 
graft. By two weeks there were no GFP-positive cells remaining in the subretinal 
space (Fig 4.6E) although ED-1 and ED-2 positive cells remained. There is a 
population of fluorescent cells but these exhibit broadband fluorescence (480 -  
590pm), i.e. they do not represent cells that are specifically expressing GFP (maximal 
emission at 510pm) as the signal intensity on the confocal microscope is no different 
at variable wavelengths (Fig 4.6C,D). Four months after surgery no grafted cells 
could be detected (Fig 4.7C) yet there was considerable preservation of 
photoreceptors (Fig 4.7A). Occasional ED-1 positive cells could still be observed in 
the inner retina (Fig 4.7D).
4.4 Discussion
This study has demonstrated that RPE cells can be transfected ex vivo with the Human 
Foamy Virus, and that the expression is stable. After grafting GFP-expressing RPE 
cells to the subretinal space of the RCS rat, the fluorescent marker was easily imaged 
with the cSLO. Fluorescent in vivo imaging showed a rapid loss of specific 
fluorescence and by four weeks it was not possible to distinguish any fluorescent- 
labelled grafted cells above the normal autofluorescence of the host RPE cells. The 
histological study confirmed the loss of GFP-positive cells by 2 weeks post­
transplantation. Numerous apoptotic cells were seen and this loss of cells was 
accompanied by an infiltration of macrophages (ED-1 and ED-2 positive cells). 
Despite the loss of donor cells, photoreceptors were maintained for up to four months 
post-transplantation. This study has demonstrated a number of key points. Firstly, the
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Figure 4.5: Histology and Immunohistochemistry of Retina One Week after 
grafting LD7.4/GFP Labelled Cells
The panel illustrates marked retinal disruption with a mixed cell population in the 
subretinal space (SRS); A and B) are cresyl violet stained sections of adjacent areas in 
the retina; C and D) are the corresponding fluorescent images. E) Section visualised 
with anti-GFP antibody, alkaline phosphatase and vector blue showing few GFP 
labelled cells remaining (arrow), F) ED2-positive cells and G,H) many EDI-positive 
cells (arrows).
Inner Nuclear Layer (INL), Outer Nuclear Layer (ONL), Retinal Pigment Epithelium 
(RPE), Neural Retina (NR). Scale bars = 20pm
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Figure 4.5
Histology and Immunohistochemistry of Retina One Week After
Grafting LD7.4/GFP Labelled Cells
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Figure 4.6: Histology and Immunohistochemistry of Retina Two Weeks Post­
transplantation
A) Cresyl violet stained section showing marked retinal disruption. B) Fluorescence 
micrograph of the area in (A) shows many fluorescent cells. C) and D) illustrate that 
these subretinal fluorescent cells emit a broad-band fluorescent signal (i.e. the 
strength of the signal at the red (580pm) and green (510pm) wavelengths is equal) 
and appear to be macrophages (see H). E) These cells are not GFP positive but are in 
association with G) many EDI and H) ED2 positive cells.
Inner Nuclear Layer (INL), Outer Nuclear Layer (ONL), Subretinal Space (SRS), 
Retinal Pigment Epithelium (RPE), Neural Retina (NR). Scale bars = 20pm
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Figures 4.6
Histology and Immunohistochemistry of Retina Two Week After
Grafting LD7.4/GFP Labelled Cells
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Figure 4.7: Histology of Retina at 4 Months Post-transplantation
A) A cresyl violet stained section of retina with preserved photoreceptor nuclei (ONL) 
adjacent to the injection site. B) Fluorescent micrograph of an area analogous to A) 
showing fluorescent cells (arrow). C) The fluorescent cells are not GFP-expressing 
cells confirmed by the absence of GFP anti-body labelling.. D) shows a number of 
EDI positive cells remain in the area.
Inner Nuclear Layer (INL), Outer Nuclear Layer (ONL), Subretinal Space (SRS), 
Retinal Pigment Epithelium (RPE). Scale bars = 20pm
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Figure 4.7
Histology and Immunohistochemistry of Retina Four Months After
Grafting LD7.4/GFP Labelled Cells
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Human Foamy Virus can act as a very efficient vector for transfection of RPE cells 
and that expression is maintained through numerous passages. This has important 
implications for the use of the RPE cell as a delivery system for molecules that could 
benefit the retina in degenerative conditions such as AMD or retinitis pigmentosa. 
One such strategy might be to transfect RPE cells with novel anti-angiogenic agents 
such as Truncated Tryp (Otani et al., 2003), reducing the risk of CNV recurrence 
following transplantation. Similarly they could be used as a delivery system for 
growth factors (such as GDNF or CNTF) that are known to be beneficial for the 
neural retina (LaVail et al., 1992; Lawrence et al., 2004). Thus, in addition to 
replacing lost or removed RPE cells, the grafts could provide supplementary support 
for the remaining photoreceptors and choriocapillaris.
Secondly, macrophage infiltration after transplantation is an early event but they 
persist in the subretinal space and inner retina up to four months post-operative. The 
continued presence of macrophages in the subretinal space may reduce the toxic effect 
of accumulating outer segment debris and thereby contribute to photoreceptor 
survival. In experimental autoimmune uveitis the macrophages in early and late 
disease are different and produce altered levels of nitric oxide (NO), and what is 
observed in this study may mirror that phenomenon.
Thirdly, this technique has the potential to be used in longitudinal studies on the same 
series of animals and the results from this and from the sectioned material confirm the 
findings in Chapter 3, that photoreceptor survival after transplantation in the RCS rat 
is not dependant on the prolonged presence of grafted RPE cells (Keegan et al., 
2002). Although the principal role of macrophages is to remove dead cells, it is 
possible that paradoxically they may release factors that support photoreceptor 
survival after donor cell death. For instance, IL-lp or bFGF secreted by host
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macrophages or microglia could contribute to photoreceptor survival. The beneficial 
effects of these agents in the RCS rat have been demonstrated in other studies 
(Akimoto et al., 1999; Whiteley et al., 2001). The finding that photoreceptors persist 
in the RCS rat long after donor cells are lost emphasises the importance of adequate 
donor cell labelling in order to make an accurate assessment of the beneficial effect of 
any potential treatment. In summary, the Human Foamy Virus efficiently and stably 
transfects RPE cells and this could have a therapeutic application. In agreement with 
the findings in Chapter 3, LD 7.4 RPE cells transplanted to the retina preserve 
photoreceptor morphology and function in the RCS rat for several months, yet most of 
the graft itself appears to be lost by about 2 weeks.
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5. TRANSPLANTATION OF IMMORTALISED XENOGENEIC 
HUMAN RPE (hlRPE-7 AND ARPE 19) CELL LINES TO THE 
SUBRETINAL SPACE OF IMMUNOSUPPRESSED 
DYSTROPHIC RCS RATS
5.1 Introduction
As described in Chapters 1 and 3, major restrictions for RPE transplantation are 
imposed by the limited supply of human donor eyes and the finite numbers of 
phenotypically stable and functional RPE cells that can be harvested from primary 
culture. Furthermore, the impracticality of performing full safety testing on primary 
cultures from every donor further limits their wide-scale clinical use. Relatively little 
attention has been given to functional parameters in the systematic assessment of graft 
efficacy (Little et al., 1998). Neither levels of photoreceptor rescue (Gouras et al, 
1989; Li et al., 1991; Little et al., 1996; Lopez et al., 1989) nor ERG measurements 
(Jiang et al., 1994) are indicators of how much vision is restored following 
intervention.
The human cell line, hlRPE-7, was developed in the Institute of Ophthalmology. It 
has been genetically modified to extend its in vitro life span and it will be tested 
alongside a spontaneously derived human RPE line (ARPE 19, Dunn et al., 1996). 
These lines can undergo an extensive number of cell doublings and can be subjected 
to rigorous testing to produce cell banks of pathogen-free and phenotypically identical 
cells for use in transplantation. The purpose of this chapter is to describe the 
characterisation of hlRPE-7, and to assess the effects of transplanting both cell lines 
into immunosuppressed dystrophic RCS rats. Head-tracking behaviour and threshold
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sensitivity reponses (recorded from the SC) will be used to assess the degree of 
preserved visual function.
5.2 Experimental design
This experiment is designed to compare xenograft cell and photoreceptor survival and 
to assess maintenance of visual function.
Thirty-three rats (hlRPE7, n=20 and ARPE19, n=13) received subretinal grafts 
(2xl05 cells per injection) and 10 had sham injections. All animals were maintained 
on oral cyclosporine A (210mg/l of drinking water) from 2 days before transplantation 
until sacrifice. Grafted rats ( hlRPE7, n=5; ARPE19, n=6) were allowed to survive 
for 5 months post-operatively with the remainder being sacrificed at earlier time 
points for histological assessment of short-term changes associated with 
transplantation. A further 6 non-operated age-matched dystrophic and 3 non- 
dystrophic RCS rats provided cyclosporine treated controls. To examine donor cell 
survival, a separate group of rats (hlRPE-7, n=5 and ARPE19, n=7) received cell 
grafts that had been pre-labelled in vitro with 20pM bromodeoxyuridine (BrdU, 
Sigma, Poole, UK) 48 hours prior to transplantation.
Animals were head-tracked at 10 weeks (hlRPE-7 only) and 20 weeks (both hlRPE-7 
and ARPE19 groups) postoperatively. The BrdU group was tested at 20 weeks post- 
operatively. Behavioural data was analysed as described in 2.4.2. Electrophysiological 
data (see 2.4.3) collected from individual points of up to 5 of the above animals were 
averaged and subjected to statistical analysis using both a randomisation test and a t- 
test to compare hlRPE-7 thresholds against sham thresholds. The randomisation test 
used was based on the analysis of variance F statistic. Both statistical procedures 
produced identical results. The graphical representation of the statistical analysis was 
derived from the randomisation results.
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Figure 5.1: Flow Diagram of Transplantation Studies using Immortalised
Human (hlRPE-7 and ARPE19) RPE Cells
See section 5.2
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Figure 5.1
Flow Diagram of Transplantation Studies Using 
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At the end of the experiment, at five or six months of age, eyes were retrieved for 
polyester wax embedding. Photoreceptor counts and histological maps were generated 
on three grafted eyes (hlRPE-7) and two sham-operated eyes, as described in 3.2, at 
six months of age. The experiment is shown schematically in Fig 5.1.
Additionally, PCR amplification of SV40 large T-antigen was performed on hlRPE7 
cells and sections of unoperated dystrophic and hlRPE7 transplanted eyes after 
various survival times. Globes from hlRPE7 grafted animals were removed and 
incubated in digestion buffer (50mM Tris-HCl pH 8.0 lOOmM EDTA, lOOmM NaCl, 
1% SDS) overnight at 55°C. Digested globes were subsequently extracted twice with 
phenol:chloroform (25:24:1). Genomic DNA was precipitated in 96% ethanol and 
removed with a sterile loop. DNA pellets were washed in 70% ethanol, air dried and 
resuspended in lOmM Tris-HCl, ImM EDTA. PCR amplification of the SV40 large 
T-antigen was performed using 1U Qiagen HotStar Taq system and lOpmoles of 
primers (forward 5’ TGTATAGTGCCTTGACTAGAG 3’ and reverse 5’ 
GCTGTCAGCAAATATAGCAGC 3’) in a 50pl reaction generating a 296bp 
fragment of the SV40 large T-antigen gene sequence. Reactions were subjected to an 
initial denaturation step of 95°C for 15 min followed by 45 cycles of 95°C for 30s, 
57°C for 30s, 72°C for 30s. Reactions were maintained at 72 °C for 10 minutes prior 
to analysis on ethidium bromide stained agarose TAE gels. Genomic DNA was 
isolated from cell cultures using the GenElute Mammalian Genomic DNA Kit 
(Sigma, Dorset, UK).
5.3 Results
5.3.1 Cell line characterisation and tumour-forming properties
After extensive selection and characterisation of the SV40 large T-antigen transfected 
cells, a single line designated hlRPE7 was selected for subretinal transplantation into
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RCS rats (see 2.3.1.3) since it exhibited a non-transformed phenotype and expressed 
RPE markers including ZO-1, and cytokeratins 5, 8 and 18. Expression of ZO-1 and 
cytokeratins 5 and 8 in hlRPE-7 cells is illustrated (see Fig 2.2). Independent 
assessment of phenotypic cell transformation was performed following subcutaneous 
injection of 10 million hlRPE-7 cells in 200jul of PBS plus lOmM sucrose into 10 
irradiated (5 grays) athymic Swiss mice at an age of 8 weeks. After 3 and 15 weeks 
hlRPE7 cells failed to produce tumours in all examined mice unlike U87 human 
glioblastoma cells that were injected as a positive control. hlRPE7 cells also failed to 
form aggregates or foci when plated into soft agar. ARPE19 cells were similarly 
characterised and shown to have generally similar expression patterns.
5.3.2 T-cell proliferation assay
To evaluate the potential of the RPE cell lines to induce T cell proliferation, a mixed 
lymphocyte reaction assay was performed. The two RPE cell lines, hlRPE7, and 
ARPE19, did not induce significant T cell proliferation (Fig 5.2) irrespective of IFN-y 
activation or the number of RPE cells used. As expected, the two B cell lines used as 
positive controls were able to induce significant T cell proliferation in the absence of 
other co-stimulatory factors, particularly at a concentration of 2x104 cells/well (Fig 
5.2).
5.3.3 Functional Assessment
The effectiveness of the two types of cell transplants in preventing visual loss was 
monitored by head-tracking performance (see 2.4.2 and Fig 5.3A), and this revealed a 
distinction between graft and sham-injected animals by 10 weeks postoperatively (Fig 
5.3B). Both non-dystrophic animals and dystrophic animals that received a transplant 
of hlRPE7 cells were able to track all grating stimuli and were significantly better 
than sham-operated and non-operated dystrophic control animals (Fig 5.3B). By 20
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Figure 5.2: Mixed Lymphocyte Response of Human RPE Cell Lines
Example of a mixed lymphocyte reaction. hlRPE7, ARPE19 or the B cell lines 7 and 
29 (2xl04 cells per well) were cultured in the presence of human T cells (2xl05 cells 
per well). RPE cells did not induce a significant T cell proliferation (no significant 
difference between hlRPE7 or ARPE19) whereas a significant proliferation was 
observed when cocultured with the B7 and B29 B cells. Significant difference from 
RPE cell lines * p<0.0005.
128
Figure 5.2
Mixed Lymphocyte Response o f Human RPE Cell Lines
weeks postoperatively (Fig 5.3C,D), sham-operated controls were unable to track a 
visual stimulus while hlRPE7 and ARPE19 transplanted animals performed as well 
as non-dystrophic animals when tracking a visual stimulus of 0.125 cycles/degree. At 
a grating of 0.25 cycles/degree grafted animals tracked significantly better than both 
sham-operated and dystrophic animals although at 0.5 cycles/degree this ability was 
lost. Thus, in contrast to sham-operated and dystrophic animals, hlRPE7 transplanted 
animals were able to track visual stimuli at both 10 and 20 weeks postoperatively. 
Animals in the BrdU group demonstrated a similar behaviour profile to the main 
group. The unlabelled and labelled groups performed significantly better than sham at 
20 weeks (p <0.01) on post-hoc analysis. There was no difference between ARPE19 
and hlRPE7 groups (p > 0.05) at 20 weeks.
After head-tracking testing was completed, visual performance was studied 
electrophysiologically in the hlRPE7 group. The threshold sensitivity response to 
light was used to define the area of visual field rescue. In non-dystrophic rats visual 
thresholds never exceeded 0.7 log candela/m2 above background (Fig 5.4A). By 
contrast, the thresholds of non-operated dystrophic rats were in the order of 4 log 
units higher (Fig 5.4B). Sham-injected rats showed some highly localised functional 
rescue in the temporal retina with lowest averaged thresholds of 2.6 log units (Fig 
5.4D). However, the hlRPE7 transplanted rats exhibited substantially greater levels of 
visual preservation with thresholds averaged from data from 5 individual rats of as 
low as 1.6 log units and individual points as low as 0.7 log units (Fig 5.4C). The 
precise region of maximal sensitivity varied slightly among animals, due to small 
variations in the siting of the graft, leading to higher values when superimposing 
individual maps to obtain averages. When the grafted retinae were averaged, 52% of 
the area was associated with thresholds lower than 3.0 log, and 16% with thresholds
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Figure 5.3: Head-Tracking to High Contrast Square-Wave Gratings.
A) Ten weeks post-transplantation, total amount of time hlRPE7 grafted animals 
spent tracking a moving square-wave grating, in seconds, over a period of 4 minutes.
B) Head-tracking 20 weeks post-hlRPE7 transplantation. Error bars represent 
standard error of the mean. *p<0.01 represents a significant difference as compared to 
both Sham and Dystrophic groups. +p<0.05 represents a significant difference as 
compared to the hlRPE7 group. C) Comparative analysis of mean tracking over all 
frequencies for ARPE19, hlRPE7 and sham showed a significant difference (F = 
7.05, df = 2,23, p < 0.01 Student-Neuman-Keuls post hoc analysis) between sham and 
both transplant groups but no significant difference between transplant groups.
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Figure 5.3
Head-Tracking to High Contrast Square-Wave Gratings
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Figure 5.4: Threshold Light Sensitivity Maps at 6 Months of Age
RCS rats were divided into 4 groups: A) normal (3 non-dystrophic rats); B) no 
treatment (6 dystrophic rats); C) hlRPE-7 cells injected into one eye (5 dystrophic 
rats); and D) sham-injected (5 dystrophic rats). Schematic representation of a dorsal 
view of the superior colliculus showing respective thresholds for 76 individual 
recording sites (colour-coded squares) at 6 months. A log scale of thresholds 
measured in candela/m2 is shown. Each point shows the mean response for that 
position in the 3-6 animals used in each experimental group. Variance was calculated 
at each point allowing statistical evaluation of differences between groups. To test 
efficacy of hlRPE-7 grafts versus sham-injected animals, significance was 
determined at each of the 76 points using a randomisation test. E) An area of 
significantly preserved visual function was recorded for the hiRPE7-transplanted 
animals. The letters D (dorsal), V (ventral), N (nasal), and T (temporal) indicate the 
corresponding topological representation of the retina onto the superior colliculus and 
all figures retain the same orientation. The arrow represents the grafted quadrant.
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Figure 5.4
Threshold Light Sensitivity Maps at 6 Months of Age
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lower than 2.0 log units, while in sham-injected retinae these proportions were 7% 
and 0% respectively. When significance between the sham and hlRPE-7 injected rats 
was determined, 29 of the 76 points analysed showed a significant improvement in 
visual function (p<0.05) (Fig 5.4E). The area of maximal rescue was invariably 
confined to the region of cell injection.
The mean blood cyclosporine level in these animals as assessed at the termination of 
the experiments was 321.6pg/l (+/- 21.9).
5.3.4 Histology and Polymerase Chain Reaction (PCR) Results
At 5 months post-transplantation cells labelled with BrdU occupied sites on Bruch’s 
membrane as a monolayer (Fig 5.5B,C) or interspersed with unlabelled host cells (Fig 
5.5D). They were associated with regions of photoreceptor rescue and on occasion 
could be seen above the RPE monolayer (Fig 5.5A, B). Pigment distribution in the 
donor cells (forming part of the RPE monolayer) was polarised to the apical domain 
as in adjacent unlabelled host RPE cells. PCR amplification of SV40 large T-antigen 
in eyecups from hlRPE-7 grafted animals at 1, 2 and 7 weeks and 5 months post­
transplantation also indicated the presence of SV40 large-T (Fig 5.5E). There was no 
histological evidence of an inflammatory reaction and infiltrating immune cells were 
not observed in Nissl-stained (cresyl violet) sections. Histological analysis of non- 
dystrophic rat retinae showed an outer nuclear layer (ONL) about 8-10 cells thick (Fig 
5.6A), while in non-operated dystrophic rats, this was reduced to an occasional cell 
lying in the outer border of the inner nuclear layer. In sham-operated dystrophic rats 
(Fig 5.6C) it was usual to find a few photoreceptors around the injection site in the 
region of the disciform scar. By contrast, retinae that had received hlRPE-7 cell 
transplants, showed larger areas of photoreceptor survival, as much as 6 cells thick in 
the general area of the injection site typically thinning to 2 cells further from
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Figure 5.5: Localisation of ARPE 19 Cells at 6 Months Following
Transplantation
A representative cresyl violet stained frozen section imaged under Nomarski optics A) 
demonstrating rescue of photoreceptors in an eye at 6 months that received a graft of 
BrdU pre-labelled ARPE 19 cells. Scale bar: 50pm. B) and C) There is extensive 
rescue of photoreceptor cells that lie over the BrdU-labelled donor cells The grafted 
cells are mainly located on Bruch’s membrane (serial section to A above); Scale bar: 
50pm. Immunoreactive cells are also occasionally seen above the RPE monolayer 
(arrowed) separated in this image by an artifactual detachment (*). A higher power 
view of the cells seen in B are shown forming a monolayer on Bruch’s membrane 
(arrowed) in C; Scale bar: 10pm. D) is an image of an area of retina distant from A-C) 
above in which labelled donor cells (arrowed) are integrated between non-labelled 
host RPE on Bruch’s membrane. Pigment is distributed apically as in surrounding 
host RPE. Scale bar: 10pm. Inner Plexiform Layer (IPL), Inner Nuclear Layer (INL), 
Outer Plexiform Layer (OPL), Outer Nuclear Layer (ONL), Retinal Pigment 
Epithelium (RPE), Neural Retina (NR). E) PCR amplification of SV40 large T- 
antigen DNA. Genomic DNA isolated from non-transplanted eyes (i), hlRPE7 cells 
(ii), or eyes transplanted with hlRPE-7 cells at 1 (iii & iv), 2 (v & vi), and 7 (vii & 
viii) weeks and 5 months (ix & x) post-transplantation were subject to PCR 
amplification. There is persistence of SV40 large T-antigen at 5 months post-grafting 
suggesting graft cell survival.
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Figure 5.5
Localisation of ARPE 19 Cells at 6 Months of Age 
Following Transplantation
the graft focus (Fig 5.6B). Further analysis showed that an area of retina with a 
preserved layer of photoreceptors two or more cells thick corresponded quite closely 
with an area of visual field with threshold sensitivities 2 log units or better over 
baseline.
5.4 Discussion
These results show that genetically modified human cell lines, which in vitro exhibit 
long-term stability and phenotypic and immunological characteristics of RPE cells, 
support photoreceptor survival and limit the deterioration of visual function for up to 
5 months after transplantation into the subretinal space of RCS rats. In these 
cyclosporine-treated animals the grafted cells showed no evidence of inducing an 
overt inflammatory response. In addition, despite long-term immunosuppression, 
there was no evidence of uncontrolled growth of the grafted cells.
In cell grafting strategies for clinical application, cell lines have the advantage that 
they can be expanded as required and readily tested for safety, including chromosome 
abnormalities, tumourogenicity and potential pathogens. These important 
characteristics make them preferable to primary or short-term cultured cells for 
transplantation, which enter crisis after limited cell doublings. A number of other RPE 
cell lines have been described, although they have not been characterised as fully as 
the present cell lines nor have their efficacy in transplantation been examined. Other 
'immortalisation' techniques are emerging, which may be preferable to the use of 
SV40-T antigen or spontaneously derived lines. The question of immune rejection of 
grafted human cell lines has yet to be addressed. From the present studies, it might be 
possible to establish a collection of cell lines with different histocompatibilities or 
alternatively to further genetically modify the cells to express down-regulatory
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Figure 5.6: Anatomical Rescue of Photoreceptors at 6 Months of Age Following 
Transplantation of hlRPE7 Cells to RCS Rats
Semi-thin sections of retinae taken from animals used in the electrophysiological 
studies: A) 6-month-old non-dystrophic RCS rat showing full outer nuclear layer 
thickness. B) hlRPE7 transplanted RCS rat 5 months post-grafting demonstrating 
significant preservation of the outer nuclear layer: this level of rescue corresponds to a 
threshold sensitivity 2 log units above background. Area shown was 1400pm from 
injection site. C) Sham-operated RCS rat, 5 months post-operative, showing complete 
loss of the outer nuclear layer: there is also marked disruption of the inner nuclear 
layer. All sections were stained with toluidine blue. GC: ganglion cell layer. IPL: 
inner plexiform layer. INL: inner nuclear layer. OPL: outer plexiform layer. ONL: 
outer nuclear layer. IS: inner segments. OS: outer segments. RPE: retinal pigment 
epithelial cell layer. Scale bar: 20pm.
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Figure 5.6
Anatomical Rescue of Photoreceptors at 6 Months of Age 
Following Transplantation of hlRPE7 Cells
molecules, such as the cytokine IL-10, capable of inducing local immunosuppression 
(Croxford et al., 2001).
Sham injections delay functional deterioration, perhaps by flushing debris from the 
subretinal space or by activating microglia or macrophages and by provoking growth 
factor production, but by 10 weeks post-transplantation the effect of the graft is 
clearly distinguishable from the sham effect.
The measurement of collicular threshold sensitivity used in this study provides an 
indication of relative preservation of visual field. Its importance lies in the fact that 
there is both evidence of some degree of correlation between the amounts of 
functional rescue and anatomical preservation and that the data collected compares 
with visual field perimetry testing in humans (Beck et al., 1985). A reliance on 
functional assessment is clearly preferable when providing a background for clinical 
treatments, since it is not clear what relation commonly used measures (such as 
thickness of photoreceptor layer) have to degree of functional rescue. ERG has been 
used extensively to assess visual function after photoreceptor loss, but while it gives 
information as to changed electrical activity in the retina, it does not provide direct 
information about the image forming capability. Furthermore, ERG measures are 
known to correlate poorly with visual capacity in retinitis pigmentosa patients (Szlyk 
et al., 1997). This study shows clear evidence of functional efficacy of grafting human 
RPE cell lines into the subretinal space and that rescue occurs in the general region in 
which the grafted cells are located. It is still not clear whether these cells function by 
phagocytosing outer segments or by producing trophic factors, which act on host RPE 
or on cells of the outer retina. In vitro studies have shown that the donor cell line used 
here does phagocytose outer segment fragments and in addition produce a range of 
factors such as BDNF and bFGF known to support photoreceptor survival. It should
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be noted that in parallel studies (Lawrence et al., 2000; 2004), Schwann cells or 
Schwann cells engineered to over express BDNF and GDNF grafted into the 
subretinal space of RCS rats also supported prolonged photoreceptor survival. 
However, they did not appear to phagocytose outer segments themselves nor did they 
influence phagocytosis by host RPE.
In summary, the ability of human RPE cell lines to rescue visual function has been 
demonstrated in the RCS rat using physiological and behavioural tests that are 
analogous to those used to assess visual function in humans. The use of cell lines 
could provide a potential and very valuable approach to the prevention of retinal 
degeneration in humans.
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6. TRANSPLANTATION OF NEONATAL SYNGENEIC 
SCHWANN CELLS TO THE SUBRETINAL SPACE OF 
RHODOPSIN KNOCKOUT MICE
6.1 Introduction
Retinitis pigmentosa comprises a group of inherited retinal degenerative diseases 
characterised by photoreceptor loss, vascular changes, invasion of the inner retina by 
retinal pigment epithelial cells (RPE) and blindness. Photoreceptor loss can be limited 
in experimental models of RP by delivery of growth factors either by direct injection 
into the eye or by gene therapy approaches (as outlined in Chapter 1).
Previous work (Lawrence et al., 2000) showed that Schwann cells grafted subretinally 
into the dystrophic RCS rat supported photoreceptor survival for up to 9 months 
postoperatively. The rationale for using these cells was that they produce such 
retinally active growth factors as CNTF (Sendtner et al., 1992), BDNF (Meyer et al., 
1992), GDNF (Hammerberg et al., 1996) and bFGF (Neuberger et al., 1993). After 
transplantation to the central nervous system (CNS), they can promote neural 
regeneration (Neuberger et al., 1993). As such, they potentially present an additional 
trophic factor delivery approach for the eye.
A further study, Lawrence et al., (2004) showed that a Schwann cell line, engineered 
to over express GDNF or BDNF, transplanted into the SRS of dystrophic RCS rats 
produced good photoreceptors rescue and maintenance of visual function. The 
rhodopsin knockout mouse was used to assess whether the rescue potential of 
Schwann cells may extend beyond the RCS rat to include RP models in which there is 
an intrinsic photoreceptor defect, rather than an RPE defect. The retina of the 
rhodopsin knockout mouse has a normal complement of photoreceptors at birth 
although rod outer segments never develop (Humphries et al., 1997). By 8 weeks an
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ERG is no longer detectable (Toda et al., 1999) and by 3 months nearly all 
photoreceptors are lost except for some residual cones. By transplanting Schwann 
cells to the subretinal space at an age prior to the loss of significant numbers of 
photoreceptors, it is possible to explore whether rescue of remaining cells can be 
achieved.
6.2 Experimental Design
Rhodopsin knockout (Rho-/-) mice (n=15) received unilateral subretinal transplants of 
neonatal Schwann cells (1 x 104 cells in 2pl of DMEM plus DNase) or sham 
injections (2pl of DMEM + DNase: n=15) at PN35. Unoperated eyes served as 
controls. Since a small population of contaminating fibroblasts remained in the 
Schwann cell preparations, a further group of Rho-/- animals (n=5) received 
subretinal injections of fibroblasts to both eyes (See Fig 6.1).
At PN70 animals (Schwann cell transplanted Rho-/-, n=10; fibroblast transplanted 
(n=5); sham-operated, n=10 and unoperated controls, n=6) were overdosed with 
Euthatal (Rhone Merieux, UK) and the tissue processed for electron microscopy (see 
Appendix I). In order to quantitate the number of surviving photoreceptors in each 
group of treated animals, semi thin sections were cut through the region of the 
transplant and stained with toluidine blue (Sigma, Poole, UK). A temporal to nasal 
orientation was maintained throughout using a suture placed in the ventral corneo­
scleral junction as a marker. Representative sections (adjacent to or within 200 pm of 
the injection site) from each retina were photographed and the photographs montaged. 
The total number of photoreceptors was counted blind, by the same person, for each 
sample in 100 pm bins (approximately 50 per eye). Maximal cell counts for each bin 
location in each experimental group and mean cell counts for each bin location in 
each experimental group across the retinae (temporal to nasal) were generated and
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Figure 6.1: Flow Diagram of Transplantation Studies to Rho -/- Mouse using
Mouse Schwann Cells
See section 6.2.
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Figure 6.1
Flow Diagram of Transplantation Studies Using Mouse Schwann 
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compared. Analyses were performed using StatView (SAS Corporation, USA) for PC. 
All group data were subjected to a one-way analysis of variance in the temporal 
region of the retina (highlighted). Post-hoc analysis was carried out on significant 
group findings. Additionally some retinae from each group were sectioned for 
ultrastructural studies.
6.3 Results
6.3.1 Donor cells
Schwann cell cultures of high purity (more than 95%) were obtained (Fig 2.3). The 
Schwann cells had a typical spindle-shape morphology, which was readily 
distinguishable from contaminating fibroblasts which had large nuclei and extensive 
flattened cytoplasm.
6.3.2 RT-PCR
The Schwann cells expressed mRNA for BDNF, CNTF and GDNF (Fig 6.2). There 
was no evidence of NGF or bFGF message.
6.3.3 Rhodopsin Knockout Mouse: Retinal histology
Histological analysis of grafted animals (n=10) at PN70 showed a distinct region of 
photoreceptor preservation in the temporal retina (Fig 6.3 J,K,L and Fig 6.5), 6-7 cells 
deep and approximately 800pm wide. This was in contrast to fibroblast-grafted (Fig
6.3 G,H,I), sham-operated (Fig 6.3D,E,F) and unoperated animals (Fig 6.3 A,B,C) 
where generally only one to two layers of photoreceptors, mostly cones, remained. 
Although more photoreceptors survived in the Schwann cell transplanted retinae, 
typical outer segments never formed. Cone inner segment morphology was distinctly 
preserved (Fig 6.3 K,L). Schwann cells were identified in the general region of the 
area of rescue (Fig 6.4A, B), where as described previously (Lawrence et al., 2000) 
they could be identified by their indented nuclei, which were larger
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Figure 6.2: RT-PCR Showing Growth Factor Profile of Mouse Schwann Cells in
vitro.
RT-PCR profile of primary Schwann cells harvested from 129 (PN5-7) pups for 
growth factor mRNA. The specific factors screened for here include: Nerve Growth 
Factor (NGF), Ciliary Neurotrophic Factor (CNTF), Brain-Derived Neurotrophic 
Factor (BDNF), basic Fibroblast Growth Factor (bFGF) and Glia-Derived 
Neurotrophic Factor (GDNF). There is strong expression of BDNF and CNTF and 
weak expression of GDNF. Messenger RNA is undetectable for NGF and bFGF.
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Figure 6.2
Growth Factor Profile (rt-PCR) of Neonatal Mouse Schwann Cells
In Vitro
than the elongated nuclei of fibroblasts, distributed among the Schwann cells (Fig 
6.4B). Although the retina immediately overlying the graft was disrupted there was 
marked preservation of photoreceptors. Some of the fibroblasts seen in the vicinity of 
the graft may have been transplanted with the Schwann cells and some may be host 
fibroblasts introduced from the sclera at the time of surgery. Because animals that 
received grafts of pure fibroblasts showed no improved photoreceptor rescue and no 
cone inner segment preservation, the rescue seen in the Schwann cell graft recipients 
(with some fibroblast contamination) is likely due to the Schwann cells themselves. 
Maximal photoreceptor counts for each group, along the length of the retina temporal 
to nasal, are presented in Fig 6.5A. The outlined area demonstrates a region of 
approximately 2300pm in the vicinity of the temporal injection site, where there was 
a marked increase in photoreceptor survival. This region was subjected to statistical 
analysis. The Schwann cell transplant group had significantly more photoreceptors 
than the fibroblast graft, sham-operated and unoperated groups (F=148.01, dfr=3,32, 
/?<0.001). There was approximately a 55% increase in photoreceptor survival in the 
Schwann cell transplant group compared with the sham-operated group and a 225% 
increase in the Schwann cell transplant group as compared with the fibroblast 
transplant group and the unoperated group. Furthermore, the sham-operated group had 
approximately twice as many photoreceptors as the fibroblast and unoperated group, 
which was significant (sham versus fibroblast transplant group: t= l3.06, df=16, 
/?<0.01; sham versus the unoperated control: t= 17.13, df= 16, p  <0.01). A similar area, 
2300pm, (indicated by the outline box in Fig 6.5B) was analysed for the mean data 
from each group. Once again, a region in the temporal retina showed a significant 
rescue effect in the Schwann cell transplant group over fibroblast transplant, sham and 
unoperated control groups (F=33.15, df=3,38,/?<0.001). There was approximately a
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Figure 6.3: Comparative Anatomy of Control (A, B&C), Sham-operated (D, 
E&F), Fibroblast Grafted (G, H&I) and Schwann Cell Grafted (J, K&L) Rho -/- 
Retinae at PN70.
A) Semi-thin section of a control retina at PN70. There is near complete loss of 
the outer nuclear layer (ONL).
B) A higher power view of the boxed area in A demonstrates these features more 
clearly. There is total absence of outer segment structure and a grossly 
compromised inner segment (IS) layer. (*) outer limiting membrane (OLM).
C) An electron micrograph showing stunted photoreceptor inner segments (IS) 
and OLM (*).
D) Semi-thin section of a sham-operated retina. It shares some features of a 
control retina, i.e. thinning of the ONL and loss of inner segment morphology.
E) A higher power view of the boxed area in D.
F) An electron micrograph of the same sham-operated eye (seen in D and E) 
shows that inner segments are rare and there are no outer segments. 
Hypertrophied Muller cell processes (mp) surround remaining photoreceptors. 
OLM (*).
G) Semi-thin section of a retina that received a fibroblast transplant. The ONL is 
reduced and inner segments are much reduced.
H) A higher power view of the boxed area in G.
I) An electron micrograph of a fibroblast grafted retina. There is a total absence 
of outer segment structure and a grossly compromised IS layer. Hypertrophied 
Muller cell processes (mp) surround remaining photoreceptors.
J) Semi-thin section of a retina that received a Schwann cell transplant. There is 
considerable preservation of the outer nuclear layer (ONL) compared with the
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unoperated control, sham-operated and fibroblast grafted retinae (A, D and G 
respectively).
K) A higher power view of the area boxed in J. There are no outer segments, but 
there is preservation of cone inner segment morphology (arrowed) at PN70 
compared with fibroblast, sham and control retinae.
L) An electron micrograph from the area of retina illustrated in J and K that had 
received a graft. Note the more distinct cone inner segment morphology 
(arrowed) compared with that seen in C, F and I. As in those panels there are 
no demonstrable rod or cone outer segments. Note also that there is some 
hypertrophy of Muller glial cell processes (mp).
Scale bars A, B, D, E, G, H, J and K: 25pm; C, F, I and L: 2pm.
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Figure 6.3
Comparative Anatomy of Control, Sham-Operated, Fibroblast 
Grafted and Schwann Cell Grafted Retinae at PN70
Figure 6.4: Schwann Cells in the Subretinal Space of PN70 Rho-/- Mouse
Grafted at PN35.
A) Semi-thin section showing Schwann cells grafted into the subretinal space at 
PN35 and harvested at PN70. The cells are layered over the host retinal pigment 
epithelium (RPE). The overlying retina is disrupted but the photoreceptor layer 
(ONL) is preserved. Inner nuclear layer (INL). Scale bar: 50|am.
B) A higher power view of the area boxed in A. The Schwann cells (SC) are seen 
interspersed with some fibroblasts. The Schwann cells have larger, indented nuclei 
(arrowed) compared with fibroblast nuclei, which are elongated (*). The 
fibroblasts may have been introduced as a contaminant at the time of grafting or 
pushed in from the host sclera at the time of surgery. The mixed cells lie in a 
group on host RPE. Scale bar: 50pm.
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Figure 6.4
Schwann Cells in the Subretinal Space of PN70 Mouse
Grafted at PN35
30% increase in photoreceptor survival in the Schwann cell transplant group 
compared with the sham-operated group and a 66% increase in the Schwann cell 
transplant group compared with the fibroblast transplant and unoperated group. As 
before, a significant increase in photoreceptors was observed in the sham-operated 
groups compared with the fibroblast transplant group and the unoperated control 
group (sham versus fibroblast transplant group: t= 5.96, df= 44, p< 0.01; sham versus 
unoperated knockout control: t= 3.43, df= 44, /?<0.01). Thus, there was a focal rescue 
effect adjacent to the site of injection and in this particular area the effect was 
significant.
6.4 Discussion
The results show that Schwann cells grafted into the rho-/- mouse can preserve a focal 
region of photoreceptors up to at least PN70. The results are of interest as they show 
that Schwann cells are able to preserve photoreceptors in an animal model where the 
defect lies in the photoreceptors themselves (Fig 6.3 and 6.5) in contrast to previous 
work showing rescue in RCS rats where the defect lies in the RPE. In the eyes with 
evident grafts the cells appear normal, and integrate into the subretinal space (albeit 
with occasional fibroblasts: Fig 6.4B). Fibroblasts appear to produce little or no 
rescue, and the rescue effect observed is most likely due to the Schwann cells alone. 
None of the cells appear to provoke evident inflammatory reactions, although there is 
a Muller cell response. However, because glial hypertrophy occurred after sham- 
surgery and in both transplant groups, this is likely to be a respose to surgical 
intervention. In parallel studies in RCS rats (Lawrence et al., 2000), outer segments 
were preserved in the vicinity of the Schwann cell grafts for quite extensive periods of 
time in contrast to fibroblast and sham-injected eyes. In the present model, rod outer 
segments never develop in the rho-/- mouse, and nor are they seen after Schwann cell
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grafting or AAV-CNTF treatment (Liang et al., 2001). However, after Schwann cell 
grafting, inner segment cone morphology appears to be better preserved. It is 
presumed that the Schwann cells preserve photoreceptors by delivering growth factors 
into the subretinal space, because in vitro at least, they are a source of several factors 
known to preserve photoreceptors from degeneration. The cones could be directly 
rescued or secondarily through rod rescue in a manner similar to that described in 
other studies (Mohand-Said et al., 1997). The primary target of the growth factors is 
still unclear, but the finding in C57BL/6J mice that intravitreal injections of CNTF, 
BDNF and FGF2 (bFGF) activate intracellular signalling mechanisms in Muller glia 
(and other inner retinal cells) but not photoreceptors (Wahlin et al., 2000) suggests 
that the photoreceptor rescue may be via a second order pathway. The degree of 
rescue was less extensive than that shown by Liang et al., (2001) who delivered 
secretable CNTF mediated by adeno-associated virus (AAV) at a much earlier time- 
point (PN2-5). Delivery at this earlier time may be important since the main peak of 
apoptosis in the outer nuclear layer of the rho-/- mouse (129Sv background) is at 
about PN35 (Humphries et al., 2001) proceeding rapidly to approximately PN63, and 
in the present study grafting did not take place until PN35. This later time was chosen, 
as it would be more analogous with a potential treatment point in humans. However, it 
is possible that by transplanting late in the process of degeneration, the cell death 
cycle is already in progress and can only be delayed. In addition, donor cells are likely 
to be more locally distributed than an AAV-mediated product, so reducing their 
overall efficacy. Liang et al., (2001) showed that cells engineered with non- 
secretable CNTF could not promote photoreceptor survival. Because Schwann cell 
CNTF may not be readily available in a secretable form and other growth factors 
produced by them could give rise to the observed effect. Although photoreceptors
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Figure 6.5: Analyses of Photoreceptor Numbers in Schwann Cell Grafted versus 
Fibroblast Grafted, Sham-operated and Control Retinae.
A) This graph illustrates photoreceptor counts across the retina from temporal to nasal 
(left to right). Maximal counts for each group at each bin location are shown. The 
Schwann cell transplant group tends to have higher cell counts in the temporal 
(surgical region) than sham-operated, fibroblast grafted or unoperated control retinae. 
This difference is significant (p<0.001).
B) Mean photoreceptor counts for all the groups (n=5 in each group). Again the 
Schwann cell transplant effect is demonstrated in the temporal retinal region. The 
difference between Schwann cell grafted retinae and sham-operated, fibroblast grafted 
and unoperated control retinae over this temporal region (outlined) is again significant
(p<0.001).
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Figure 6.5
Analyses of Photoreceptor Numbers in Grafted Versus Sham- 
operated and Control Retinae
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have been preserved in this study, no outer segments were generated, and this was 
also observed after AAV-CNTF delivery (Liang et al., 2001). As indicated in that 
study an ERG response was not demonstrated. Unoperated controls are also without 
outer segments and never show evidence of an ERG (Toda et al., 1999). Furthermore, 
Sieving's group (Machida et al., 2000) have determined the electrophysiological 
relationship between outer segment length and photoreceptor nuclei number and 
showed that, without outer segments, it is not possible to generate an a-wave. Thus, 
the absence of outer segments would indicate that an intact ERG response is unlikely. 
In agreement with these findings a preliminary ERG investigation of the present 
group of transplanted animals prior to fixation failed to demonstrate any significant 
response. Viral (rAAV or lentivirus) secretable CNTF injected into the eyes of other 
rodent models of RP (Liang et al., 2001; Timmers et al., 2002) provided long-term 
photoreceptor preservation but had no or negative effects on ERG amplitudes. 
However, patients with RP may also fail to show full-field ERGs and have greatly 
reduced numbers of photoreceptors with shortened or absent inner and outer 
segments, yet have some functional vision remaining (Sieving et al., 1999). 
Therefore, an absent ERG does not necessarily indicate that there is no visual 
processing. Rod rescue per se would not be expected to rescue visual function in this 
animal. However, other investigators (Mohand-Said et al., 2000) have proposed that 
by rescuing rods, cones that may otherwise die will be preserved. The present 
preparation provides a special situation in which to examine this possibility.
In summary, Schwann cell grafts limit photoreceptor loss. The most parsimonious 
explanation for this phenomenon is that they function by delivering a range of growth 
factors. The potential of a steady continuous release of a mixture of factors from 
transplanted cells affords some advantage over intravitreal injection. Local release at
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the site of need avoids the inherent problem of delivering factors at non-physiological 
levels to other tissues of the eye or body. The use of syngeneic grafts also obviates the 
need for immune suppression, which can be a serious problem in transplantation 
studies. The degree of functional vision preserved by such grafts remains to be 
established.
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Chapter 7
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7. DISCUSSION 
7.1 Summary
Cell transplantation strategies for the treatment of retinal disease are an exciting and 
novel prospect for the future. While the findings presented in this thesis are very 
encouraging, there is much to do before clinicians will be confident enough to offer 
this technique routinely to their patients. The results do, however, offer clues for 
future developments.
The potential of expanded, extended life cell lines for treating conditions 
characterised by retinal pigment epithelium failure (such as AMD) is considerable. To 
date most human RPE transplants have been derived from foetal tissue, which is 
neither ethically very desirable nor practical, considering the amount of material that 
would be required. The use of cell lines permits extensive safety checks to be carried 
out prior to clinical trials which is very necessary since conditions like AMD are non- 
fatal.
Schwann cell transplantation represents an attractive option for the treatment of 
retinal dystrophies. It is a simple concept that should gain acceptance more readily in 
the clinical community. The potential to perform autografts should allay many fears 
since problems of immunological rejection and the presence of foreign infective 
agents in donor tissue would be removed. Growth factor delivery appears to be a 
viable treatment option in these diseases, yet to establish a continuous delivery of a 
factor at a physiological dose remains elusive: Schwann cells are biologically active 
cells producing physiological amounts of neurotrophins that can be placed at the 
desired site of action.
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There is still much to be done to refine these treatment strategies in the laboratory, yet 
the potential exists for these therapies to enter the clinical realm in an experimental 
capacity within a reasonable timeframe.
7.2 Mechanisms of photoreceptor rescue by donor cells
7.2.1. LD7.4 RPE allografted into the SRS of non-immunosuppressed dystrophic RCS 
rats
The studies have demonstrated that allografts of LD7.4 cells, placed in the subretinal 
space of non-immunosuppressed dystrophic RCS rats, produce superior rescue at both 
functional and anatomical levels when compared with sham-operated rats. The benefit 
persisted up to six months of age (five months post-transplantation). Closer analysis 
of the data revealed deterioration in function with time, suggesting the existence of 
cellular events that compromise rescue. Grafted cells could not be identified by 
immunohistochemistry beyond four weeks post-transplantation (Fig 3.7) yet PCR 
studies have demonstrated the presence of DNA unique to the grafted cells up to 3 
months following transplantation (Fig 3.8). There are, however, numerous ED-1 
positive cells post-transplantation (Fig 4.5G,H) that persist in the retina to 5 months 
(Fig 4.7D). These results suggest that photoreceptor morphology and function can be 
preserved in this model of retinal degeneration for a period of time in the presence of 
grafted LD7.4 cells, yet function and morphology appear to persist beyond the 
survival time of the donor cells. There are a number of possible explanations for this. 
Firstly, many factors have been shown to preserve photoreceptors in the dystrophic 
RCS rat e.g. bFGF (Faktorovich et al., 1990) or IL-1J3 (Whiteley et al., 2001) albeit 
for short periods of time. Additionally, IL-lp protects photoreceptors in the light- 
damaged rat model (LaVail et al., 1992) but importantly it is also associated with the 
recruitment/ proliferation of macrophages (Bamforth et al., 1997). Macrophages
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infiltrate LD7.4 cell grafts in non-immunosuppressed rats and resident host microglia 
will also be activated. It is possible that photoreceptor rescue may be mediated by 
prolonged production of pro-inflammatory cytokines by microglia (Ng and Streilein, 
2001). Alternatively, the macrophages and activated microglia may phagocytose 
photoreceptor outer segment debris and reduce the build-up of toxic products in the 
SRS. A phagocytic role for microglia was seen when retinae were grafted 
intracerebrally (Baneijee and Lund, 1992). However, when Li and Turner (1991) 
transplanted macrophages to the subretinal space they could not identify any 
protective effect.
Another possibility is that neurotrophins released by RPE cells (Kanuga et al., 2002) 
and other host cells (such as Muller glia) in the transplanted retina may reduce the 
number of photoreceptors that undergo apoptosis during the early stages of retinal 
degeneration (Tso et al., 1994). This could be why grafts fail to support 
photoreceptors in older animals (Li et al., 1991), when maximal apoptosis has already 
occurred. Lastly, it is possible that a few donor cells do survive for longer intervals 
but they have somehow escaped detection in the material sampled. If this is the case, 
then very few donor RPE cells must be supporting numerous photoreceptors, which 
again suggests there is diffusion of some supportive growth factor.
Subsequent studies (e.g. See 7.3) will concentrate on identifying more precisely the 
mechanisms that are involved in photoreceptor rescue. For instance, LD7.4 cells will 
be transplanted into macrophage-depleted rats to determine whether donor cells and 
photoreceptors survive for shorter or longer periods in the absence of macrophages.
7.2.2 hlRPE7 and ARPE19 cells xenografted into the SRS of immunosuppressed 
dystrophic RCS rats
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These human cell lines have been shown to survive for up to 5 months following 
transplantation in the studies reported here and for even longer in other studies 
(Coffey et al., 2002). The grafted cells appear to maintain their polarity on Bruch’s 
membrane suggesting that they could be functional (Fig 5.5B, C and D). The presence 
of polarised molecules (e.g. apical Na+-K+ ATPase) on the donor RPE cells has yet to 
be confirmed in vivo with immunohistochemistry however it has been shown in vitro 
(Turowski et al., 2004). The fact that donor cells are found adjacent to areas of 
maximal photoreceptor rescue implies a direct supporting role for these cells. As with 
the LD7.4 cells (7.2.1), these cells may support photoreceptors by release of the 
growth factors they produce (Kanuga et al., 2002) or they may indirectly support 
photoreceptors by stimulating other retinal cells to release supportive factors. There is 
no direct evidence that donor RPE cells can phagocytose outer segment debris, 
although the debris zone is much reduced in regions of good rescue. However, 
resident microglia or macrophages could be responsible for debris removal. Given the 
information derived from the LD7.4 studies, it cannot automatically be assumed that 
the grafted human cells function by simply replacing defective RPE cells.
7.2.3 Syngeneic Schwann cells transplanted into the subretinal space of rhodopsin 
knockout mice
The mechanism by which Schwann cells maintain photoreceptors is presumed to be 
due to the local delivery of growth factors. Cells used for mouse-to-mouse grafts 
express message for GDNF, CNTF and BDNF (Fig 6.2) although an in vivo growth 
factor profile has yet to be determined.
LaVail and colleagues (LaVail et al., 1998) have determined the rescue profile of 
injected growth factors in various mouse models of retinal disease e.g. the P23H, rd, 
rds and the Q344Ter mouse. While individual trophic factors were found to be
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beneficial in many cases, no single factor maintained photoreceptors in all the 
degenerative models tested (LaVail et al., 1998). Differences have also been noted in 
the efficacy of different factors in different species, e.g. bFGF appears to be beneficial 
in rat models but not in mouse models of retinal degeneration (LaVail et a l, 1998; 
Green et al., 2001). However, treatment with a combination of growth factors has the 
potential to work better than individual factors alone, as demonstrated in vivo (LaVail 
et al 1998) in vitro (Ogilvie et al., 2000; Caffe et al., 2001) and is suggested by 
studies using rod transplants to preserve cones (Mohand-Said et al., 1998, 2000). The 
rationale for delivering multiple growth factors in physiological doses is a sensible 
one and Schwann cell transplants may provide that opportunity.
7.3 Relationship of Studies to Treatments for Clinical Disease
7.3.1. RPE transplantation for AMD
The aim of the work presented here is to begin to provide a solid scientific platform 
from which to develop realistic and suitable treatments for patients with retinal 
degeneration. Previous clinical studies were built on a less than comprehensive base 
(Algvere et al., 1994, 1997 & 1999), and if nothing else, pointed to the real problems 
that need to be addressed before serious clinical application can be contemplated. The 
present work begins to address the gaps in previous knowledge in this field. It has 
demonstrated an anatomical benefit of RPE cell line transplants (both human and rat) 
to the RCS rat and has shown preservation of visual function by simple behaviour 
(head-tracking) and more complex retinal sensitivity (collicular threshold mapping) 
methods.
The application of these functional tests has revealed an important feature of 
allografts in the RCS rat paradigm, namely the deterioration of function over time 
(chapter 3). Before embarking on clinical trials it will be essential to explore further
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the mechanisms that underlie this deterioration, some of which have been discussed in
7.2.1 and 7.2.2. Before clinical studies commence ways must be found of prolonging 
graft survival in the subretinal space by either immunosuppression or pre-transplant 
manipulation of the donor cells to down-regulate their MHC II expression or delete 
co-stimulatory molecules. There are a number of possible areas in the immunological 
system that could be manipulated (see Fig 7.1)
Studies are underway to examine the mechanisms involved in cell loss using depletion 
strategies. Other transplant paradigms may provide clues to interpreting and 
improving RPE cell transplantation. Pancreatic islet cell transplantation, a treatment 
strategy for type I diabetes, involves grafting islet cells rich in p-cells (secreting 
insulin) to various sites in the abdomen including liver and renal capsule. Early loss of 
these cells is associated with macrophage infiltration at the graft site similar to that 
seen here with RPE allografts. Intra-hepatic islet cell graft survival can be 
significantly improved by depleting host macrophages with dichloromethylene 
diphosphate (clodronate) liposomes (Bottino et al., 1998). Macrophage depletion may 
reduce the capacity for antigen presentation thereby suppressing the activation of 
alloreactive CD4+ T-cells. Clodronate, used in corneal transplant strategies, has a 
similar effect. Subconjunctival administration of clodronate-loaded liposomes with a 
high-risk graft leads to long-term survival of the transplants (van der Veen et al., 
1994). By depleting macrophages there is a reduction in cytotoxic activity, antibody 
production (Siegers et al., 2000) and impaired complement-dependant antibody 
activity (van der Veen et al., 1994) following transplantation.
Reduction of the CD4+ cell population in these transplant strategies has also led to 
improved transplant survival and indicates the down-stream mechanisms involved. 
Anti-CD4+ antibodies have been used successfully to prolong allograft survival in rat
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Figure 7.1: Potential Sites of Intervention to Limit Graft Cell Loss as a Result of 
Host Inflammatory or Immune Responses
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experimental transplant models including the heart and kidney (Yin et al., 1998) both 
with and without dual therapy with anti CD8+.
Blocking the CD40-CD40L co-stimulatory pathway has also been shown to prolong 
graft survival in islet cell transplant paradigms (Kover et al, 2000) and corneal 
transplants (Qian et al., 2001). By blocking a key co-stimulatory pathway (CD40- 
CD40-L) which is involved in T-cell activation (CD40 on T-cells and CD40L on 
antigen-presenting cells, APCs), down-stream upregulation of co-stimulatory (B7-1 
and B7-2) is prevented.
Development of an immortalised syngeneic RPE cell line from the congenic RCS rat 
strain is underway at the Institute of Ophthalmology. This new cell line, together with 
primary cultures derived from non-dystrophic RCS and PVG rats, will be used in key 
baseline immunological experiments. The experiments described above should 
provide essential information about the importance of the alloresponse and whether 
the immortalisation procedure confers additional immunogenicity. Further studies 
using the allogeneic cell line (LD7.4) will aim to identify the post-transplantation host 
immune responses in the subretinal space, local lymph nodes, spleen and humoral 
system. Using a simplified model of the sequence of events that may follow 
transplantation (Figure 7.1), strategies are planned that will interfere with the different 
arms of the immune response. It is envisaged that the results will provide information 
leading to the identification of those host responses that are responsible for poor graft 
survival. This will then allow future strategies to be devised that will lead to improved 
cell graft survival. The ability to genetically manipulate a clonal cell line, which can 
subsequently be transplanted, will greatly aid these aims.
Grafted human RPE cell lines also rescue photoreceptor function and morphology 
(Chapter 5) in the dystrophic RCS rat. Using immunosuppression, the donor cells
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survive up to five months post-operative. Future work will concentrate on identifying 
functional proteins at the cellular level (e.g. apical Na+-K+ ATPase or CRALBP) 
allowing the identification in vivo of the factors considered essential for the proper 
functioning of these cells (Bok et al., 1993).
The ability to reliably label donor cells, track them with time and utilise a simple 
functional outcome (head-tracking) will prove very important tools in experimental 
RPE transplantation. Once optimum grafting conditions have been determined using 
BrdU pre-labelled cells, cells labelled with the Human Foamy Virus/GFP will be used 
again to image the graft longitudinally in vivo using confocal SLO. It may be possible 
to assess the effect on donor cell survival of immunosuppression and its withdrawal, 
allowing extrapolation to the clinical setting. It may be that immunosuppression is 
only necessary around the critical time when the blood-retinal barrier is opened at the 
time of transplant surgery. All these studies will aim to a) identify the mechanisms 
involved in cell loss and b) develop the therapies that will limit that loss.
7.3.2. Schwann cell transplantation for Retinitis Pigmentosa
Studies have shown the efficacy of Schwann cell transplantation in two disparate 
animal models of hereditary retinal disease, the RCS rat (Lawrence et al., 2000) and 
the rhodopsin knockout mouse (chapter 6). The limitations of these models are 
discussed in 7.4.1 and 7.4.2. The results show transplantation of a cell type that can 
act as local factory for neurotrophin production can delay retinal degeneration.
The finding that a non-specific treatment, such as Schwann cell transplantation, can 
work in hereditary retinal dystrophies is very exciting. The potential exists to 
transplant a patient's own Schwann cells, which can be harvested, for example, from 
their sural nerve (in the leg), grown and purified in culture and grafted into the
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paramacular region to preserve remaining cones. Any potential immune or infective 
problems should have been overcome.
The issues remaining to be addressed experimentally with this treatment are: i) the 
application of Schwann cell grafting (transvitreal) to a larger eye (e.g. the cat), this is 
the approach likely to be adopted for human transplant surgery and ii) assessing the 
impact of local growth factor release on first to third order neurons in a well- 
characterised model (Lewis et al., 2003): this work is in progress and preliminary 
studies are being conducted at the Institute of Ophthalmology, iii) The in vivo growth 
factor profile of donor Schwann cells should be measured using in situ hybridisation, 
iv) Different transplant times should be tested in the rho-/- mouse to determine 
whether a more optimal intervention time exists. These experiments should provide 
information about any detrimental effects to the host system of prolonged 
neurotrophin release, the growth factor expression profile of the grafted Schwann 
cells through time and the optimum time to intervene surgically in a patient's 
management.
With microchip technology still a distant prospect it is important to concentrate on 
methods by which cone function can be maintained in these patients for as long as 
possible. Only 2-4 rows of cone photoreceptor nuclei are required for functional 
vision, demonstrated experimentally in Chapters 3 & 5, and posthumously in patients 
with RP (Sieving, 1999) This level of preservation should be our initial aim in a 
clinical trial using Schwann cells.
7.4 Relevance of the animal models
7.4.1 Roval College of Surgeons (RCS) rat
The cause and progression of the retinal dystropy in the Royal College of Surgeons rat 
is described in 1.3.1. It has been used for AMD research because it has a primary
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retinal pigment epithelium defect with secondary neural retinal damage. While it is 
not an ideal model of AMD it is a useful bio-assay for potential treatments of retinal 
pigment epithelial disease. That is the context in which the RCS rat has been used in 
this series of studies. Experimental strategies can be analysed knowing that without an 
intervention the photoreceptors will degenerate within 12 weeks (Dowling and 
Sidman, 1962). The availability of behavioural and functional tests makes the link 
between photoreceptor preservation and function accessible. In addition to 
photoreceptor degeneration, the RCS rat is characterised by secondary vascular 
changes that result in the loss of ganglion cells (Villegas-Perez et al., 1996, 1998). 
Similar changes are observed in patients with retinitis pigmentosa (Milam et al., 
1998) and a group of patients has been identified with a mutation in the Mertk gene 
with a retinitis pigmentosa phenotype (Gal et al., 2000). This validates using this 
model to test therapies for the RP group.
The rat model has been used in numerous transplant studies. Its disdvantages are 1) 
the small size of the rodent eye and the correspondingly large size of the lens; 2) the 
lack of a macula; 3) vascular changes relate to the remodelling of the inner retinal 
circulation, not to changes in the choroidal circulation and 4) the absence of drusen. 
Another rodent model for AMD is the APO (*) E3-Leiden mouse which develops 
basal laminar deposit (BLD) similar ultrastructurally to human BLD (Kliffen et al., 
2000) but secondary changes such as atrophy and/or CNV have not been 
demonstrated.
7.4.2. The rhodonsin knockout mouse
The rhodopsin knockout mouse retinal anatomy and progression of photoreceptor loss 
has been described in section 1.3.2.
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Figure 7.2: Hypothetical Photoreceptor Degeneration in the RCS Rat and the 
Effect of Transplantation or Sham-surgery
This figure illustrates the rate of photoreceptor degeneration seen in four groups of 
animals: congenic, dystrophic, sham-operated dystrophic and transplanted dystrophic 
retinae. The dystrophic RCS rat retina loses photoreceptors rapidly (see section 1.3.1). 
Sham-operated animals have delayed photoreceptor degeneration but ultimately all 
photoreceptors are lost (Fig 3.5 and Fig 5.6) by 5 months of age. Transplanted 
animals display the best preservation of photoreceptors yet there is still a fall off of 
numbers over time.
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Since many of the human forms of retinitis pigmentosa are due to mutations in the 
rhodopsin gene (e.g. P23H; Daiger RetNet 2004), studies on this rodent model are 
important and relevant. Although there is no direct genotypic correlation, in rod or 
rod-cone human RP, rods are also lost first followed by secondary degeneration of the 
cones. Additionally, this model provides a system whereby interventions designed to 
protect cones can be examined. The genetic heterogeneity of human RP (in addition to 
its existence in different races) argues for the development of unifying treatments that 
tackle the common final pathways in these diseases, such as growth factors (LaVail et 
al., 1998), Schwann cells (Lawrence et al., 2000 and Chapter 6), retinal prostheses 
(Rizzo et al., 2001;Margalit et al 2002; Humayun et al., 2003) or neural retinal 
transplants (Kwan et al., 1999).
Apart from the beneficial effects of Schwann cell grafting demonstrated in the rho-/- 
mouse (Chapter 6), Liang et al., 2001 (using another rho-/- mouse strain, Lem et al.,
1999) have demonstrated the potential protective benefit of a gene therapy approach 
delivering a single growth factor (CNTF) to the retina. Although excellent 
preservation of photoreceptors was achieved, they were unable to demonstrate ERG 
recordings in these retinae, in agreement with the findings reported in Chapter 6. 
Therefore, to preserve retinal function at the electrophysiological level in the 
rhodopsin knockout mouse, rhodopsin production may have to be introduced by gene 
therapy such that outer segments are formed, as with peripherin in the rds mouse (Ali 
et al., 2000).
7.4.3 Other Animal Models
Large animal models for AMD have so far been used to create an RPE deficient 
environment by debriding the host RPE, leaving Bruch's membrane bare. This has 
been carried out in rabbits (Lopez et al., 1995; Majji and de Juan, 2000), pigs (Del
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Priore et al., 1995b, 1996), cats (Leonard et al., 1997) and monkeys (Valentino et al.,
1995). These models are appropriate for studying the efficacy of RPE transplants in 
geographic atrophy. The studies lasted for about 8 weeks which was probably of too 
short a duration to draw significant conclusions. What they did demonstrate was the 
ability of various cell types to attach to host Bruch's membrane and to support 
overlying photoreceptors, preventing or diminishing underlying choriocapillaris 
atrophy (Majji & de Juan, 2000). Other strategies for generating large animal models 
of AMD involve the creation of a choroidal neovascular membrane, usually with 
argon laser, in monkeys (Obana et al., 2000) and rats (Frank et al., 1989; Kvanta et 
al., 2000). While these techniques did generate a CNV membrane as occurs in AMD, 
the nature of the membrane was quite distinct from many seen in true AMD. Laser- 
induced CNV are typically type II membranes (i.e. subretinal) unlike the majority of 
CNV in AMD which are type I classic or occult (diffuse) and are sub-RPE (see Fig 
1.9). The importance of this distinction is seen when the membranes are removed 
during submacular surgery. Removal of subretinal membranes tends to be beneficial 
since an intact RPE is left behind, explaining the success of CNV removal in some of 
these patients (12%: Thomas et al., 1994). However, with sub-RPE membranes the 
RPE is removed and Bruch's membrane is damaged, which compromises the ability of 
RPE to attach (Tezel and Del Priore, 1999 or Tezel et a l, 1999). A true model of 
AMD would couple a compromised RPE layer with an impermeable Bruch's, CNV 
(Type I and II) and/or geographic atrophy.
Aged monkeys have been identified with naturally occurring drusen (Hope et al., 
1992; Olin et al., 1995) and other retinal changes. These monkeys demonstrate many 
of the clinical, angiographic, functional and histological features consistent with 
human age-related macular degeneration (Dawson et al., 1989; Hope et al., 1992;
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Monaco et al., 1990) though the cohort studied did not demonstrate CNV. These 
monkeys are the closest animal model that exists to the human form of AMD yet they 
still do not display all the features found in humans. No transplant studies have been 
performed on these animals and if they were to be studied, a long-term project, up to 
five years, would be necessary to determine efficacy.
7.4.4. What is a good model for AMD?
An ideal model of AMD would accurately recreate the slow progressive nature of the 
disease by gradually destroying the RPE. However, for developing experimental 
therapies the necessary time course is probably not realistic. Furthermore, the 
classification of AMD lies largely with the terminal pathology. Some genetic linkages 
have been identified but these probably reflect small subsets, unlike the RP spectrum 
where the majority are inherited. Analogous models are acceptable for transplantation 
studies provided the limitations of the models are respected. Developing good models 
beyond those currently available clearly deserve further attention. There are two 
situations in which this should be pursued: firstly, a large animal model in which a 
type 1 neovascular membrane has been induced. This would permit the removal of the 
membrane as in humans, and the placement of RPE cells on damaged Bruch’s 
membrane. In vitro studies by Del Priore’s group suggest that fresh RPE will not 
attach to outer layers of Bruch’s membrane and undergo apoptosis within 48 hours 
(Tezel et al., 1999). Studies on this type of model would help greatly to predict the 
behaviour of RPE cell grafts in vivo. Leonard et al., (1997) assessed the effect of RPE 
debridement in vivo using two systems, hydraulic and abrasive removal of RPE. The 
former was associated with regrowth of RPE and restoration of normal anatomy, 
whereas abrasive removal was associated with poorer recovery, ultrastructurally seen 
to be due to Bruch's membrane damage and incomplete RPE recovery. Use of the
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abrasive technique would enable us to test the ability of transplanted RPE cell lines to 
survive on damaged host Bruch's membrane and to support overlying photoreceptors, 
preventing underlying choriocapillaris atrophy. While debridement models are 
attainable in a large animal eye the exact relevance to AMD is unclear since AMD is 
characterised by many other functional and histopathological changes (Green and 
Enger 1993) in adjacent structures such as Bruch's membrane and choriocapillaris. 
Secondly, the development of a small animal model, such as a mouse or rat, would be 
beneficial for larger scale studies assessing functional as well as morphological 
outcome. Methods are currently being developed to deliver patches and suspensions 
of RPE trans-vitreally to the rodent subretinal space instead of trans-sclerally. This 
different surgical approach (which may be used in humans) could have a bearing on 
the immunological response. Trans-scleral allografts (Jiang et al., 1994) could be 
detected by conjunctival dendritic cells and foreign antigen presented to host T-cells, 
triggering an immune-mediated destruction of the tissue (van Buskirk et al., 1997). 
With the absence of valid animal models for AMD, in particular large animal models, 
one might argue that it is reasonable to graft into humans now. In initial transplant 
studies, patients could be used who are not suitable for other available treatments, 
such as PDT, where the potential, however small, exists to preserve some remaining 
visual function. These pilot studies would have the primary aim of examining graft 
survival and host responses.
7.5 Models for Hereditary Retinal Degeneration
As the genotypes for RP are widely known, with many more being discovered almost 
on a monthly basis (Daiger RetNet 2004), the number of genetically specific models 
for RP is great. The range of species is broad, as are the loci of disruption, and they 
have been reviewed extensively (Hafezi et al., 2000; Li et al., 2001). These models
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(see 1.3.3.2) provide great opportunities to examine a range of therapies for retinal 
degeneration and basic mechanisms that underlie these processes. Research into 
various therapies has been discussed in the Introduction (Section 1.5). While it is 
exciting that numerous specific gene based therapies have been applied (Ali et al., 
2000; Vollrath et al., 2001; Acland et al., 2001) it is advisable to research more 
broad-based strategies to tackle degeneration globally, thus making them clinically 
viable, such as using anti-apoptotic agents (e.g. Caspase-3 inhibitors, Bode and 
Wolfrom 2003), growth factors or Schwann cell grafts.
The Abyssinian cat is a potentially powerful model in pre-clinical studies for potential 
therapies. The normal cat retina has been well characterised as has its response to 
experimental retinal detachment (Lewis et al., 2003). Unlike the rabbit, the cat retinal 
vasculature is similar to humans and is a more viable model. Chong et al., (1999) 
have described the beneficial effects of multiple intra-vitreal injections of 
recombinant human CNTF (Axokine™). With pressures to develop clinical therapies 
this model is an elegant platform to test other broad-based therapies such as Schwann 
cell transplantation and studies are underway in normal cats.
The Briard dog is another exciting model and recently Bennett and colleagues have 
demonstrated preservation of retinal function in one of these dogs using gene therapy 
(Acland et al., 2001). Four years since the initial therapy the animal still portrays 
goods retinal function electrophysiologically (personal communication).
The transgenic pig (Petters et al., 1997) with an autosomal dominant rhodopsin 
mutation (Pro347Leu) substitution will prove very useful in transplantation studies as 
theoretically these pigs could be crossed with pigs with specific immunological 
genotypes thus permitting detailed immunological studies.
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The wide range of animal models for hereditary retinal disease will be valuable tools 
for investigating potential therapies in pre-clinical and parallel studies.
7.6 Further Requirements for Clinical Trials
The weight of evidence is beginning to suggest that large-scale clinical trials using 
cell transplant approaches will be feasible within the next 3-5 years. The efficacy of 
RPE cell lines and Schwann cells, demonstrated in small animal models of retinal 
degeneration, is encouraging. However, before embarking on clinical trials many 
other questions need to be considered in relation to both RPE cell transplantation and 
Schwann cell transplantation. Transplantation of human RPE cell lines to the 
immunosuppressed RCS rat preserves visual function and morphology (Chapter 5). 
The allogeneic cell line, LD7.4, also preserved visual function in the non- 
immunosuppressed RCS rat yet the cells did not survive for a protracted period of 
time. This observation raises some immediate issues: the validity of this animal model 
in these studies, the ability of grafted allogeneic cells to survive and the type of 
response (immune and inflammatory) stimulated by placing grafts in the rodent 
subretinal space.
While the RCS rat is used as a model of photoreceptor degeneration secondary to RPE 
dysfunction it is not directly analogous to AMD. The ability of donor cells to preserve 
photoreceptors in this model, even after their apparent disappearance, poses a problem 
of interpretation. Do the cells act directly by taking over the necessary functions of 
RPE, such as phagocytosis and phototransduction? Do they act by producing growth 
factors (e.g. bFGF) thus maintaining the photoreceptors? And if so is that sufficient to 
maintain long term efficacy?
They may stimulate activation of resident tissue resident microglia, which in turn take 
on the phagocytic role (Ng and Streilein, 2001), preventing the build up of toxic
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debris. Grafting allogeneic RPE cells may just shift the degeneration curve and not 
prevent the inevitable photoreceptor loss, as hypothesised in Figure 7.2. The RCS rat 
is subject to secondary degenerative events including early compromise of the blood- 
retinal barrier which may negate any immune privilege that could exist in the normal 
subretinal space. This still has to be investigated fully.
Grafts may fail due to inflammatory and immunological consequences following RPE 
cell transplantation. In Chapter 4, the influx of ED-1 expressing macrophages and the 
activation of resident microglia, are significant secondary events accompanying cell 
transplantation. Modification of these factors as outlined in 7.3.1 and Fig 7.1 will lead 
to a greater understanding of the mechanisms involved in host responses to RPE 
grafts. Preliminary studies indicate no benefit in using cyclosporine treatment to 
manage these alloresponses, unlike the findings with xenografts (Chapter 5) and this 
is consistent with the precedent literature (Craaford et al., 1999; Craaford et al.,
2000). It is clear that the response to subretinal allografting is atypical (Jiang et al., 
1994, Chapters 3 and 4) and likely to be macrophage and microglia dependant. The 
rationale for not using cyclosporine in the allograft studies was to determine the 
timetable of events and to begin to understand the basic mechanisms involved. Once 
these have been determined, specific therapies may be utilised or developed (e.g. the 
use of anti-macrophage agents such as clodronate).
Having identified the loss of cells following transplantation, candidate processes must 
be investigated. Del Priore's group has published widely on this subject specifically 
examining apoptosis in vitro (Tezel et al., 1999) whilst others studied the apoptotic 
events in vivo (Wang et a l, 2001). Failure of grafted RPE cells to attach to Bruch's 
membrane within 48 hours results in their apoptosis, a process known as anoikis. To
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Figure 7.3: Optimum Conditions for RPE Transplantation
There are a number of key problems relating to RPE transplantation that must be 
addressed. Grafted cells must be able to attach and integrate on Bruch’s membrane 
and for this the membrane must be minimally compromised and appropriate integrins 
must be expressed (see Chapter 1). Once integrated, the cells must perform all the 
necessary functions of the RPE cell, such as restoring the integrity of the blood-retinal 
barrier through cell contact and tight junction formation, phagocytosis and retinal 
metabolism. Finally, the cells must survive in the host subretinal space and resist both 
innate and specific immune responses and apoptosis. These processes may be 
controlled with anti-inflammatory agents, immunosuppressants and anti-apoptotic 
agents.
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Figure 7.3
Optimum Conditions For RPE Transplantation
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ensure maximal graft survival this process must be modified or larger areas of viable 
substrate must be made available. The process itself may be modified by further 
genetic manipulation of the cells by inserting anti-apoptotic genes (e.g. bcl-2: Chen et 
al., 1996). The cells could be grafted already attached to artificial membranes (eg. 
hydrogel, Singh et al., 2001; poly (DL-lactic-co-glycolic acid) film Lu et al., 1998; 
Sheridan et al 2004), and biological (e.g. amniotic) membrane (Capeans et al., 2003) 
or anterior lens capsule (Kiilgaard et al., 2002). This may have two benefits: 1) a 
reduced number of cells would have to be grafted (c.f. suspensions) thus reducing the 
antigenic load and 2) the cells could be inserted already polarised on a pre-formed 
substrate.
Considering retinal cell transplantation, specifically RPE transplantation, it is clear 
that many factors may compromise graft survival. Optimum conditions for graft 
survival have been outlined schematically in Fig 7.3.
7.7 Limiting Secondary Retinal Effects
Other cellular and vascular changes occur in the degenerating retina (see 
Introduction). These processes will have to be considered when devising therapies, 
particularly the timing of transplantation. Grafts need to be inserted prior to the onset 
of major photoreceptor loss. Once photoreceptors are lost inner retinal remodelling 
begins and normal retinal connectivity is disrupted. Donor cells are more likely to 
maintain normal synaptic transmission and useful vision if transplanted at an early 
stage of the disease. If this is to be the case then the surgeon must be sure that the 
treatment will be beneficial.
7.8 Demonstrating Real Functional Vision
Data presented here, and in publications arising from this work, uniquely show 
preservation of a high order of visual function (Lund et al., 2001a, Coffey et al.,
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2002a). It is of tremendous importance to clinicians, who may consider performing 
transplants on patients in the future, that these studies demonstrate more than just 
morphological preservation. Work published from the our group has demonstrated 
preservation of cortical vision at the single neuron level (Coffey et al, 2002a). In 
addition, our collaborator, Dr. P.Coffey has recently used cortical optical imaging on 
RCS rats that had received RPE transplants and shown preservation of global cortical 
function (Gias et al, 2002). This technique provides more evidence of downstream 
transplant efficacy in this animal model and could be combined with ERG testing to 
give a retinal and a cortical image in the same animal. It could also be applied to large 
animal models such as the cat.
7.9 Previous clinical studies and their shortcomings
The design of a clinical trial for transplantation is very important. Patient selection, 
study goals and study outcome measures are key to the ultimate success of these 
therapies. Previous studies on RPE transplants to patients have not been successful. 
No patients in the published studies have shown improved vision following 
transplantation, but these were not clinical trails. They were exploratory operations 
testing safety. The first series of patients received grafts following removal of CNV 
membranes (Algvere et a l, 1994, 1997). Having initially done well, their visual 
acuity deteriorated accompanied by subretinal fibrosis and retinal oedema. These 
changes were attributed to graft rejection, but no immunological studies were 
undertaken in this group. The conclusion was based on earlier monkey studies that 
examined cellular infiltration in the retinae following grafting and comparing them 
with fluorescein angiography (Sheng et al, 1995). Rejection was defined as 
fragmentation, disruption or disappearance of the graft in association with 
inflammatory cells. The appearance of oedema is confusing, since rejection and loss
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of RPE should lead to overlying retinal atrophy, not oedema. Oedema would suggest 
that a barrier to bulk fluid outflow exists in these patients. The patients were screened 
as follows: pre- and postoperative colour photos with fluorescein angiography, and 
retinal function was assessed with a scanning laser ophthalmoscope (SLO) and 
microperimetry. In another transplant study a patient with geographic atrophy (Weisz 
et al., 1999) was assessed very thoroughly before and after surgery by visual acuity 
testing (ETDRS chart), fundus photography, fluorescein angiography, SLO 
microperimetry and reading rate. The follow-up also included humoral immune 
response against inter-photoreceptor binding protein (IRBP), S-antigen and whole 
RPE and cellular immunity was tested against IRBP, S-antigen, phosducin, rhodopsin, 
mixed retinal antigens and bovine RPE microsomal proteins. Again, there appeared to 
be no benefit to the patient, the graft site was associated with angiographic leakage 
(consistent with vasculitis) and was interpreted by the group as evidence of rejection, 
in spite of the fact that the panel of tests above was either totally normal or near 
normal.
7.10 Aims of future studies
7.10.1 Introduction
Future clinical trials will have to incorporate the type of pre- and post-surgery 
assessment used by Weisz et al., 1999, detailed in figure 7.4, and including additional 
tests such as contrast sensitivity testing, reading vision, static perimetry, multi-focal 
ERG recording (Hood, 2000), autofluorescence imaging (von Ruckmann et al., 1999), 
optical coherence tomography imaging and quality of life assessment. Trials will also 
depend on accurate phenotyping (including natural history) and in cases of retinal 
dystrophies, genotyping of the disease. Trials that are ongoing at Moorfields Eye 
Hospital are seeking to develop a database of such AMD patients (Scholl et al.,
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2003); there is already a database of patients with hereditary dystrophies. These 
patients would provide a valuable resource in the design of new studies because not 
only are they needed for the therapeutic group but also for suitable control groups 
(both interventional and non-interventional). A failing of the previous transplant 
studies has been the absence of suitable control groups.
7.10.2. Choice of patients for AMD trials and the conduct of the trials 
In designing suitable trials a stepwise progression will be the most sensible course. 
Initial studies should aim to demonstrate the viability of RPE cells in the subretinal 
space of patients with AMD (for RPE). Once graft viability has been proven in 
patients with advanced AMD then trials may be designed with the aim of preserving 
and improving visual function in patients with moderate to severe disease. Finally, a 
randomised control trial involving established therapies, such as argon laser and PDT 
in AMD could be incorporated and compared with the experimental procedure (Fig 
7.4).
Initial studies should concentrate on restoring RPE to Bruch's membrane following 
removal of a neovascular membrane (Type 1). The role of autofluorescence imaging 
and OCT is paramount in post-operative assessment of these patients. Follow-up trials 
would concentrate on preservation of vision and assessment would be based on acuity 
and contrast sensitivity testing together with more sophisticated assessments such as 
microperimetry and/or static macular perimetry. The second tier of studies would 
involve patients with high-risk second eyes (MPS Group, 1997) since there is a risk of 
progression to debilitating disease in this group. This particular cohort could be used 
in a longer-term study (over five years) to examine the longitudinal benefit of 
preventing progression.
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Figure 7.4: Proposed Design for RPE Transplantation Trial for AMD
This figure gives an outline of the trial stages. Trial stage I would recruit a group of 
patients with advanced age-related macular degeneration. This would primarily assess 
safety and immunological responses but graft viability and retinal integrity over the 
graft would be examined using fluorescein angiography (FFA), autofluorescent 
imaging and optical coherence tomography (OCT) with microperimetry. Later studies 
(stage II) would involve patients with moderate visual loss and would primarily 
examine the effect of the graft on visual function. In addition to the tests outlined 
above, patients would undergo visual acuity, contrast sensitivity, microperimetric and 
multifocal electroretinographic (mfERG) testing. The stage III trials would hopefully 
be built on positive results from stage I and II, and would be a comparative 
randomised, controlled trial against natural history and/or photodynamic therapy 
(PDT).
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Figure 7.4
Proposed Trial Design for RPE Transplantation in AMD
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7.10.3 Choice of patients for inherited retinal dvstropy trials and conduct of trials 
A similar stepwise approach would be adopted for these patients with initial studies to 
assess the viability of Schwann cells in the SRS. Patient selection is very important 
since choosing the wrong patient cohort initially could jeopardise any trial, skew 
results and disguise a specific benefit. As with trials in AMD, investigators must be 
sure of the study goals. Initial aims should be the preservation of residual cone 
structure and function, with prolongation of useful vision for 5 years considered a 
successful outcome. Since studies will be on patients with hereditary dystrophies the 
fellow eye could serve as the control.
Two approaches would be valid: a) to treat patients whose inherited degenerative 
disease had an equivalent animal model e.g. a P23H mutation using methods that had 
been tested on those animals or b) treat patients with a specific disease characterised 
by a rapid, reliable and symmetrical deterioration in cone function after rod loss such 
as X-linked RP. A potential first trial would recruit severely affected heterozygotes 
(X-linked RP) to determine whether central cones could be preserved. If a beneficial 
effect can be demonstrated these patients' younger relatives with manifest disease may 
be enrolled in to a second level study to examine the long-term benefit of the same 
treatment but with earlier intervention.
Post-operative assessment in these patients would concentrate on macular function 
and should include acuity and contrast sensitivity testing and electrophysiological 
assessment including pattern ERG (pERG), multifocal ERG and static macular 
perimetry.
7.11 The Holy Grail
The aim is to build on the studies presented in this thesis, and others presented 
elsewhere, to provide a treatment or a range of treatment options for patients with
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retinal disease, specifically age-related macular degeneration and retinitis pigmentosa. 
It is important that the momentum is not lost: there are millions of patients world­
wide affected by retinal disease desperate for treatments, and the public health and 
economic benefits for a viable treatment would be great. To be able, in 10 years time, 
to see a patient in clinic with age-related macular disease or retinitis pigmentosa and 
list them for a surgical procedure, much as is done now for comeal transplantation, 
and confidently tell them that they will benefit from the intervention would be a 
fantastic achievement.
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APPENDIX I 
BUFFERS
Phosphate buffered saline (PBS)
Stock solution lOx working dilution.
For 1 litre:
900ml distilled water 
2g Potassium Chloride
2g Potassium dihydrogen phosphate (KH2 PO4 )
80g Sodium Chloride
11 .4g Di-sodium hydrogen phosphate (Na2HPC>4).
Make up to 11 with distilled water. pH 7.3.
Gomori Phosphate Buffer (0.5M)
For 1 litre:
900 ml distilled water
30g sodium dihydrogen phosphate (Na^PCU)
142g di-sodium hydrogen phosphate (Na2HP0 4 )
Make up to 11 with distilled water. pH 7.4.
Phosphate buffers for electron microscopy
For 1 litre, 0.2M:
Solution A: 31.2g sodium dihydrogen phosphate 2 H2O 
Solution B: 28.4g di-sodium hydrogen phosphate
To make 100ml 0.2M phosphate buffer at ph 7.4, mix 23ml solution A with 77ml 
solution B.
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Sodium cacodylate buffer for electron nicroscopy
For 100ml of 0.1 M buffer, dissolve 2.14g sodium cacodylate in lOOmls. distilled 
water. pH to 7.4 with 1 or 2 drops of concentrated hydrochloric acid.
FIXATIVES
4% Paraformaldehyde in phosphate buffered saline
For 1 litre:
40g paraformaldehyde (TAAB, Aldermaston, UK)
800ml distilled water 
40 drops IN sodium hydroxide
Heat to 60°C (but no higher, or paraformaldehyde will dissociate).
Add 100 ml stock PBS (lOx concentration).
Make up to 1 litre with distilled water. 
pH 12-1 A. Filter before use.
Paraformaldehyde-lysine-periodate fixative (PLP)
For 1 litre:
Solution A: 13.7g lysine monohydrochloride in 375ml distilled water.
Solution B: 1.4g disodium hydrogen phosphate (anhydrous) in 100ml distilled water. 
Solution C: 20g paraformadehyde in 200ml distilled water. Add 2 drops IN sodium 
hydroxide and heat to 60°C. When dissolved allow to cool.
Mix A with B and then add C. pH to 6.8.
Make up to 11 with Gomori’s buffer which has been diluted to 0.25M.
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Add 2.14g sodium periodate solution just before use. Filter before use.
Fixative for electron microscopy
For 1 litre:
25g paraformaldehyde in 300 ml distilled water 
25 drops IN NaOH. Heat to 60°C to dissolve.
When cool add lOOmls 25% glutaraldehyde (EM grade).
Make up to 500ml with distilled water.
Add 500ml of 0.2M phosphate buffer (see buffer for electron microscopy). 
Check pH (7.4) and filter.
Just before use add lOmls 1% picric acid solution per litre.
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HISTOLOGICAL STAINS 
Cresyl violet, Nissl counterstain.
0 .5 .  cresyl violet 2mins
Distilled water 2 x 2mins
70% alcohol 2mins
95% alcohol/acetic acid A few dips
(95mls 95% alcohol and 5ml acetic acid)
95% alcohol 2mins
100% alcohol 2x2mins
Xylene 2 x 5mins
Mount in DPX 
Haematoxylin/Eosin
1. Wash sections in tap water.
2. Stain in Mayer’s haematoxylin, 2-4mins.
3. Wash in tap water until blue.
4. Differentiate with acid alcohol (95% alcohol, plus 1% hydrochloric acid).
5. Wash in tap water until blue.
6. Counterstain in 0.25% aqueous Eosin yellowish for about lmin. NB. Eosin is water 
soluble.
7. Dehydrate through 70%, 80%, 95% and absolute alcohol.
8. Clear in xylene.
9. Mount in DPX.
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PROTOCOL FOR EMBEDDING TISSUE IN POLYESTER WAX
1. Fix in PLP or 4% paraformaldehyde by immersion or perfusion. Mark dorsal pole 
with a suture.
2. Wash 2x in PBS over 30 mins.
3. 50% alcohol for lh.
4. 70% alcohol for lh.
5. 80% alcohol for lh.
6. 95% alcohol for lh. Remove lens.
7. 95% alcohol for lh.
8. 95% alcohol: polyester wax, 2:1 for lh at approximately 39°C.
9. 95% alcohol: polyester wax, 1:1 for lh.
10. Neat wax for lh.
11. Fresh wax overnight. Make sure tissue sinks.
12. Embed in fresh wax. Cool and store blocks at 4°C.
PROTOCOL FOR IMMUNOHISTOCHEMISTRY USING DAB AS A 
CHROMAGEN
Bring ciyostat sections to room temperature and dry in a current of cool air for lh. 
Dewax polyester sections by dipping briefly in absolute alcohol and 95% alcohol for 
lOmins. Dry in a current of air for 30mins.
1. For all sections: Block in 5% defatted milk (unless using Jackson secondary 
antibodies) or 5% serum (appropriate to the animal in which the secondary antibody 
was raised) in PBS.
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2. Drain sections and cover with primary antibody diluted to the required 
concentration in antibody diluent (1% bovine serum albumen, Sigma, in PBS). NB. 
Do not use bovine serum albumen if using Jackson secondary antibodies. Place in a 
humidified chamber overnight at 4°C.
3. Wash 3x 5mins in PBS.
4. Incubate sections in appropriate biotinylated secondary antibody, diluted in 
antibody diluent or PBS 1:150. Add 1% rat serum. Incubate in humidified chamber 
for 30mins at room temperature.
5. Wash 3xl0mins PBS. Make up Streptavidin/ horseradish peroxidase (HRP) 
complex by mixing ldrop of solution A with ldrop of solution B in 2.5mls PBS. 
Allow to stand for 30mins before use.
6. Cover sections with streptavidin complex. Place in humidified chamber for 30mins 
at room temperature.
7. Wash 3x lOmins in PBS.
8. Place sections in filtered 1% nickel chloride in distilled water for 5mins.
9. Transfer sections directly to filtered DAB solution (50mg/100ml DAB buffer 
activated with lOpl hydrogen peroxide.
10. Wash 3x lOmins in PBS.
11. Counterstain if necessary, dehydrate through graded alcohols, xylene and mount 
in DPX.
DAB Buffer:
80g sodium dihydrogen phosphate. 2H20  
13.5g imidazole
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Make up to 500ml with distilled water. Use at 1+9 for DAB. pH should be 5.8 
(optimal for DAB reaction).
BrdU VISUALISATION USING VECTOR BLUE CHROMAGEN
1. If slides have been stored at -70°C, bring to room temperature
2. Dry slides in a current of cool air for lh.
3. Distilled water (DW) 1 x 5min.
4. Tris Buffered Saline (TBS) pH 7.6, 2 x 5  min.
TBS recipe: 0.05M Tris/HCl (7.88g/l) + 0.15M NaCl (8.34g/l), pH to 7.6 with 
NaOH.
5. 2NHCL + 0.5% Triton for 30-35min. at 37°C. (2ml. Cone HC1 + 10ml DW+ 50pl 
Triton).
6. Borax (0.1M di-sodium tetraborate, 38.138g/l) for lOmin at RT.
7. TBS pH 7.6, 3 x 5min.
8. Block with 5% goat serum in TBS, pH 7.6 (no BSA) + 0.05% Tween for 30min at 
RT.
9. BrdU antibody, monoclonal (1:1000, Sigma) in TBS, pH 7.6 (no BSA) + 2% rat 
serum + 0.05% Tween overnight at 4°C.
10. TBS pH 7.6, 3 x 5min.
11. Secondary antibody: Biotinylated preadsorbed goat anti-mouse IgG (Jackson 
ImmunoResearch). 1:200 in TBS pH 7.6 (no BSA) + 2% rat serum for 30 min at room 
temperature (RT). Make up Streptavidin/alkaline phosphatase complex using TBS pH
7. 6, no BSA, 30mins before use.
12. TBS pH 7.6, 3 x 5min.
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13. Streptavidin/AP for 30 min at RT.
14. TBS pH7.6, 2 x 5min
15. Tris buffer, pH 8.2, no salt. 1 x 5min.
TB pH 8.2, 0.1M recipe: TrisHCL 7.08g/l + Tris Base 6.68g/l.
16. Vector blue (Vector Labs), make up as specified in kit using Tris buffer, pH 8.2 + 
5drops levamisole + 0.1% Tween, in the dark at RT, approx. lOmins. Monitor 
microscopically.
17. Wash in TBS, pH 8.2, 1 x 5 min.
18. Dehydrate through graded alcohols, clear in Neoclear.
19. Mount in Vectamount.
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PROCESSING TISSUE FOR ELECTRON MICROSCOPY
1. Fix tissue in 2.5% paraformaldehyde and 2.5% gluraraldehyde in 0.1 M phosphate 
buffer, pH7.2-7.4.
2. Wash in 0.1 M sodium cacodylate buffer with agitation for 20 mins.
3. Postfix in 1% aqueous osmium tetroxide for 2h.
4. Rinse in distilled water with agitation for 20 mins.
5. Dehydrate through ascending alcohols, 50%, 70% and 90%, 2xl0min each.
100% ethanol, 3xl0min with agitation.
6. Epoxypropane, 3xl0min each.
7. Equal parts epoxypropane and Araldite epoxy resin (Taab Laboratories) with 
agitation for at least 2h or overnight.
8. Araldite resin with agitation for at least 2h or overnight.
9. Embed in fresh Araldite and polymerise at 60°C for at least 12h.
10. Allow to cool before cutting.
Araldite epoxy resin mixture: CY212 25ml
DDSA 20ml
DMP 30 0.8-0.9ml. Stir mixture
thoroughly.
Stains for Electron Microscopy:
Alcoholic Uranyl Acetate: Dissolve 0.3g uranyl acetate in lOmls methanol.
Reynold’s Lead Citrate: Dissolve 1.33g lead nitrate in 30ml distilled water. Add 1.76g 
sodium citrate 2 H2O. Shake at intervals over 30mins. Add 8ml IN NaOH. Add 12ml 
distilled water. Store in sealed syringes (away from air/C02) at 4°C. Sections stained 
for 5mins in each stain.
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NEUROTACS™ II: IN SITU APOPTOSIS DETECTION KIT
(R&D Systems Europe, Abingdon, UK).
SOLUTIONS REQUIRED
lOx Phosphate buffered saline (PBS):
Sodium dihydrogen phosphate 3.45g
Di-sodium hydrogen phosphate 10.65g
Sodium chloride 86.19g
Dissolve in 800ml DNase-free water and make up to 1 litre.
lx  PBS:
10ml lOxPBS in 450ml DNase-free water. Check pH 7.4.
NeuroPore solution provided in kit.
Quenching solution:
30% hydrogen peroxide 5ml
Methanol 45ml
Prepare just before use. Ensure that hydrogen peroxide solution is no more than 2 
months old.
lx TdT labelling buffer:
lOx labelling buffer 5ml
DNase-free water 45ml
Keep on ice.
Labelling reaction mix:
TdT dNTP mix lpl
TdT enzyme lpl
50x Mn2 1 pi
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lx TdT labelling buffer 50pl
Prepare by thawing TdT dNTP and the 5 Ox Mn2 at room temperature, and then place 
on ice. Remove TdT from freezer only long enough to remove required volume (to 
maintain enzyme reactivity). Prepare labelling reaction mix just before use and keep 
on ice.
lxTdT stop buffer:
1 Ox TdT stop buffer 5ml
DNase-free water 45ml
Streptavidin-HRP working solution:
Streptavidin-HRP 1 pi
lxPBS 50pl
Store on ice until used.
DAB working solution:
30% hydrogen peroxide 50pl
DAB 250pl
lx PBS 50ml.
Prepare no more than 30mins before use. Thaw DAB at 37°C and keep at room 
temperature.
TACS-Nuclease working solution:
TACS-nuclease lpl
TACS-nuclease buffer 50pl
Prepare just before use and keep on ice.
Blue counterstain:
Provided in kit. Use ammonium water to blue the counterstain.
Ammonium water:
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30% ammonium hydroxide solution 0.25ml 
Tap water 500ml.
Prepare just before use.
METHOD FOR LABELLING FIXED FROZEN SECTIONS
1. Remove sections from freezer and bring to room temperature. Dry under a current 
of cool air for at least one hour or overnight.
2. Immerse slides in lx PBS for 10 mins at room temperature (RT). Dry glass around 
sample.
3. Pipette 50pl NeuroPore onto each slide and cover with a coverslip. Incubate in an 
humidity chamber for 15-30mins at RT.
4. Wash 2x 2mins in DNase-free water.
5. Prepare a nuclease-generated positive control: pipette 50pl TACS-nuclease 
working solution onto one of the prepared slides. Cover with a coverslip and incubate 
for 10-60mins in an humidity chamber. Wash 2x 2mins in DNase-free water. Keep 
remaining slides in DNase-free water.
6. Immerse slides in quenching solution for 5mins at RT.
7. Wash withlx PBS for lmin at RT.
8. Immerse in lx TdT buffer for 5mins at RT. Dry around sections but it is essential 
that sections themselves do not dry otherwise there is a risk of staining artifacts.
9. Add 50pl Labelling Reaction Mix to each sample. Cover with a coverslip. For an 
unlabelled control, cover one sample with labelling mix that lacks TdT. (ie. lpl TdT 
dNTP mix in 50pl labelling buffer). Incubate for lh at 37°C in an humidity chamber.
10. Stop the reaction with lx TdT stop buffer for 5mins at RT.
11. Wash 2x 2mins in lx PBS.
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12. Dry around each sample and add 50jnl streptavidin-HRP solution to each sample.
Do not allow to dry out, cover with a coverslip if necessary. Incubate for lOmins at
RT.
13. Was 2x 2mins in lx PBS.
14. Immerse in DAB solution for 2-lOmins.
15. Wash 2x 2mins with distilled water at RT.
16. Immerse in Blue Counterstain for 5-30secs.
17. Wash and dehydrate sections by dipping in the following solutions: 
tap water (lOx)
ammonium water until the stains turns from purple to blue.
70% ethanol (2 changes, lOx each)
95% ethanol (2 changes, lOx each)
100% ethanol (2 changes, lOx each)
Xylene (2 changes, lOx each).
18. Mount in DPX.
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